<?xml version="1.0" ?><ns2:com.thomsonreuters.ls.service.contract.soap.trials.v2.TrialRecordsOutput xmlns:ns2="local"><serviceExecutionTime>311</serviceExecutionTime><Trial id="188950"><TitleDisplay>Therapeutic Control of Aspirin-Exacerbated Respiratory Disease</TitleDisplay><TitleOfficial>Therapeutic Control of Aspirin-Exacerbated Respiratory Disease</TitleOfficial><OutcomesAvailable>No</OutcomesAvailable><EndpointsAchieved>Unspecified</EndpointsAchieved><Identifiers><Identifier type="NCT">NCT01597375</Identifier><Identifier type="Organisational Study">2010P002961</Identifier></Identifiers><Indications><Indication id="711">Respiratory disease</Indication></Indications><BiomarkerNames><BiomarkerName id="125" role="Therapeutic effect marker" type="Cellular">Leukocyte count</BiomarkerName><BiomarkerName id="235" role="Therapeutic effect marker" type="Genomic;Proteomic">Prostaglandin G/H synthase 2</BiomarkerName><BiomarkerName id="237" role="Therapeutic effect marker" type="Biochemical">Leukotriene E4</BiomarkerName><BiomarkerName id="2054" role="Therapeutic effect marker" type="Cellular">Blood platelets</BiomarkerName><BiomarkerName id="2713" role="Therapeutic effect marker" type="Physiological">Forced expiratory volume</BiomarkerName><BiomarkerName id="5212" role="Therapeutic effect marker" type="Biochemical">Thromboxane B2</BiomarkerName><BiomarkerName id="6894" role="Therapeutic effect marker" type="Genomic;Proteomic">Tryptase</BiomarkerName><BiomarkerName id="10811" role="Therapeutic effect marker" type="Biochemical">Prostaglandins</BiomarkerName><BiomarkerName id="11397" role="Therapeutic effect marker" type="Biochemical">Prostaglandin D2</BiomarkerName><BiomarkerName id="14240" role="Therapeutic effect marker" type="Proteomic">Eicosanoids</BiomarkerName><BiomarkerName id="30834" role="Therapeutic effect marker" type="Physiological">Fractional concentration of exhaled nitric oxide</BiomarkerName></BiomarkerNames><InterventionsPrimaryByRegimen regimenType="single"><Interventions><Intervention type="InterventionPrimary"><Name>aspirin</Name></Intervention></Interventions></InterventionsPrimaryByRegimen><InterventionsPrimaryByRegimen regimenType="single"><Interventions><Intervention type="InterventionPrimary"><Name>prasugrel</Name><Drug id="19001">prasugrel</Drug></Intervention></Interventions></InterventionsPrimaryByRegimen><InterventionsControlByRegimens></InterventionsControlByRegimens><DrugsAsInterventionPrimary><DrugAsInterventionPrimary><Drug id="19001">prasugrel</Drug><IndicationsPioneer><Indication id="711">Respiratory disease</Indication></IndicationsPioneer><Companies><Company><Company id="21048">Brigham &amp; Women's Hospital</Company><RelationshipDirect>NONE</RelationshipDirect><RelationshipInDirect>NONE</RelationshipInDirect></Company></Companies></DrugAsInterventionPrimary></DrugsAsInterventionPrimary><CrossReferences><SourceEntity id="19001" type="Drug"><TargetEntity id="273686" type="siDrug">Prasugrel hydrochloride</TargetEntity></SourceEntity><SourceEntity id="21048" type="Company"><TargetEntity id="4296476182" type="organizationId">Brigham and Women's Hospital Inc</TargetEntity></SourceEntity><SourceEntity id="711" type="ciIndication"><TargetEntity id="J98.9" type="ICD10"></TargetEntity><TargetEntity id="10038683" type="MEDDRA"></TargetEntity><TargetEntity id="D012140" type="MeSH"></TargetEntity><TargetEntity id="-2143937119" type="omicsDisease"></TargetEntity><TargetEntity id="269" type="siCondition"></TargetEntity></SourceEntity><SourceEntity id="4913" type="Action"><TargetEntity id="613" type="Mechanism">P2Y12 (P2T) Antagonists</TargetEntity></SourceEntity></CrossReferences><Phase>Phase 2 Clinical</Phase><RecruitmentStatus id="4">Completed</RecruitmentStatus><NumberOfSites>1</NumberOfSites><CompaniesSponsor><Company id="21048">Brigham &amp; Women's Hospital</Company></CompaniesSponsor><CompaniesCollaborator></CompaniesCollaborator><IsCommerciallySignificant>No</IsCommerciallySignificant><ActionsPrimaryInterventionsPrimary><Action id="4913">P2Y12 purinoceptor antagonist</Action></ActionsPrimaryInterventionsPrimary><Class><Class id="312">Platelet aggregation inhibitor</Class></Class><Technologies><Technology id="751">Film coating</Technology><Technology id="585">Oral formulation</Technology><Technology id="902">Orally disintegrating tablet</Technology><Technology id="1652">Prodrug</Technology><Technology id="762">Small molecule therapeutic</Technology><Technology id="595">Tablet formulation</Technology></Technologies><TermsPatientSelection><Term>Aged Adults (65-79 yrs)</Term><Term>Middle-aged Adults (45-64 yrs)</Term><Term>Young Adults (18-44 yrs)</Term></TermsPatientSelection><TrialCategories><Category>Small molecule</Category></TrialCategories><TermsDesign><Term>Randomized</Term><Term>Placebo Control</Term><Term>Multiple Blind</Term><Term>Treatment</Term><Term>Crossover Assignment</Term><Term>Interventional</Term></TermsDesign><TermsEndpoint><Term>Efficacy</Term></TermsEndpoint><PatientCountEnrollment>46</PatientCountEnrollment><PatientCountEvaluable>40</PatientCountEvaluable><DateStart>2012-08-31T00:00:00Z</DateStart><DateChangeLast>2019-02-22T04:30:34Z</DateChangeLast><DateAdded>2014-05-21T00:00:00Z</DateAdded><Contacts><Contact type="Scientific contact"><Affiliation>Brigham and Women's Hospital</Affiliation><Name>Elliot Israel, MD</Name></Contact><Contact type="Scientific contact"><Affiliation>Brigham and Women's Hospital</Affiliation><Name>Joshua Boyce, MD</Name></Contact></Contacts><CriteriaInclusion>&lt;Inclusion&gt;&lt;ul&gt;&lt;li&gt;Participants with AERD:&lt;ul&gt;&lt;li&gt;History of physician-diagnosed asthma&lt;/li&gt;&lt;li&gt;History of nasal polyposis&lt;/li&gt;&lt;li&gt;History of at least one clinical reaction to oral aspirin or other nonselective COX inhibitor with features of both lower (cough, chest tightness, wheezing, dyspnea) and upper (rhinorrhea, sneezing, nasal obstruction, conjunctival itching and discharge) airway involvement&lt;/li&gt;&lt;li&gt;Stable asthma (post-bronchodilator FEV1 of 70% or better, no increase in baseline dose of oral glucocorticoids for at least 3 months, and no history of hospitalization or emergency room visits for asthma for at least the prior 6 months)&lt;/li&gt;&lt;li&gt;No current smoking, defined as no daily tobacco smoking for at least 6 months and not more than one instance of tobacco smoking in the last 3 months&lt;/li&gt;&lt;li&gt;Non-pregnant&lt;/li&gt;&lt;li&gt;Only those individuals who would otherwise meet clinical qualifications for aspirin desensitization and treatment with high-dose aspirin will be considered for enrollment in the study&lt;/li&gt;&lt;/ul&gt;&lt;/li&gt;&lt;li&gt;Participants who are aspirin tolerant asthmatics:&lt;ul&gt;&lt;li&gt;History of physician-diagnosed asthma&lt;/li&gt;&lt;li&gt;No current nasal polyposis confirmed by nasal examination&lt;/li&gt;&lt;li&gt;No history of any adverse reaction to aspirin or a COX inhibitor&lt;/li&gt;&lt;li&gt;Stable asthma (post-bronchodilator FEV1 of 70% or better, no increase in baseline dose of oral glucocorticoids for at least 3 months, and no history of hospitalization or emergency room visits for asthma for at least the prior 6 months)&lt;/li&gt;&lt;li&gt;No current smoking&lt;/li&gt;&lt;li&gt;Non-pregnant&lt;/li&gt;&lt;/ul&gt;&lt;/li&gt;&lt;li&gt;Non-asthmatics with allergic rhinitis:&lt;ul&gt;&lt;li&gt;No history of physician-diagnosed asthma&lt;/li&gt;&lt;li&gt;No current nasal polyposis confirmed by nasal examination&lt;/li&gt;&lt;li&gt;No history of any adverse reaction to aspirin or a COX inhibitor&lt;/li&gt;&lt;li&gt;No current smoking&lt;/li&gt;&lt;li&gt;Non-pregnant&lt;/li&gt;&lt;li&gt;Clinical history of symptoms consistent with allergic rhinitis and previously documented allergy to at least one environmental, immunoglobulin E (IgE) testing&lt;/li&gt;&lt;li&gt;Normal lung function (baseline FEV1 of 80% of predicted or better)&lt;/li&gt;&lt;li&gt;A score of&amp;lt;/= 4 on the Asthma Screening Questionnaire (33) and negative responses to asthma history questions&lt;/li&gt;&lt;/ul&gt;&lt;/li&gt;&lt;/ul&gt;&lt;/Inclusion&gt;</CriteriaInclusion><CriteriaExclusion>&lt;Exclusion&gt;&lt;ul&gt;&lt;li&gt;Participants with AERD:&lt;ul&gt;&lt;li&gt;Current breastfeeding&lt;/li&gt;&lt;li&gt;History of bleeding diathesis or current use of anticoagulant or antiplatelet drugs&lt;/li&gt;&lt;li&gt;Hypersensitivity to montelukast or thienopyridines&lt;/li&gt;&lt;li&gt;History of peptic ulcer disease or gastrointestinal bleed&lt;/li&gt;&lt;li&gt;Current severe gastro-esophageal reflux disease (GERD), defined as patient currently requiring &gt; 2 total doses of medication per day to treat persistent symptoms: either &gt; 2 doses of any single medication type (antacid, proton pump inhibitor, or H2 receptor antagonist), or &gt; 2 types of medication per day to treat symptoms&lt;/li&gt;&lt;li&gt;History of systemic or life-threatening respiratory reaction to aspirin requiring intubation or administration of adrenalin&lt;/li&gt;&lt;li&gt;Current use of any oral beta blocker (due to the risk of bronchospasm associated with beta blockers)&lt;/li&gt;&lt;li&gt;History of transient ischemic attack or stroke, or diabetes&lt;/li&gt;&lt;li&gt;Current presence of uncontrolled hypertension&lt;/li&gt;&lt;li&gt;History of hepatic impairment or alcoholism, or evidence of abnormal liver function at screening visit. Aspartate transaminase (AST) and alanine transaminase (ALT) levels may not exceed 1.5 x the upper limit of normal at screening visit (AST may not exceed 52 IU/l, ALT may not exceed 78 IU/l)&lt;/li&gt;&lt;/ul&gt;&lt;/li&gt;&lt;li&gt;Participants with aspirin tolerant asthma and non-asthmatics with allergic rhinitis:&lt;ul&gt;&lt;li&gt;Current breastfeeding&lt;/li&gt;&lt;li&gt;History of bleeding diathesis or current use of anticoagulant or antiplatelet drugs&lt;/li&gt;&lt;li&gt;Hypersensitivity to montelukast or thienopyridines&lt;/li&gt;&lt;li&gt;History of peptic ulcer disease or gastrointestinal bleed&lt;/li&gt;&lt;li&gt;Current severe GERD&lt;/li&gt;&lt;li&gt;Current use of any oral beta blocker&lt;/li&gt;&lt;/ul&gt;&lt;/li&gt;&lt;/ul&gt;&lt;/Exclusion&gt;</CriteriaExclusion><MeasuresOutcome><MeasuresPrimary><Measure><Description>Difference in PD2 (Provocative Dose of Aspirin That Elicits an Increase in Nasal Symptom Score of 2 During an Aspirin Challenge) on Prasugrel Versus Placebo: the PD2 is the provocative dose of aspirin that elicits an increase in nasal symptom score of 2 during an aspirin challenge</Description><Timeframe>Difference in PD2 (provocative dose of aspirin that elicits an increase in nasal symptom score of 2 during an aspirin challenge) between Visits 2 and 3 (weeks 8 and 14), calculated at visit 3</Timeframe></Measure><Measure><Description>Change from baseline expression levels of COX-2 transcript and protein in peripheral blood leukocytes of subjects with AERD after 8 weeks of treatment with aspirin: this study will compare this outcome within each participant between baseline (established at Visit 1, prior to initiation of prasugrel therapy) and at the completion of 8 weeks of aspirin therapy</Description><Timeframe>Evaluated at visits 1 and 4 (weeks 4 and 22)</Timeframe></Measure></MeasuresPrimary><MeasureSecondary><Measure><Description>Difference in participant's provocative dose of aspirin when pretreated with prasugrel versus placebo: will monitor the dose of aspirin at which the participant shows symptoms (increased discomfort, 15% drop in FEV1) during the aspirin challenge/desensitization. We will compare the provocative aspirin dose obtained from the aspirin challenge occurring after pretreatment with prasugrel to the dose obtained after pretreatment with placebo</Description><Timeframe>Evaluated at visits 2 and 3 (weeks 8 and 14)</Timeframe></Measure><Measure><Description>Change in Total Nasal Symptom Score(TNSS)from baseline to aspirin challenge/desensitization: this study has two parts. The primary outcome in Part 1 will be the maximum Total Nasal Symptom Score (TNSS) attained for subjects with AERD during the clinical reaction to aspirin challenge. The primary analysis will compare this outcome within each participant after treatment with prasugrel versus placebo. Nasal symptoms (congestion, rhinorrhea, itching, and sneezing) in response to the provocative dose of aspirin during aspirin challenge/desensitization will be monitored based on a 0- to 5-point scale (0, none-5, very severe)</Description><Timeframe>Data obtained at visits 2 and 3 (weeks 8 and 14) and change calculated at visit 3</Timeframe></Measure><Measure><Description>Change in urinary LTE4 During Aspirin Challenge on Placebo Versus Prasugrel: will compare the participant's Leukotriene E4 (LTE4) obtained at baseline with the LTE4 obtained from the aspirin challenge done after pretreatment with prasugrel, the aspirin challenge done after pretreatment with placebo, and lastly the LTE4 obtained after 8 weeks on aspirin. We will also compare the levels of LTE4 of participants with AERD to those obtained from participants who have aspirin tolerant asthma and those with allergic rhinitis (no asthma)</Description><Timeframe>Change from visits 2 at visit 3 (weeks 8, 14), calculated and reported at visit 3</Timeframe></Measure><Measure><Description>Effect desensitization to and treatment with aspirin has on baseline characteristics of AERD: will note differences in the asthma control test, prostaglandin (PG) metabolites, fractional exhaled nitric oxide (FeNO) obtained before any treatment, after treatment with prasugrel, after treatment with placebo, and after treatment with aspirin for 8 weeks</Description><Timeframe>Evaluated at visits 1, 2, 3, 4 (weeks 4, 8, 14, 22)</Timeframe></Measure><Measure><Description>Baseline differences in platelet chemistry in subjects with AERD compared to controls: to determine if there are baseline differences in the percentages of activated platelets, platelet-leukocyte aggregates, or the plasma levels of soluble platelet products in subjects with AERD, compared to aspirin tolerant asthmatics (ATA) and non-asthmatic controls</Description><Timeframe>Evaluated at visit 1 (week 4)</Timeframe></Measure><Measure><Description>Effect of prasugrel on platelet chemistry in subjects with AERD during aspirin challenge: to determine if treatment with prasugrel changes the baseline percentages of activated platelets or platelet-leukocyte aggregates or changes the plasma levels of soluble platelet products during clinical reaction to aspirin</Description><Timeframe>Evaluated at visit 2 and 3 (week 8 and 14)</Timeframe></Measure><Measure><Description>Change From Baseline in Fractional Exhaled Nitric Oxide (FeNO) Measurement After Aspirin Desensitization and High Dose Aspirin Treatment at 8 Weeks: the investigators will note difference in the fractional exhaled nitric oxide (FeNO) obtained before any treatment ( baseline ) and after one day Aspirin desensitization followed by 8 weeks Aspirin treatment (650 mg oral aspirin tablet twice daily)</Description><Timeframe>Evaluated at baseline and reported at 8 weeks</Timeframe></Measure><Measure><Description>Change From Baseline in Asthma Control Questionnaire-7 (ACQ-7) Score After Aspirin Desensitization and High Dose Aspirin Treatment at 8 Weeks: the investigators will note difference in the Asthma Control Questionnaire-7 (ACQ-7) score [ The ACQ has 7 questions on a 7-point scale (minimum score of 0=no impairment, maximum score of 6= maximum impairment)] obtained before any treatment ( baseline ) and after one day Aspirin desensitization followed by 8 weeks Aspirin treatment (650 mg oral aspirin tablet twice daily)</Description><Timeframe>Evaluated at baseline and reported at 8 weeks</Timeframe></Measure><Measure><Description>Change From Baseline in Prostaglandin Metabolites (PGD-M) Measurement After Aspirin Desensitization and High Dose Aspirin Treatment at 8 Weeks: the investigators will note difference in the Prostaglandin metabolites (PGD-M) measurement obtained before any treatment ( baseline ) and after one day Aspirin desensitization followed by 8 weeks Aspirin treatment (650 mg oral aspirin tablet twice daily)</Description><Timeframe>Evaluated at baseline and reported at 8 weeks</Timeframe></Measure><Measure><Description>Changes in lung function, urinary eicosanoids, plasma tryptase, platelet-leukocyte aggregates, and platelet activation were also recorded</Description></Measure></MeasureSecondary></MeasuresOutcome><ProtocolAndOutcomes><AimsAndScope>&lt;AimAndScope&gt;&lt;para&gt;The purpose of this study is to find out if giving       &lt;ulink linkType="Drug" linkID="19001"&gt;prasugrel&lt;/ulink&gt; can reduce reactions to aspirin in subjects      with aspirin exacerbated respiratory disease (AERD), and to learn why taking aspirin every      day can work as a treatment for people with AERD.  The investigators also want to understand what is different about the cells and urine from      subjects who have AERD, in comparison to subjects who have asthma but do not have AERD and      subjects who have allergic rhinitis but do not have asthma.  Lastly, the investigators want      to understand how aspirin acts differently in subjects who have AERD, in comparison to      subjects who have asthma but do not have AERD.&lt;/para&gt;&lt;/AimAndScope&gt;</AimsAndScope><ProtocolDescription>&lt;ProtocolDescription&gt;&lt;para&gt;The study consist of two arms:&lt;br/&gt;Arm 1: subjects will receive placebo prior to their first aspirin challenge/desensitization and &lt;ulink linkType="Drug" linkID="19001"&gt;prasugrel&lt;/ulink&gt; before their second aspirin challenge/desensitization.&lt;br/&gt;Arm 2: subjects will receive &lt;ulink linkType="Drug" linkID="19001"&gt;prasugrel&lt;/ulink&gt; prior to their first aspirin challenge/desensitization and placebo before their second aspirin challenge/desensitization.&lt;/para&gt;&lt;para&gt;Subjects  will receive &lt;ulink linkType="Drug" linkID="19001"&gt;prasugrel&lt;/ulink&gt; as a 60 mg loading dose. After they will take 10 mg po daily if they weigh &amp;gt; 60 kg or 5 mg po daily if they weigh &amp;lt; 60 kg.  Subjects  will receive  &lt;ulink linkType="Drug" linkID="19001"&gt;prasugrel&lt;/ulink&gt; 4 weeks prior to the aspirin challenge/desensitization.&lt;/para&gt;&lt;/ProtocolDescription&gt;</ProtocolDescription></ProtocolAndOutcomes><AdverseEventsByInterventions></AdverseEventsByInterventions><DoseRouteByInterventions><DoseRouteByIntervention><Intervention id="431163">prasugrel</Intervention><Treatments><Treatment><Dose>5 milligram</Dose><Route>Oral</Route></Treatment><Treatment><Dose>10 milligram</Dose><Route>Oral</Route></Treatment><Treatment><Dose>60 milligram</Dose><Route>Oral</Route></Treatment></Treatments></DoseRouteByIntervention></DoseRouteByInterventions><SitesByCountries><SitesByCountry country="US"><Sites><Site><Name>Asthma Research Center</Name><Address1>Boston</Address1><Address2>Massachusetts</Address2><Address3>02115</Address3><CountrySubDivision code="MA">Massachusetts</CountrySubDivision><Contacts></Contacts></Site></Sites></SitesByCountry></SitesByCountries><PatientSegmentTerms><PatientSegmentByDisease><Disease>Asthma</Disease><PatientSegments><PatientSegment><PatientSegment id="3303">Subjects with Stable Asthma</PatientSegment></PatientSegment><PatientSegment><PatientSegment id="3322">Subjects with comorbid conditions</PatientSegment></PatientSegment></PatientSegments></PatientSegmentByDisease></PatientSegmentTerms><TrialRegistries><Registry><Name id="1000">NLM ClinicalTrials.gov</Name><Identifiers><Identifier type="NCT">NCT01597375</Identifier></Identifiers></Registry></TrialRegistries><OutcomeMeasureTerms><PrimaryEndpoints><PrimaryEndpoint disease="Asthma" id="6049"><Endpoint>Assessment of Laboratory/Diagnostic Measures</Endpoint><SubEndpoints><SubEndpoint disease="Asthma" id="6275">Genetic analysis</SubEndpoint></SubEndpoints></PrimaryEndpoint><PrimaryEndpoint disease="Asthma" id="6074"><Endpoint>Assessment of Therapy Related Outcomes</Endpoint></PrimaryEndpoint><PrimaryEndpoint disease="Allergic rhinitis" id="14322"><Endpoint>Assessment of Total Nasal Symptom Score</Endpoint><SubEndpoints><SubEndpoint disease="Allergic rhinitis" id="14323">Change from baseline in total nasal symptom score</SubEndpoint></SubEndpoints></PrimaryEndpoint><PrimaryEndpoint disease="Allergic rhinitis" id="14385"><Endpoint>Assessment of Laboratory/Diagnostic Measures</Endpoint><SubEndpoints><SubEndpoint disease="Allergic rhinitis" id="14399">Genetic analysis</SubEndpoint></SubEndpoints></PrimaryEndpoint></PrimaryEndpoints><SecondaryEndpoints><SecondaryEndpoint disease="Asthma" id="5997"><Endpoint>Assessment of Inflammatory &amp; Oxidative Stress Markers</Endpoint><SubEndpoints><SubEndpoint disease="Asthma" id="6005">Assessment of exhaled nitric oxide</SubEndpoint></SubEndpoints></SecondaryEndpoint><SecondaryEndpoint disease="Asthma" id="6049"><Endpoint>Assessment of Laboratory/Diagnostic Measures</Endpoint><SubEndpoints><SubEndpoint disease="Asthma" id="6063">Assessment of urinary analysis</SubEndpoint></SubEndpoints></SecondaryEndpoint><SecondaryEndpoint disease="Asthma" id="6074"><Endpoint>Assessment of Therapy Related Outcomes</Endpoint><SubEndpoints><SubEndpoint disease="Asthma" id="6076">Asthma control</SubEndpoint></SubEndpoints></SecondaryEndpoint><SecondaryEndpoint disease="Allergic rhinitis" id="14368"><Endpoint>Assessment of Therapy Related Outcomes</Endpoint></SecondaryEndpoint><SecondaryEndpoint disease="Allergic rhinitis" id="14376"><Endpoint>Assessment of Inflammatory &amp; Oxidative Stress Markers</Endpoint></SecondaryEndpoint><SecondaryEndpoint disease="Allergic rhinitis" id="14385"><Endpoint>Assessment of Laboratory/Diagnostic Measures</Endpoint><SubEndpoints><SubEndpoint disease="Allergic rhinitis" id="14397">Assessment of urinary analysis</SubEndpoint></SubEndpoints></SecondaryEndpoint></SecondaryEndpoints></OutcomeMeasureTerms><EligibilityCriteriaTerms><InclusionCriteria><Inclusion disease="Asthma" id="2700"><Criterion>Subjects with Stable Asthma</Criterion></Inclusion><Inclusion disease="Asthma" id="2721"><Criterion>Subjects with Protocol Specified Symptom Scales/Scores</Criterion></Inclusion><Inclusion disease="Asthma" id="2837"><Criterion>Subjects with Co-morbid Conditions</Criterion></Inclusion><Inclusion disease="Asthma" id="4322"><Criterion>Subjects with Diagnosis of Asthma</Criterion></Inclusion><Inclusion disease="Allergic rhinitis" id="14516"><Criterion>Patient Diagnosed with Allergic Rhinitis Based on Positive Skin Prick Test</Criterion></Inclusion><Inclusion disease="Allergic rhinitis" id="14522"><Criterion>Patient Diagnosed with Allergic Rhinitis Based on Increased Serum Ig E Levels</Criterion></Inclusion><Inclusion disease="Allergic rhinitis" id="14524"><Criterion>Subjects with Symptomatic Disease</Criterion></Inclusion><Inclusion disease="Allergic rhinitis" id="14546"><Criterion>Subjects with Normal/Adequate Systemic and Physical Function Status</Criterion><SubCriteria><SubCriterion disease="Allergic rhinitis" id="14551">Based on lung function/forced expiratory volume in 1 second values</SubCriterion></SubCriteria></Inclusion></InclusionCriteria><ExclusionCriteria><Exclusion disease="Allergic rhinitis" id="11933"><Criterion>Subjects co-morbid with Respiratory Diseases/Disorders</Criterion><SubCriteria><SubCriterion disease="Allergic rhinitis" id="11935">Subjects co-morbid with asthma</SubCriterion></SubCriteria></Exclusion><Exclusion disease="Allergic rhinitis" id="11945"><Criterion>Subjects with Co-morbid Conditions</Criterion><SubCriteria><SubCriterion disease="Allergic rhinitis" id="11952">Subjects co-morbid with hematological disease/disorders</SubCriterion></SubCriteria></Exclusion><Exclusion disease="Allergic rhinitis" id="11957"><Criterion>Subjects with Hypersensitivity/Contraindications to Drugs/Excipients</Criterion></Exclusion><Exclusion disease="Allergic rhinitis" id="11960"><Criterion>Subjects with History of/Current Use of a Prohibited Medication</Criterion></Exclusion><Exclusion disease="Asthma" id="20244"><Criterion>Subjects co-morbid with Hematological/Coagulation Disorders</Criterion></Exclusion><Exclusion disease="Asthma" id="20245"><Criterion>Subjects co-morbid with infections</Criterion></Exclusion><Exclusion disease="Asthma" id="20247"><Criterion>Subjects with Co-morbid Conditions</Criterion></Exclusion><Exclusion disease="Asthma" id="20252"><Criterion>Subjects with Hypersensitivity/Contraindication to Device/Procedures</Criterion></Exclusion><Exclusion disease="Asthma" id="20255"><Criterion>Subjects with History of/Scheduled for Other Treatments</Criterion></Exclusion><Exclusion disease="Allergic rhinitis" id="28373"><Criterion>Subjects with history of respiratory disease/disorder</Criterion><SubCriteria><SubCriterion disease="Allergic rhinitis" id="11937">Subjects with history of nasal/paranasal disorders</SubCriterion></SubCriteria></Exclusion></ExclusionCriteria></EligibilityCriteriaTerms><PrimaryCompletionDate type="Actual">2016-12-14T00:00:00Z</PrimaryCompletionDate><DateEnrollmentEnd type="actual">2017-01-31T00:00:00Z</DateEnrollmentEnd><EnrollmentPeriod>53.03 Months</EnrollmentPeriod><EnrollmentRate>0.87 Patients/Month</EnrollmentRate><DateFirstReceived>2012-04-30T00:00:00Z</DateFirstReceived><FundersType><Type>Academic</Type></FundersType><ChangeHistory><Change type="added"><Date>2014-05-21T00:00:00Z</Date><Reason id="301">Clinical trial added</Reason></Change><Change type="updated"><Date>2017-01-11T00:00:00Z</Date><Reason id="302">Recruitment Status Changed</Reason></Change><Change type="updated"><Date>2018-05-31T00:00:00Z</Date><Reason id="302">Recruitment Status Changed</Reason></Change><Change type="added"><Date>2019-02-21T00:00:00Z</Date><Reason id="311">Trial Treatment added</Reason></Change><Change type="added"><Date>2019-02-21T00:00:00Z</Date><Reason id="311">Trial Treatment added</Reason></Change><Change type="added"><Date>2019-02-21T00:00:00Z</Date><Reason id="311">Trial Treatment added</Reason></Change><Change type="added"><Date>2019-02-21T00:00:00Z</Date><Reason id="316">Trial Outcome Measure Added</Reason></Change><Change type="added"><Date>2019-02-21T00:00:00Z</Date><Reason id="316">Trial Outcome Measure Added</Reason></Change><Change type="added"><Date>2019-02-21T00:00:00Z</Date><Reason id="316">Trial Outcome Measure Added</Reason></Change><Change type="added"><Date>2019-02-21T00:00:00Z</Date><Reason id="316">Trial Outcome Measure Added</Reason></Change><Change type="added"><Date>2019-02-21T00:00:00Z</Date><Reason id="320">Trial Biomarker Added</Reason></Change><Change type="added"><Date>2019-02-21T00:00:00Z</Date><Reason id="320">Trial Biomarker Added</Reason></Change><Change type="added"><Date>2019-02-21T00:00:00Z</Date><Reason id="320">Trial Biomarker Added</Reason></Change><Change type="added"><Date>2019-02-21T00:00:00Z</Date><Reason id="320">Trial Biomarker Added</Reason></Change></ChangeHistory></Trial><Trial id="189527"><TitleDisplay>Selective Internal Radiation Therapy (SIRT) in Patients With Unresectable Colorectal Cancer Liver Metastases Who Failed Prior Intra-arterial Pump Chemotherapy</TitleDisplay><TitleOfficial>Phase I Study of Selective Internal Radiation Therapy (SIRT) in Patients With Unresectable Colorectal Cancer Liver Metastases Who Failed Prior Intra-arterial Pump Chemotherapy</TitleOfficial><OutcomesAvailable>Yes</OutcomesAvailable><EndpointsAchieved>Unspecified</EndpointsAchieved><Identifiers><Identifier type="NCT">NCT00972036</Identifier><Identifier type="Organisational Study">09-030</Identifier></Identifiers><Indications><Indication id="3462">Metastatic liver cancer</Indication><Indication id="989">Colorectal tumor</Indication></Indications><BiomarkerNames></BiomarkerNames><InterventionsPrimaryByRegimen regimenType="single"><Interventions><Intervention type="InterventionPrimary"><Name>SIR-spheres (Selective Internal Radiation Therapy)</Name></Intervention></Interventions></InterventionsPrimaryByRegimen><InterventionsControlByRegimens></InterventionsControlByRegimens><DrugsAsInterventionPrimary></DrugsAsInterventionPrimary><CrossReferences><SourceEntity id="22122" type="Company"><TargetEntity id="4296508772" type="organizationId">Memorial Sloan-Kettering Cancer Center</TargetEntity></SourceEntity><SourceEntity id="30259" type="Company"><TargetEntity id="4295856752" type="organizationId">Sirtex Medical Ltd</TargetEntity></SourceEntity><SourceEntity id="3462" type="ciIndication"><TargetEntity id="10055110" type="MEDDRA"></TargetEntity></SourceEntity><SourceEntity id="989" type="ciIndication"><TargetEntity id="10061451" type="MEDDRA"></TargetEntity><TargetEntity id="D015179" type="MeSH"></TargetEntity><TargetEntity id="-1280257855" type="omicsDisease"></TargetEntity><TargetEntity id="594" type="siCondition"></TargetEntity></SourceEntity></CrossReferences><Phase>Phase 1 Clinical</Phase><RecruitmentStatus id="4">Completed</RecruitmentStatus><NumberOfSites>1</NumberOfSites><CompaniesSponsor><Company id="22122">Memorial Sloan-Kettering Cancer Center</Company></CompaniesSponsor><CompaniesCollaborator><Company id="30259">SIRTeX Medical Ltd</Company></CompaniesCollaborator><IsCommerciallySignificant>No</IsCommerciallySignificant><Technologies></Technologies><TermsPatientSelection><Term>Aged Adults (65-79 yrs)</Term><Term>Elderly Adults (80 and over)</Term><Term>Middle-aged Adults (45-64 yrs)</Term><Term>Young Adults (18-44 yrs)</Term></TermsPatientSelection><TrialCategories><Category>Medical device</Category></TrialCategories><TermsDesign><Term>Open Label</Term><Term>Treatment</Term><Term>Single Group Assignment</Term><Term>Interventional</Term></TermsDesign><TermsEndpoint><Term>Efficacy</Term><Term>Safety</Term></TermsEndpoint><PatientCountEnrollment>32</PatientCountEnrollment><PatientCountEvaluable>19</PatientCountEvaluable><DateStart>2009-08-31T00:00:00Z</DateStart><DateEnd type="actual">2014-12-31T00:00:00Z</DateEnd><DateChangeLast>2018-06-23T11:06:47Z</DateChangeLast><DateAdded>2014-05-23T00:00:00Z</DateAdded><Contacts><Contact type="Scientific contact"><Affiliation>Memorial Sloan Kettering Cancer Center</Affiliation><Name>Constantinos Sofocleous, MD, PhD</Name></Contact></Contacts><CriteriaInclusion>&lt;Inclusion&gt;&lt;ul&gt;&lt;li&gt;Histological confirmation of colorectal cancer&lt;/li&gt;&lt;li&gt;Unequivocal imaging of hepatic metastases&lt;/li&gt;&lt;li&gt;Dominant liver metastases (small amount extrahepatic disease allowed)&lt;/li&gt;&lt;li&gt;Unresectable liver metastases&lt;/li&gt;&lt;li&gt;Liver metastases non-eligible for, or progressed after ablation&lt;/li&gt;&lt;li&gt;Failed prior HAC&lt;/li&gt;&lt;li&gt;ECOG performance status 0 to 1&lt;/li&gt;&lt;li&gt;WBC&amp;gt;/=  1.5 x 10(9)/l&lt;/li&gt;&lt;li&gt;Platelets&amp;gt;/=  50 x 10(9)/l&lt;/li&gt;&lt;li&gt;Creatinine&amp;lt;/= 1.5 mg/dl&lt;/li&gt;&lt;li&gt;Bilirubin&amp;lt;/= 1.5 mg/dl&lt;/li&gt;&lt;li&gt;Age&amp;gt;/=  18 years&lt;/li&gt;&lt;li&gt;Female patients must either be postmenopausal, sterile (surgically or radiation- or chemically-induced), or if sexually active, must agree to use an acceptable method of contraception&lt;/li&gt;&lt;li&gt;Male patients must be surgically sterile, or if sexually active, must agree to use an acceptable method of contraception&lt;/li&gt;&lt;li&gt;Life expectancy of at least 3 months without any active treatment&lt;/li&gt;&lt;li&gt;No chemotherapy regimen administration for at least 4 weeks prior to SIRT administration&lt;/li&gt;&lt;/ul&gt;&lt;/Inclusion&gt;</CriteriaInclusion><CriteriaExclusion>&lt;Exclusion&gt;&lt;ul&gt;&lt;li&gt;Evidence of severe cirrhosis (CHILDS B and C), portal hypertension with gastroesophageal varices and liver failure as determined by clinical, radiological or laboratory assessment&lt;/li&gt;&lt;li&gt;Previous radiotherapy delivered to the liver&lt;/li&gt;&lt;li&gt;Pregnant or breast-feeding&lt;/li&gt;&lt;li&gt;Any of the following are contraindications to the use of Yttrium-90 microspheres, and are therefore exclusion criteria:&lt;ul&gt;&lt;li&gt;With a Tc-99m macroaggregated albumin (MAA) hepatic arterial perfusion scintigraphy that shows any disposition to the gastrointestinal tract that cannot be corrected by angiographic and embolization techniques&lt;/li&gt;&lt;li&gt;With &gt; 20% shunting of blood to the lungs as estimated in the Lung Scintigram performed after the intraarterial injection of Tc MAA. Radiation pneumonitis has been seen in patients receiving doses of Yttrium-90 &gt; 30 Gy in a single treatment. This corresponds to the shunt over 20% presence of vascular abnormalities, bleeding diathesis, making catheterization of the hepatic artery contraindication&lt;/li&gt;&lt;/ul&gt;&lt;/li&gt;&lt;/ul&gt;&lt;/Exclusion&gt;</CriteriaExclusion><MeasuresOutcome><MeasuresPrimary><Measure><Description>To determine the safety, toxicity, and maximum tolerated dose of SIR-Spheres in patients with unresectable metastatic colorectal cancer to the liver (CLM) who have received previous hepatic arterial infusion chemotherapy (HAC)</Description><Timeframe>Two years</Timeframe></Measure></MeasuresPrimary><MeasureSecondary><Measure><Description>To obtain preliminary evidence of any clinical efficacy of the SIRT therapy in these heavily pretreated patients with unresectable CLM who have received hepatic arterial infusion pump and have failed at least one line of prior chemotherapy</Description><Timeframe>Two years</Timeframe></Measure><Measure><Description>Liver progression-free survival (LPFS), progression-free survival (PFS) and overall survival (OS) were calculated using Kaplan-Meier methodology</Description></Measure></MeasureSecondary></MeasuresOutcome><ProtocolAndOutcomes><AdverseEvents>&lt;AdverseEvents&gt;&lt;para&gt;In March 2014, results were published. Grade 3 toxicity was observed in three patients (15%), within 6 weeks of SIRT. Radiation-induced liver disease was not reported. Among 19 patients, liver ablation was reported in 21.1% patients, after SIRT  [&lt;ulink linkType="Reference" linkID="1560867"&gt;1560867&lt;/ulink&gt;].&lt;/para&gt;&lt;/AdverseEvents&gt;</AdverseEvents><AimsAndScope>&lt;AimAndScope&gt;&lt;para&gt;This study was performed to evaluate the safety of Selective Internal Radiation Therapy (SIRT) in patients with liver only colorectal cancer metastases that have received hepatic arterial infusion pump and have progressed through at least one line of chemotherapy.&lt;/para&gt;&lt;/AimAndScope&gt;</AimsAndScope><Outcomes>&lt;Outcomes&gt;&lt;para&gt;In March 2014, results were published. It was observed that, 31.2 months was the median follow-up after SIRT. After 4 to 8 weeks and 3 to 4 months post SIRT, responses by RECIST, PERCIST and CEA were 0, 20, and 32% and 5, 33 and 21%, respectively. At 3 to 4 months, 53% of patients had stable disease. After SIRT, 5.2, 2.0 and 14.9 months were the median LPFS, PFS, and OS values respectively.  After SIRT, 47% patients received additional HAC and 89% patients received systemic chemotherapy [&lt;ulink linkType="Reference" linkID="1560867"&gt;1560867&lt;/ulink&gt;].&lt;/para&gt;&lt;/Outcomes&gt;</Outcomes><ProtocolDescription>&lt;ProtocolDescription&gt;&lt;para&gt;SIR-spheres would be administered at 70, 85 and 100% of the calculated individual patient dose (approximately 1 month prior to SIR-spheres administration). The first cohort would receive SIR spheres at 70% of the individually calculated patient dose, the second would receive 85% of the calculated patient dose, and the third would receive 100% of the calculated patient dose.&lt;/para&gt;&lt;/ProtocolDescription&gt;</ProtocolDescription><Regimens>&lt;Regimens&gt;&lt;para&gt;Patients received treatment with SIRT [&lt;ulink linkType="Reference" linkID="1560867"&gt;1560867&lt;/ulink&gt;].&lt;/para&gt;&lt;/Regimens&gt;</Regimens></ProtocolAndOutcomes><AdverseEventsByInterventions></AdverseEventsByInterventions><DoseRouteByInterventions></DoseRouteByInterventions><SitesByCountries><SitesByCountry country="US"><Sites><Site><Name>Memorial Sloan-Kettering Cancer Center 1275 York Avenue</Name><Address1>New York</Address1><Address2>New York</Address2><Address3>10065</Address3><CountrySubDivision code="NY">New York</CountrySubDivision><Contacts></Contacts></Site></Sites></SitesByCountry></SitesByCountries><PatientSegmentTerms><PatientSegmentByDisease><Disease>Colorectal tumor</Disease><PatientSegments><PatientSegment><PatientSegment id="3824">Subjects with TNM  stage IV/Metastatic/Advanced Colorectal Cancer</PatientSegment></PatientSegment><PatientSegment><PatientSegment id="3860">Subjects with Treatment Resistant Disease</PatientSegment><SubSegments><SubSegment id="3861">Subjects with chemotherapy resistant disease</SubSegment></SubSegments></PatientSegment></PatientSegments></PatientSegmentByDisease></PatientSegmentTerms><TrialRegistries><Registry><Name id="1000">NLM ClinicalTrials.gov</Name><Identifiers><Identifier type="NCT">NCT00972036</Identifier></Identifiers></Registry></TrialRegistries><OutcomeMeasureTerms><PrimaryEndpoints><PrimaryEndpoint disease="Colorectal tumor" id="8429"><Endpoint>Assessment of Safety and Tolerability</Endpoint><SubEndpoints><SubEndpoint disease="Colorectal tumor" id="9147">Assessment of toxicities</SubEndpoint></SubEndpoints></PrimaryEndpoint><PrimaryEndpoint disease="Colorectal tumor" id="8451"><Endpoint>Assessment of Pharmacokinetic/Pharmacodynamic Parameters</Endpoint></PrimaryEndpoint></PrimaryEndpoints><SecondaryEndpoints><SecondaryEndpoint disease="Colorectal tumor" id="8440"><Endpoint>Assessment of Therapy Related Outcomes</Endpoint><SubEndpoints><SubEndpoint disease="Colorectal tumor" id="8453">Efficacy/feasibility Assessment</SubEndpoint></SubEndpoints></SecondaryEndpoint></SecondaryEndpoints></OutcomeMeasureTerms><EligibilityCriteriaTerms><InclusionCriteria><Inclusion disease="Colorectal tumor" id="4483"><Criterion>Subjects with Advanced/Metastatic Cancer</Criterion></Inclusion><Inclusion disease="Colorectal tumor" id="4509"><Criterion>Subjects with Histologically Confirmed Colorectal Cancer</Criterion></Inclusion><Inclusion disease="Colorectal tumor" id="4518"><Criterion>Subjects with Unresectable Colorectal  Cancer</Criterion></Inclusion><Inclusion disease="Colorectal tumor" id="4519"><Criterion>Subjects with Protocol Specified Life Expectancy</Criterion><SubCriteria><SubCriterion disease="Colorectal tumor" id="4522">Subjects with life expectancy of three months or more</SubCriterion></SubCriteria></Inclusion><Inclusion disease="Colorectal tumor" id="4526"><Criterion>Subjects with Protocol Specified Performance Status </Criterion><SubCriteria><SubCriterion disease="Colorectal tumor" id="4527">Subjects with ECOG/WHO/Zubrod score performance status of 0</SubCriterion><SubCriterion disease="Colorectal tumor" id="4528">Subjects with ECOG/WHO/Zubrod score performance status of 1</SubCriterion></SubCriteria></Inclusion><Inclusion disease="Colorectal tumor" id="4544"><Criterion>Subjects with History of Anti Cancer Therapy</Criterion><SubCriteria><SubCriterion disease="Colorectal tumor" id="4545">Subjects with history of anti-cancer chemotherapy</SubCriterion></SubCriteria></Inclusion><Inclusion disease="Colorectal tumor" id="4558"><Criterion>Subjects with Treatment Resistant Disease</Criterion></Inclusion><Inclusion disease="Colorectal tumor" id="32554"><Criterion>Subjects with Normal/Acceptable Organ Function</Criterion><SubCriteria><SubCriterion disease="Colorectal tumor" id="4564">Subjects with normal/acceptable liver function</SubCriterion><SubCriterion disease="Colorectal tumor" id="4569">Subjects with normal/acceptable hematopoetic/marrow function</SubCriterion></SubCriteria></Inclusion><Inclusion disease="Colorectal tumor" id="33970"><Criterion>Subjects with Protocol Specified Renal Function</Criterion><SubCriteria><SubCriterion disease="Colorectal tumor" id="4565">Subjects with normal/acceptable renal function</SubCriterion></SubCriteria></Inclusion></InclusionCriteria><ExclusionCriteria><Exclusion disease="Colorectal tumor" id="5848"><Criterion>Subjects co-morbid with gastrointestinal diseases/disorders</Criterion></Exclusion><Exclusion disease="Colorectal tumor" id="5879"><Criterion>Subjects with Co-morbid Conditions</Criterion><SubCriteria><SubCriterion disease="Colorectal tumor" id="5886">Subjects co-morbid with hepatobiliary diseases/disorders</SubCriterion></SubCriteria></Exclusion><Exclusion disease="Colorectal tumor" id="5923"><Criterion>Subjects with Hypersensitivity/Contraindication to Device/Procedures</Criterion></Exclusion><Exclusion disease="Colorectal tumor" id="5949"><Criterion>Subjects with history of/scheduled to receive radiation therapy</Criterion></Exclusion><Exclusion disease="Colorectal tumor" id="26894"><Criterion>Subjects with History of/Scheduled to Receive Therapy</Criterion><SubCriteria><SubCriterion disease="Colorectal tumor" id="5934">Subjects with history of/scheduled for chemotherapy</SubCriterion></SubCriteria></Exclusion></ExclusionCriteria></EligibilityCriteriaTerms><PrimaryCompletionDate type="Actual">2014-12-31T00:00:00Z</PrimaryCompletionDate><DateEnrollmentEnd type="actual">2012-01-31T00:00:00Z</DateEnrollmentEnd><EnrollmentPeriod>29.03 Months</EnrollmentPeriod><EnrollmentRate>1.10 Patients/Month</EnrollmentRate><DateFirstReceived>2009-09-03T00:00:00Z</DateFirstReceived><FundersType><Type>Academic</Type><Type>Company</Type></FundersType><ChangeHistory><Change type="added"><Date>2014-05-23T00:00:00Z</Date><Reason id="301">Clinical trial added</Reason></Change><Change type="updated"><Date>2014-12-20T00:00:00Z</Date><Reason id="302">Recruitment Status Changed</Reason></Change></ChangeHistory></Trial><Trial id="195075"><TitleDisplay>Prevention of Pregnancy-associated Malaria in HIV-infected Women: Cotrimoxazole Prophylaxis Versus Mefloquine</TitleDisplay><TitleOfficial>Prevention of Pregnancy-associated Malaria in HIV-infected Women : Randomized-Controlled Trial Testing Cotrimoxazole Prophylaxis Versus Intermittent Preventive Treatment With Mefloquine</TitleOfficial><OutcomesAvailable>Yes</OutcomesAvailable><EndpointsAchieved>Unspecified</EndpointsAchieved><Identifiers><Identifier type="NCT">NCT00970879</Identifier><Identifier type="Organisational Study">IRD-SIDACTION-01</Identifier><Identifier type="Trial Acronym">PACOME</Identifier></Identifiers><Indications><Indication id="268">Plasmodium infection</Indication></Indications><BiomarkerNames></BiomarkerNames><InterventionsPrimaryByRegimen regimenType="single"><Interventions><Intervention type="InterventionPrimary"><Name>cotrimoxazole (sulfamethoxazole/trimethoprim)</Name></Intervention></Interventions></InterventionsPrimaryByRegimen><InterventionsPrimaryByRegimen regimenType="single"><Interventions><Intervention type="InterventionPrimary"><Name>mefloquine</Name></Intervention></Interventions></InterventionsPrimaryByRegimen><InterventionsPrimaryByRegimen regimenType="single"><Interventions><Intervention type="InterventionPrimary"><Name>mefloquine + cotrimoxazole (sulfamethoxazole/trimethoprim)</Name></Intervention></Interventions></InterventionsPrimaryByRegimen><InterventionsControlByRegimens></InterventionsControlByRegimens><DrugsAsInterventionPrimary></DrugsAsInterventionPrimary><CrossReferences><SourceEntity id="1026299" type="Company"><TargetEntity id="5037041091" type="organizationId">National University Hospital</TargetEntity></SourceEntity><SourceEntity id="1061556" type="Company"><TargetEntity id="5036351879" type="organizationId">Programme national de lutte contre le sida Benin</TargetEntity></SourceEntity><SourceEntity id="1061570" type="Company"><TargetEntity id="5035553260" type="organizationId">Polyclinique St Francois St Antoine SAS</TargetEntity></SourceEntity><SourceEntity id="1079074" type="Company"><TargetEntity id="5038067554" type="organizationId">Universite d'Abomey-Calavi</TargetEntity></SourceEntity><SourceEntity id="1085774" type="Company"><TargetEntity id="5040056046" type="organizationId">Sidaction</TargetEntity></SourceEntity><SourceEntity id="27038" type="Company"><TargetEntity id="5037638670" type="organizationId">Institut Recherche Pour Le Developpement</TargetEntity></SourceEntity><SourceEntity id="268" type="ciIndication"><TargetEntity id="10025487" type="MEDDRA"></TargetEntity><TargetEntity id="673" type="ORPHANET"></TargetEntity><TargetEntity id="-2144313480" type="omicsDisease"></TargetEntity><TargetEntity id="850" type="siCondition"></TargetEntity></SourceEntity></CrossReferences><Phase>Phase 3 Clinical</Phase><RecruitmentStatus id="4">Completed</RecruitmentStatus><NumberOfSites>5</NumberOfSites><CompaniesSponsor><Company id="27038">Institut de Recherche pour le Developpement (IRD)</Company></CompaniesSponsor><CompaniesCollaborator><Company id="1026299">National University Hospital</Company><Company id="1061556">Programme national de lutte contre le sida, Benin</Company><Company id="1061570">Hopital Saint-Antoine</Company><Company id="1079074">Université d'Abomey-Calavi</Company><Company id="1085774">Sidaction</Company></CompaniesCollaborator><IsCommerciallySignificant>No</IsCommerciallySignificant><Technologies></Technologies><TermsPatientSelection><Term>Aged Adults (65-79 yrs)</Term><Term>Elderly Adults (80 and over)</Term><Term>Middle-aged Adults (45-64 yrs)</Term><Term>Young Adults (18-44 yrs)</Term><Term>Female</Term></TermsPatientSelection><TrialCategories><Category>Small molecule</Category></TrialCategories><TermsDesign><Term>Randomized</Term><Term>Open Label</Term><Term>Prevention</Term><Term>Parallel Assignment</Term><Term>Interventional</Term></TermsDesign><TermsEndpoint><Term>Efficacy</Term><Term>Safety</Term></TermsEndpoint><PatientCountEnrollment>430</PatientCountEnrollment><PatientCountEvaluable>292</PatientCountEvaluable><DateStart>2009-12-31T00:00:00Z</DateStart><DateEnd type="actual">2012-12-31T00:00:00Z</DateEnd><DateChangeLast>2018-05-15T08:53:38Z</DateChangeLast><DateAdded>2014-09-10T00:00:00Z</DateAdded><Contacts><Contact type="Scientific contact"><Affiliation>Cotonou University Hospital &amp; Faculté des Sciences de la Santé, Benin</Affiliation><Name>Marcel D Zannou, Professor</Name></Contact><Contact type="Scientific contact"><Affiliation>Institut de Recherche pour le Developpement</Affiliation><Name>Michel Cot, MD, PHD</Name></Contact><Contact type="Scientific contact"><Affiliation>Saint Antoine Hospital, Assistance Publique-Hôpitaux se Paris</Affiliation><Name>Pierre-Marie Girard, Professor</Name></Contact><Contact type="Public contact"><Affiliation>Unviversity Hospital Hubert Koutoukou Maga; Cotonou; Benin</Affiliation><Email>jocen12@yahoo.fr</Email><Name>Jocelyn Akakpo</Name></Contact><Contact type="Public contact"><Affiliation>Unviversity Hospital Hubert Koutoukou Maga; Cotonou; Benin</Affiliation><Email>djmzannou@yahoo.fr</Email><Name>Marcel Zannou</Name></Contact><Contact type="Public contact"><Affiliation>Cotonou University Hospital and Faculte des Sciences de la Sante, Benin</Affiliation><Email>djmzannou@yahoo.fr</Email><Name>Marcel Zannou</Name></Contact><Contact type="Public contact"><Affiliation>Hopital d Instruction des Armees Camp Guezo; Cotonou; Benin</Affiliation><Name>Felix Atado-Kpede</Name></Contact><Contact type="Public contact"><Affiliation>Institut de Recherche pour le Developpement</Affiliation><Email>michel.cot@ird.fr</Email><Name>Michel Cot</Name><Phone>33153739621</Phone></Contact><Contact type="Public contact"><Affiliation>Clinique Louis Pasteur; Porto-Novo; Benin</Affiliation><Email>luciendo@intnet.bj</Email><Name>Lucien Dossou-Gbete</Name></Contact><Contact type="Public contact"><Affiliation>Saint Antoine Hospital, Assistance Publique-Hopitaux se Paris</Affiliation><Name>Pierre-Marie Girard</Name></Contact><Contact type="Public contact"><Affiliation>Hopital de la Mere et de l Enfant Lagune; Cotonou; Benin</Affiliation><Name>Komongui</Name></Contact></Contacts><CriteriaInclusion>&lt;Inclusion&gt;&lt;ul&gt;&lt;li&gt;Confirmed HIV seropositivity&lt;/li&gt;&lt;li&gt;Permanent residency in the study catchment's area&lt;/li&gt;&lt;li&gt;Confirmed pregnancy, gestational age&amp;lt; 28 weeks&lt;/li&gt;&lt;li&gt;More than 18 years of age&lt;/li&gt;&lt;li&gt;Karnofsky index &gt;/= 80&lt;/li&gt;&lt;li&gt;Willingness to deliver at the hospital&lt;/li&gt;&lt;li&gt;Written informed consent&lt;/li&gt;&lt;/ul&gt;&lt;/Inclusion&gt;</CriteriaInclusion><CriteriaExclusion>&lt;Exclusion&gt;&lt;ul&gt;&lt;li&gt;History of allergy to study drugs: sulpha drugs, mefloquine, quinine&lt;/li&gt;&lt;li&gt;History or presence of major illnesses : severe renal disease , severe hepatic disease, severe neuropsychiatric disease&lt;/li&gt;&lt;li&gt;Mefloquine or halofantrine received within the 4 weeks prior to enrolment&lt;/li&gt;&lt;/ul&gt;&lt;/Exclusion&gt;</CriteriaExclusion><MeasuresOutcome><MeasuresPrimary><Measure><Description>Proportion of placental malaria (presence of parasites in the placental blood smear at delivery)</Description><Timeframe>Delivery</Timeframe></Measure></MeasuresPrimary><MeasureSecondary><Measure><Description>Mother-to-child HIV transmission rate in each treatment arm</Description><Timeframe>2 months after breastfeeding cessation</Timeframe></Measure><Measure><Description>To document the effect of cotrimoxazole in reducing infections in HIV-infected women, the investigators will measure the incidence of bacterial and parasitic infections (other than malaria) during pregnancy</Description><Timeframe>Course of pregnancy</Timeframe></Measure><Measure><Description>Congenital anomalies</Description><Timeframe>First 6 months of life</Timeframe></Measure><Measure><Description>Cord blood malaria infection at delivery (infant parasitemia)</Description><Timeframe>Delivery</Timeframe></Measure><Measure><Description>Placental malaria mean parasite density at delivery</Description><Timeframe>Delivery</Timeframe></Measure><Measure><Description>Pre-term deliveries (&lt; 37 weeks)</Description><Timeframe>Delivery</Timeframe></Measure><Measure><Description>Proportion of low birth weight infants (&lt; 2500 g) and mean birth weight</Description><Timeframe>Delivery</Timeframe></Measure><Measure><Description>Proportion of maternal anemia (&lt; 11 g/dl) and severe maternal anemia (&lt; 8 g/dl) at delivery and during pregnancy</Description><Timeframe>Course of pregnancy and delivery</Timeframe></Measure><Measure><Description>Safety profile of the two treatments: proportion and detailed description of adverse effects in each treatment arm</Description><Timeframe>Course of pregnancy (mother) anf first 6 months of life (infant)</Timeframe></Measure><Measure><Description>Spontaneous abortions (early: &lt; 28 weeks, late: &gt;/= 28 weeks) and still births</Description><Timeframe>Course of pregnancy and delivery</Timeframe></Measure><Measure><Description>Microscopic placental parasitemia</Description></Measure></MeasureSecondary></MeasuresOutcome><ProtocolAndOutcomes><AdverseEvents>&lt;AdverseEvents&gt;&lt;para&gt;In September 2012, the results were published, the most frequent adverse reactions were dizziness and vomiting. In HIV-infected women (65% versus 78%, p = 0.009), the adverse reactions were less frequent [&lt;ulink linkType="Reference" linkID="1518221"&gt;1518221&lt;/ulink&gt;]. &lt;/para&gt;&lt;para&gt;In February 2014, results were published, dizziness and vomiting were the adverse events moderate intensity were reported by 34 to 37% of women receiving mefloquine versus 0 to 3% in cotrimoxazole (p &amp;lt; 0.0001). No serious adverse events related to these drugs were found [&lt;ulink linkType="Reference" linkID="1592626"&gt;1592626&lt;/ulink&gt;].&lt;/para&gt;&lt;/AdverseEvents&gt;</AdverseEvents><AimsAndScope>&lt;AimAndScope&gt;&lt;para&gt;The purpose of this study was to evaluate the efficacy of cotrimoxazole (sulfamethoxazole/trimethoprim)prophylaxis in      prevention of malaria during pregnancy in HIV-infected women, compared to intermittent      preventive treatment with mefloquine.&lt;/para&gt;&lt;/AimAndScope&gt;</AimsAndScope><Outcomes>&lt;Outcomes&gt;&lt;para&gt;In September 2012, the results were published, detectable viral load (odd ratio = 2.46), first intake versus further intakes (odd ratio = 5.26), older age (odd ratio = 2.46) and higher education level (odd ratio = 1.71) were increased the risk for adverse reactions, whereas HIV infection (odd ratio = 0.23) were decreased the risk in multilevel analysis [&lt;ulink linkType="Reference" linkID="1518221"&gt;1518221&lt;/ulink&gt;]. &lt;/para&gt;&lt;para&gt;In February 2014, results were published, at delivery, placental parasitemia was exhibited in one woman in each cotrimoxazole alone treatment group versus women receiving mefloquine. Noninferiority was demonstrated by cotrimoxazole alone in the cotrimoxazole mandatory trial. Compared with cotrimoxazole alone (zero out of 105 versus 5 out of 103, p = 0.03) polymerase chain reaction-detected placental parasitemia was markedly reduced in the cotrimoxazole + mefloquine group [&lt;ulink linkType="Reference" linkID="1592626"&gt;1592626&lt;/ulink&gt;].  &lt;/para&gt;&lt;/Outcomes&gt;</Outcomes><ProtocolDescription>&lt;ProtocolDescription&gt;&lt;para&gt;The investigators aim to evaluate the efficacy of cotrimoxazole prophylaxis in prevention of      malaria during pregnancy in HIV-infected women. The investigators postulate that      cotrimoxazole prophylaxis would not inferior to IPT in all women, unrelated to their CD4 cell      count. In the control arm, the investigators will use mefloquine as IPT. The safety and      efficacy of this drug have already been assessed in HIV-negative patients (NCT00274235).&lt;/para&gt;&lt;para&gt;Pregnant women      would be enrolled both in the Antenatal Care unit and in the infectious diseases unit of each      setting. All women would receive insecticide-treated bednets at enrolment. Randomization would      be stratified by hospital and CD4 cell count range. Women assigned to cotrimoxazole would      receive cotrimoxazole prophylaxis daily during all the course of pregnancy. Women assigned      to mefloquine IPT would receive mefloquine three times during pregnancy. Women randomized in      this arm and having a low CD4 cell count or an advanced HIV disease would also receive      cotrimoxazole prophylaxis in prevention of HIV/AIDS opportunistic infections. Drug efficacy      would be judged on the prevalence of placental malaria at delivery.&lt;/para&gt;&lt;para&gt;This study would be  contribute to updating the recommendations concerning the prevention of      malaria during pregnancy in HIV-infected women.&lt;/para&gt;&lt;para&gt;The study would be randomized into four arms:&lt;br/&gt;Arm 1 (cotrimoxazole [high]): patients would receive sulfamethoxazole/trimethoprim (800/160 mg ) daily, from 28 weeks of gestation until delivery.&lt;br/&gt;Arm 2 (mefloquine): patients would receive mefloquine 15 mg/kg tid, between 16 and 28 weeks, 24 and 32 weeks, then 28 and 36 weeks of pregnancy.&lt;br/&gt;Arm 3 (cotrimoxazole [low]): patients would receive sulfamethoxazole/trimethoprim (800/160 mg ) daily, from 28 weeks of gestation until delivery.&lt;br/&gt;Arm 4 (mefloquine + cotrimoxazole): patients would receive sulfamethoxazole/trimethoprim (800/160 mg ) daily, from 28 weeks of gestation until delivery + mefloquine 15 mg/kg tid, between 16 and 28 weeks, 24 and 32 weeks, then 28 and 36 weeks of pregnancy.&lt;/para&gt;&lt;/ProtocolDescription&gt;</ProtocolDescription><Regimens>&lt;Regimens&gt;&lt;para&gt;Patients received mefloquine at the dose of 15 mg/kg [&lt;ulink linkType="Reference" linkID="1518221"&gt;1518221&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;Patients received cotrimoxazole either or cotrimoxazole + mefloquine intermittent preventive treatment [&lt;ulink linkType="Reference" linkID="1592626"&gt;1592626&lt;/ulink&gt;].&lt;/para&gt;&lt;/Regimens&gt;</Regimens></ProtocolAndOutcomes><AdverseEventsByInterventions><AdverseEventsByIntervention><Intervention type="InterventionPrimary"><Name>mefloquine + cotrimoxazole (sulfamethoxazole/trimethoprim)</Name></Intervention><AdverseEvents><AdverseEvent><Indication id="110">Emesis</Indication></AdverseEvent><AdverseEvent><Indication id="3454">Dizziness</Indication></AdverseEvent></AdverseEvents></AdverseEventsByIntervention></AdverseEventsByInterventions><DoseRouteByInterventions><DoseRouteByIntervention><Intervention id="444936">mefloquine</Intervention><Treatments><Treatment><Dose>15 milligram/kg</Dose><Route></Route></Treatment></Treatments></DoseRouteByIntervention></DoseRouteByInterventions><SitesByCountries><SitesByCountry country="Benin"><Sites><Site><Name>Clinique Louis Pasteur</Name><Address1>Porto-Novo</Address1><Contacts></Contacts></Site><Site><Name>Hôpital d'Instruction des Armées Camp Guézo</Name><Address1>Cotonou</Address1><Contacts></Contacts></Site><Site><Name>Hôpital de la Mère et de l'Enfant Lagune</Name><Address1>Cotonou</Address1><Contacts></Contacts></Site><Site><Name>Hôpital de zone de Suru Lere</Name><Address1>Cotonou</Address1><Contacts></Contacts></Site><Site><Name>Unviversity Hospital Hubert Koutoukou Maga</Name><Address1>Cotonou</Address1><Contacts></Contacts></Site><Site><Name>Hopital d'Instruction des Armees Camp Guezo</Name><Address1>Cotonou</Address1><Contacts></Contacts></Site><Site><Name>Hopital de la Mere et de l'Enfant Lagune</Name><Address1>Cotonou</Address1><Contacts></Contacts></Site><Site><Name>Hopital de zone de Suru Lere</Name><Address1>Cotonou</Address1><Contacts></Contacts></Site></Sites></SitesByCountry></SitesByCountries><PatientSegmentTerms><PatientSegmentByDisease><Disease>HIV infection</Disease><PatientSegments><PatientSegment><PatientSegment id="7063">Pregnant Women with HIV Infection</PatientSegment></PatientSegment><PatientSegment><PatientSegment id="7085">Subjects with comorbid conditions</PatientSegment></PatientSegment></PatientSegments></PatientSegmentByDisease><PatientSegmentByDisease><Disease>Plasmodium infection</Disease><PatientSegments><PatientSegment><PatientSegment id="10415">Subjects with comorbid conditions</PatientSegment><SubSegments><SubSegment id="10416">Subjects co-morbid with HIV infection</SubSegment></SubSegments></PatientSegment><PatientSegment><PatientSegment id="10418">Pregnant Women</PatientSegment></PatientSegment></PatientSegments></PatientSegmentByDisease></PatientSegmentTerms><TrialRegistries><Registry><Name id="1000">NLM ClinicalTrials.gov</Name><Identifiers><Identifier type="NCT">NCT00970879</Identifier></Identifiers></Registry></TrialRegistries><OutcomeMeasureTerms><PrimaryEndpoints><PrimaryEndpoint disease="HIV infection" id="9235"><Endpoint>Assessment of Markers of Co-infection</Endpoint></PrimaryEndpoint><PrimaryEndpoint disease="Plasmodium infection" id="16467"><Endpoint>Assessment of Incidence of Malaria</Endpoint><SubEndpoints><SubEndpoint disease="Plasmodium infection" id="16472">Incidence/prevalence of placental malaria</SubEndpoint></SubEndpoints></PrimaryEndpoint></PrimaryEndpoints><SecondaryEndpoints><SecondaryEndpoint disease="HIV infection" id="9167"><Endpoint>Assessment of HIV Transmission</Endpoint><SubEndpoints><SubEndpoint disease="HIV infection" id="9168">Assessment of HIV transmission rates</SubEndpoint></SubEndpoints></SecondaryEndpoint><SecondaryEndpoint disease="HIV infection" id="9235"><Endpoint>Assessment of Markers of Co-infection</Endpoint></SecondaryEndpoint><SecondaryEndpoint disease="HIV infection" id="9239"><Endpoint>Hematological Assessments</Endpoint></SecondaryEndpoint><SecondaryEndpoint disease="HIV infection" id="9246"><Endpoint>Assessment of Safety and Tolerability</Endpoint><SubEndpoints><SubEndpoint disease="HIV infection" id="9247">Assessment of adverse events/serious adverse events</SubEndpoint></SubEndpoints></SecondaryEndpoint><SecondaryEndpoint disease="Plasmodium infection" id="16467"><Endpoint>Assessment of Incidence of Malaria</Endpoint><SubEndpoints><SubEndpoint disease="Plasmodium infection" id="16472">Incidence/prevalence of placental malaria</SubEndpoint></SubEndpoints></SecondaryEndpoint><SecondaryEndpoint disease="Plasmodium infection" id="16495"><Endpoint>Assessment of Safety and Tolerability</Endpoint></SecondaryEndpoint><SecondaryEndpoint disease="Plasmodium infection" id="16503"><Endpoint>Assessment of Pregnancy Related Outcomes</Endpoint><SubEndpoints><SubEndpoint disease="Plasmodium infection" id="16504">Birthweight</SubEndpoint><SubEndpoint disease="Plasmodium infection" id="16506">Abortions</SubEndpoint></SubEndpoints></SecondaryEndpoint><SecondaryEndpoint disease="Plasmodium infection" id="16512"><Endpoint>Hematological Assessments</Endpoint><SubEndpoints><SubEndpoint disease="Plasmodium infection" id="16513">Assessment of hemoglobin/iron levels</SubEndpoint></SubEndpoints></SecondaryEndpoint><SecondaryEndpoint disease="Plasmodium infection" id="16522"><Endpoint>Anthropometric Assessments</Endpoint></SecondaryEndpoint></SecondaryEndpoints></OutcomeMeasureTerms><EligibilityCriteriaTerms><InclusionCriteria><Inclusion disease="HIV infection" id="5278"><Criterion>Subjects with HIV Infection</Criterion><SubCriteria><SubCriterion disease="HIV infection" id="6173">Pregnant women with HIV infection</SubCriterion></SubCriteria></Inclusion><Inclusion disease="HIV infection" id="5311"><Criterion>Subjects with Specific HIV Test Results</Criterion><SubCriteria><SubCriterion disease="HIV infection" id="6176">Subjects with positive HIV infection test</SubCriterion></SubCriteria></Inclusion><Inclusion disease="Plasmodium infection" id="15459"><Criterion>Immunocompromised Subjects</Criterion><SubCriteria><SubCriterion disease="Plasmodium infection" id="15460">Subjects immunocompromised with HIV infection</SubCriterion></SubCriteria></Inclusion><Inclusion disease="Plasmodium infection" id="34947"><Criterion>Subjects with Protocol Specified Reproductive Status</Criterion><SubCriteria><SubCriterion disease="Plasmodium infection" id="15464">Pregnant Women</SubCriterion></SubCriteria></Inclusion></InclusionCriteria><ExclusionCriteria><Exclusion disease="HIV infection" id="6829"><Criterion>Subjects co-morbid with CNS disorders</Criterion></Exclusion><Exclusion disease="HIV infection" id="6834"><Criterion>Subjects co-morbid with Psychiatric Disease/Disorder</Criterion></Exclusion><Exclusion disease="HIV infection" id="6843"><Criterion>Subjects with Co-morbid Conditions</Criterion><SubCriteria><SubCriterion disease="HIV infection" id="6845">Subjects co-morbid with hepatobiliary diseases/disorders</SubCriterion></SubCriteria></Exclusion><Exclusion disease="HIV infection" id="6848"><Criterion>Subjects co-morbid with renal disease/disorder</Criterion></Exclusion><Exclusion disease="HIV infection" id="6866"><Criterion>Subjects with Hypersensitivity/Contraindications to Drugs/Excipients</Criterion><SubCriteria><SubCriterion disease="HIV infection" id="6941">Hypersensitivity/Contraindications to study medications or its excipients</SubCriterion></SubCriteria></Exclusion><Exclusion disease="Plasmodium infection" id="12850"><Criterion>Subjects co-morbid with Psychiatric Disease/Disorder</Criterion></Exclusion><Exclusion disease="Plasmodium infection" id="12853"><Criterion>Subjects co-morbid with hepatobiliary disorders/diseases</Criterion></Exclusion><Exclusion disease="Plasmodium infection" id="12855"><Criterion>Subjects co-morbid with renal disease/disorder</Criterion></Exclusion><Exclusion disease="Plasmodium infection" id="12860"><Criterion>Subjects scheduled to receive disease specific therapy</Criterion></Exclusion><Exclusion disease="Plasmodium infection" id="12863"><Criterion>Subjects with Hypersensitivity/Contraindications to Drugs/Excipients</Criterion></Exclusion></ExclusionCriteria></EligibilityCriteriaTerms><PrimaryCompletionDate type="Actual">2012-07-31T00:00:00Z</PrimaryCompletionDate><DateEnrollmentEnd type="actual">2012-02-29T00:00:00Z</DateEnrollmentEnd><EnrollmentPeriod>26.03 Months</EnrollmentPeriod><EnrollmentRate>16.52 Patients/Month</EnrollmentRate><DateFirstReceived>2009-09-02T00:00:00Z</DateFirstReceived><FundersType><Type>Academic</Type></FundersType><ChangeHistory><Change type="added"><Date>2014-09-10T00:00:00Z</Date><Reason id="301">Clinical trial added</Reason></Change></ChangeHistory></Trial><Trial id="201257"><TitleDisplay>Preventing Cholestasis Using Smoflipid</TitleDisplay><TitleOfficial>Preventing Cholestasis in Premature Infants Using Smoflipid</TitleOfficial><OutcomesAvailable>No</OutcomesAvailable><EndpointsAchieved>Unknown</EndpointsAchieved><Identifiers><Identifier type="NCT">NCT01585935</Identifier><Identifier type="Secondary Organisational">2011-005456-33</Identifier><Identifier type="Organisational Study">MUV-NEO2</Identifier></Identifiers><Indications><Indication id="2217">Cholestasis</Indication></Indications><BiomarkerNames><BiomarkerName id="2387" role="Therapeutic effect marker" type="Biochemical">Bilirubin</BiomarkerName><BiomarkerName id="46725" role="Therapeutic effect marker" type="Physiological">Visual evoked potentials</BiomarkerName></BiomarkerNames><InterventionsPrimaryByRegimen regimenType="single"><Interventions><Intervention type="InterventionPrimary"><Name>Smoflipid, Medical University of Vienna</Name></Intervention></Interventions></InterventionsPrimaryByRegimen><InterventionsControlByRegimens><InterventionsControlByRegimen regimenType="single"><Interventions><Intervention type="InterventionControl"><Name>Intralipid</Name></Intervention></Interventions></InterventionsControlByRegimen></InterventionsControlByRegimens><DrugsAsInterventionPrimary></DrugsAsInterventionPrimary><CrossReferences><SourceEntity id="1015721" type="Company"><TargetEntity id="5035524798" type="organizationId">Medical University of Vienna</TargetEntity></SourceEntity><SourceEntity id="2217" type="ciIndication"><TargetEntity id="10008635" type="MEDDRA"></TargetEntity><TargetEntity id="D002779" type="MeSH"></TargetEntity><TargetEntity id="-69196619" type="omicsDisease"></TargetEntity><TargetEntity id="439" type="siCondition"></TargetEntity></SourceEntity></CrossReferences><Phase>Phase 4 Clinical</Phase><RecruitmentStatus id="4">Completed</RecruitmentStatus><NumberOfSites>1</NumberOfSites><CompaniesSponsor><Company id="1015721">Medical University of Vienna</Company></CompaniesSponsor><CompaniesCollaborator></CompaniesCollaborator><IsCommerciallySignificant>No</IsCommerciallySignificant><Technologies></Technologies><TermsPatientSelection><Term>Newborn Infants (up to 5 months)</Term></TermsPatientSelection><TrialCategories><Category>Borderline product</Category></TrialCategories><TermsDesign><Term>Randomized</Term><Term>Active Control</Term><Term>Multiple Blind</Term><Term>Prevention</Term><Term>Parallel Assignment</Term><Term>Interventional</Term></TermsDesign><TermsEndpoint><Term>Efficacy</Term><Term>Safety</Term></TermsEndpoint><PatientCountEnrollment>230</PatientCountEnrollment><DateStart>2012-01-26T00:00:00Z</DateStart><DateEnd type="actual">2017-11-13T00:00:00Z</DateEnd><DateChangeLast>2019-05-03T07:12:27Z</DateChangeLast><DateAdded>2014-07-02T00:00:00Z</DateAdded><Contacts><Contact type="Public contact"><Affiliation>With. Univ. Vienna</Affiliation><Email>andreas.repa@meduniwien.ac.at</Email><Name>Repa</Name></Contact><Contact type="Scientific contact"><Affiliation>Medical University Vienna</Affiliation><Name>Andreas Repa</Name></Contact><Contact type="Scientific contact"><Affiliation>Medical University Vienna</Affiliation><Name>Nadja Haiden</Name></Contact></Contacts><CriteriaInclusion>&lt;Inclusion&gt;&lt;ul&gt;&lt;li&gt;Birth weight&amp;lt;/= 1000 g&lt;/li&gt;&lt;li&gt;Admission to the neonatal ward in the first 24 h of life&lt;/li&gt;&lt;li&gt;Informed consent and randomization in the first 5 days of life&lt;/li&gt;&lt;/ul&gt;&lt;/Inclusion&gt;</CriteriaInclusion><CriteriaExclusion>&lt;Exclusion&gt;&lt;ul&gt;&lt;li&gt;Triplets or higher&lt;/li&gt;&lt;li&gt;Conjugated bilirubin&amp;gt; 1.5 mg/dl before inclusion to the study&lt;/li&gt;&lt;li&gt;Conditions associated with cholestasis independent of parenteral nutrition, ie, inborn errors of metabolism, viral infections (cytomegaly virus, HIV, Hep B, Hep C), immune mediated hemolytic disease (Rhesus incompatibility), cystic fibrosis and any other primary cholestatic disease&lt;/li&gt;&lt;li&gt;Congenital neurological malformations for secondary outcome&lt;/li&gt;&lt;/ul&gt;&lt;/Exclusion&gt;</CriteriaExclusion><MeasuresOutcome><MeasuresPrimary><Measure><Description>ELBW infants are at high risk for development of incidence of parenteral nutrition associated cholestasis (PNAC). There is growing evidence for a positive effect of fish oil based intravenous lipid emulsions (ILE) for the treatment of PNAC. Primary use of a fish oil containing ILE for PN may prevent the development of PNAC: PNAC definition: two consecutive conjugated bilirubin measurements &gt; 1.5 mg/dl</Description><Timeframe>Subjects will be followed for the duration of hospital stay (expected average 14 weeks); as long as parenteral nutrition is needed</Timeframe></Measure></MeasuresPrimary><MeasureSecondary><Measure><Description>Brain maturational scores assessed by amplitude integrated EEG (aEEG): aEEG measurements of study infants performed as a part of clinical routine (as specified in the trial study protocol v 1.0 to 1.3)</Description><Timeframe>Subjects will be followed for the duration of hospital stay (expected average 14 weeks)</Timeframe></Measure><Measure><Description>Visual Evoked Potentials (VEP): VEP measurements of study infants performed as a part of clinical routine (as specified in the trial study protocol v 1.0 to 1.3)</Description><Timeframe>Subjects will be followed for the duration of hospital stay (expected average 14 weeks)</Timeframe></Measure><Measure><Description>ELBW infants accumulate a deficit of omega-3-LC-PUFA (especially DHA), which are important for neurodevelopment. An ILE containing fish oil provides these fatty acids and would reduce the deficit in ELBW infants, which may improve their neurocognitive development</Description><Timeframe>12 to 24 month</Timeframe></Measure><Measure><Description>Bailey scales of infant development III: cognitive, motor and language development</Description><Timeframe>At 12 and 24 months corrected gestational age</Timeframe></Measure></MeasureSecondary></MeasuresOutcome><ProtocolAndOutcomes><AimsAndScope>&lt;AimAndScope&gt;&lt;para&gt;The study was aimed to evaluate the fish oil containing Intravenous lipid emulsion (ILE) 'Smoflipid' for its protective      effect against PNAC in ELBW infants compared to standard treatment with the soy bean based      ILE 'Intralipid'. Furthermore neurodevelopment at 12 and 24 months of corrected gestational      age would be investigated. Hypothesis: the use of a mixed lipid emulsion containing fish oil (Smoflipid) would reduce      the incidence of PNAC compared to a standard soy bean oil based lipid emulsion.&lt;/para&gt;&lt;para&gt;Main objective:&lt;br/&gt;To compare a mixed parenteral lipid emulsion containing fish oil (SMOFlipid) with a soybean oil based lipid emulsion (Intralipid) for its effect on the occurrence of parenteral nutrition associated cholestasis in extremely low birth weight infants.&lt;br/&gt;Secondary objective: to assess the impact of SMOFLipid on the long term neurocognitive development of extreme low birth weight infants at 12 and 24 months of corrected age.&lt;/para&gt;&lt;/AimAndScope&gt;</AimsAndScope><ProtocolDescription>&lt;ProtocolDescription&gt;&lt;para&gt;Study design:this would be  Double-blind, prospective, randomized trial.&lt;br/&gt;Primary Outcome: PNAC defined as two conjugated bilirubin &amp;gt; 1.5 mg/dl measurements on           two consecutive occasions.&lt;br/&gt;Secondary Outcome: The most important secondary outcome would be neurodevelopment at 12 and           24 months of corrected age.&lt;br/&gt;Exploratory Outcomes: Brain maturation measured by amplitude integrated EEG (aEEG) and flashed visual evoked potentials as available from clinical routine examinations.&lt;/para&gt;&lt;para&gt;Subjects would  receive eiether Smoflipid or Intralipid 3 g/kg/day.&lt;/para&gt;&lt;/ProtocolDescription&gt;</ProtocolDescription></ProtocolAndOutcomes><AdverseEventsByInterventions></AdverseEventsByInterventions><DoseRouteByInterventions></DoseRouteByInterventions><SitesByCountries><SitesByCountry country="Austria"><Sites><Site><Name>Medical University Vienna</Name><Address1>Vienna</Address1><Address3>1090</Address3><Contacts></Contacts></Site></Sites></SitesByCountry></SitesByCountries><PatientSegmentTerms></PatientSegmentTerms><TrialRegistries><Registry><Name id="1000">NLM ClinicalTrials.gov</Name><Identifiers><Identifier type="NCT">NCT01585935</Identifier></Identifiers></Registry><Registry><Name id="1001">European Clinical Trials Database (EudraCT)</Name><Identifiers><Identifier type="Secondary Organisational">2011-005456-33</Identifier></Identifiers></Registry></TrialRegistries><OutcomeMeasureTerms></OutcomeMeasureTerms><PrimaryCompletionDate type="Actual">2015-06-30T00:00:00Z</PrimaryCompletionDate><DateEnrollmentEnd type="actual">2015-07-31T00:00:00Z</DateEnrollmentEnd><EnrollmentPeriod>42.19 Months</EnrollmentPeriod><EnrollmentRate>5.45 Patients/Month</EnrollmentRate><DateFirstReceived>2012-04-16T00:00:00Z</DateFirstReceived><FundersType><Type>Academic</Type></FundersType><ChangeHistory><Change type="added"><Date>2014-07-02T00:00:00Z</Date><Reason id="301">Clinical trial added</Reason></Change><Change type="updated"><Date>2015-08-01T00:00:00Z</Date><Reason id="302">Recruitment Status Changed</Reason></Change><Change type="updated"><Date>2017-11-27T00:00:00Z</Date><Reason id="302">Recruitment Status Changed</Reason></Change><Change type="updated"><Date>2019-05-03T00:00:00Z</Date><Reason id="310">Protocol &amp; Results section updates</Reason></Change><Change type="added"><Date>2019-05-03T00:00:00Z</Date><Reason id="316">Trial Outcome Measure Added</Reason></Change></ChangeHistory></Trial><Trial id="20744"><TitleDisplay>ARC-1779 Injection in Patients With Von Willebrand Factor-Related Platelet Function Disorders</TitleDisplay><TitleOfficial>A Phase II Pilot Study of the Safety, Pharmacokinetics, and Pharmacodynamics of ARC-1779 Injection in Patients With Von Willebrand Factor-Related Platelet Function Disorders</TitleOfficial><OutcomesAvailable>Yes</OutcomesAvailable><EndpointsAchieved>Yes</EndpointsAchieved><Identifiers><Identifier type="Organisational Study">ARC1779-004</Identifier><Identifier type="NCT">NCT00632242</Identifier><Identifier type="Other">2007-004371-19</Identifier><Identifier type="Other">ISRCTN28462186</Identifier></Identifiers><Indications><Indication id="1133">Thrombocytopenic purpura</Indication><Indication id="1229">Von Willebrands disease</Indication></Indications><BiomarkerNames><BiomarkerName id="121" role="Disease marker" type="Genomic;Proteomic">von Willebrand factor</BiomarkerName></BiomarkerNames><InterventionsPrimaryByRegimen regimenType="single"><Interventions><Intervention type="InterventionPrimary"><Name>desmopressin</Name></Intervention></Interventions></InterventionsPrimaryByRegimen><InterventionsPrimaryByRegimen regimenType="single"><Interventions><Intervention type="InterventionPrimary"><Name>egaptivon pegol</Name><Drug id="54136">egaptivon pegol</Drug></Intervention></Interventions></InterventionsPrimaryByRegimen><InterventionsPrimaryByRegimen regimenType="duo"><Interventions><Intervention type="InterventionPrimary"><Name>desmopressin</Name></Intervention><Intervention type="InterventionPrimary"><Name>egaptivon pegol</Name><Drug id="54136">egaptivon pegol</Drug></Intervention></Interventions></InterventionsPrimaryByRegimen><InterventionsControlByRegimens></InterventionsControlByRegimens><DrugsAsInterventionPrimary><DrugAsInterventionPrimary><Drug id="54136">egaptivon pegol</Drug><IndicationsPioneer><Indication id="1133">Thrombocytopenic purpura</Indication><Indication id="1229">Von Willebrands disease</Indication></IndicationsPioneer><Companies><Company><Company id="29137">Archemix Corp</Company><RelationshipDirect>FORMER</RelationshipDirect><RelationshipInDirect>NONE</RelationshipInDirect></Company></Companies></DrugAsInterventionPrimary><DrugAsInterventionPrimary><Drug id="54136">egaptivon pegol</Drug><IndicationsPioneer><Indication id="1133">Thrombocytopenic purpura</Indication><Indication id="1229">Von Willebrands disease</Indication></IndicationsPioneer><Companies><Company><Company id="29137">Archemix Corp</Company><RelationshipDirect>FORMER</RelationshipDirect><RelationshipInDirect>NONE</RelationshipInDirect></Company></Companies></DrugAsInterventionPrimary></DrugsAsInterventionPrimary><CrossReferences><SourceEntity id="54136" type="Drug"><TargetEntity id="441291" type="siDrug">Egaptivon pegol</TargetEntity><TargetEntity id="441291" type="siDrug">Egaptivon pegol</TargetEntity></SourceEntity><SourceEntity id="29137" type="Company"><TargetEntity id="4298004487" type="organizationId">Archemix Corp</TargetEntity></SourceEntity><SourceEntity id="1133" type="ciIndication"><TargetEntity id="10043561" type="MEDDRA"></TargetEntity><TargetEntity id="D011697" type="MeSH"></TargetEntity><TargetEntity id="-241656606" type="omicsDisease"></TargetEntity><TargetEntity id="1491" type="siCondition"></TargetEntity></SourceEntity><SourceEntity id="1229" type="ciIndication"><TargetEntity id="D68.0" type="ICD10"></TargetEntity><TargetEntity id="286.4" type="ICD9"></TargetEntity><TargetEntity id="10047715" type="MEDDRA"></TargetEntity><TargetEntity id="D014842" type="MeSH"></TargetEntity><TargetEntity id="903" type="ORPHANET"></TargetEntity><TargetEntity id="-674998300" type="omicsDisease"></TargetEntity><TargetEntity id="1178" type="siCondition"></TargetEntity></SourceEntity></CrossReferences><Phase>Phase 2 Clinical</Phase><RecruitmentStatus id="4">Completed</RecruitmentStatus><NumberOfSites>2</NumberOfSites><CompaniesSponsor><Company id="29137">Archemix Corp</Company></CompaniesSponsor><CompaniesCollaborator></CompaniesCollaborator><IsCommerciallySignificant>No</IsCommerciallySignificant><ActionsPrimaryInterventionsPrimary><Action id="59980">von Willebrand factor A domain 1 inhibitor</Action></ActionsPrimaryInterventionsPrimary><Class><Class id="659">Coagulation inhibitor</Class></Class><Technologies><Technology id="761">Biological therapeutic</Technology><Technology id="740">Infusion</Technology><Technology id="648">Intravenous formulation</Technology><Technology id="103">Oligonucleotide</Technology><Technology id="348">PEGylated formulation</Technology></Technologies><TermsPatientSelection><Term>Aged Adults (65-79 yrs)</Term><Term>Middle-aged Adults (45-64 yrs)</Term><Term>Young Adults (18-44 yrs)</Term></TermsPatientSelection><TrialCategories><Category>Biological</Category></TrialCategories><TermsDesign><Term>Non-Randomized</Term><Term>Open Label</Term><Term>Treatment</Term><Term>Single Group Assignment</Term><Term>Interventional</Term></TermsDesign><TermsEndpoint><Term>Efficacy</Term><Term>Pharmacodynamics</Term><Term>Pharmacokinetics</Term><Term>Safety</Term></TermsEndpoint><PatientCountEnrollment>28</PatientCountEnrollment><PatientCountEvaluable>20</PatientCountEvaluable><DateStart>2008-01-31T00:00:00Z</DateStart><DateEnd type="actual">2008-12-31T00:00:00Z</DateEnd><DateChangeLast>2019-02-11T06:45:55Z</DateChangeLast><DateAdded>2008-07-21T14:18:49Z</DateAdded><Contacts><Contact type="Scientific contact"><Name>Dr Gilbert</Name></Contact></Contacts><CriteriaInclusion>&lt;Inclusion&gt;&lt;ul&gt;&lt;li&gt;Male or female aged between 18 to 75 years&lt;/li&gt;&lt;li&gt; vWD-2b - confirmed diagnosis or&lt;/li&gt;&lt;li&gt;TTP remission - prior episode(s) of primary acute TTP, or&lt;/li&gt;&lt;li&gt;Acute TTP - any episode, first or relapse, with presence of all of the following:&lt;ul&gt;&lt;li&gt;Microangiopathic hemolytic anemia (schistocytosis present, Coombs test
                  negative)&lt;/li&gt;&lt;li&gt;Severe thrombocytopenia&lt;/li&gt;&lt;/ul&gt;&lt;/li&gt;&lt;li&gt;Clinical diagnosis of either a primary or secondary form of TTP:&lt;ul&gt;&lt;li&gt;Primary TTP:
                  eg, familial TTP (Upshaw-Schulman syndrome), or acquired idiopathic TTP&lt;/li&gt;&lt;li&gt;Secondary TTP:  eg, TTP occurring post-bone marrow
                  transplant, drug-induced TTP, lupus-related TTP&lt;/li&gt;&lt;/ul&gt;&lt;/li&gt;&lt;li&gt;Negative qualitative urine drug test at screening, and no history of alcohol or drug
             abuse&lt;/li&gt;&lt;li&gt;Not considering or scheduled to undergo any surgical procedure during the duration of
             the study&lt;/li&gt;&lt;li&gt;Has not donated or lost more than a unit of blood within 30 days prior to screening
             visit&lt;/li&gt;&lt;li&gt;Has not received an experimental drug within 30 days prior to screening&lt;/li&gt;&lt;li&gt;Female patients must be non-pregnant (for TTP remission and vWD-2b cohorts, a serum
             pregnancy test at screening and a urine pregnancy test at day-1 pre-dose must be
             negative; for the acute TTP Cohort, a serum pregnancy test at day-1 pre-dose must be
             negative), and willing to use effective, redundant methods of contraception (ie, for
             both self and male partner) throughout the study and for at least 30 days after
             participation.  If possible, the treatment will be initiated within 5 days of the
             cessation of the preceding menstrual period&lt;/li&gt;&lt;li&gt;Male patients must agree to use a medically acceptable contraceptive (abstinence or
             use of a condom with spermicide) throughout the study and for at least 30 days after
             participation&lt;/li&gt;&lt;li&gt;Patients must be capable of understanding and complying with the protocol and must
             have signed the informed consent document prior to performance of any study-related
             procedures&lt;/li&gt;&lt;/ul&gt;&lt;/Inclusion&gt;</CriteriaInclusion><CriteriaExclusion>&lt;Exclusion&gt;&lt;ul&gt;&lt;li&gt;History of recent surgery or trauma&lt;/li&gt;&lt;li&gt;Any major, active health problem, eg, cancer or heart disease, which could render
             the patient medically unstable during the period of participation in the study&lt;/li&gt;&lt;/ul&gt;&lt;/Exclusion&gt;</CriteriaExclusion><MeasuresOutcome><MeasuresPrimary><Measure><Description>To establish the overall safety and tolerability of ARC-1779 in three varieties of von Willebrand Factor (vWF)-related platelet function disorders</Description><Timeframe>28 days</Timeframe></Measure></MeasuresPrimary><MeasureSecondary><Measure><Description>To characterize the pharmacokinetic (PK) profile of ARC-1779 intravenous infusion in patient groups</Description><Timeframe>28 days</Timeframe></Measure><Measure><Description>To characterize the pharmacodynamic (PD) profile of ARC-1779 in patients with vWF-related platelet function disorders with respect to parameters of platelet function and vWF activity</Description><Timeframe>28 days</Timeframe></Measure><Measure><Description>To assess the concentration- and dose-response relationships among ARC-1779 PK and PD parameters</Description><Timeframe>28 days</Timeframe></Measure></MeasureSecondary></MeasuresOutcome><ProtocolAndOutcomes><AdverseEvents>&lt;AdverseEvents&gt;&lt;para&gt;In March 2011, results were published. &lt;ulink linkType="Drug" linkID="54136"&gt;ARC-1779&lt;/ulink&gt; was generally well tolerated without any signs of bleeding. Pharmacokinetics and pharmacodynamics of &lt;ulink linkType="Drug" linkID="54136"&gt;ARC-1779&lt;/ulink&gt; were well predictable and in agreement with those observed in a previous trial with healthy volunteers  [&lt;ulink linkType="Reference" linkID="1526964"&gt;1526964&lt;/ulink&gt;].&lt;/para&gt;&lt;/AdverseEvents&gt;</AdverseEvents><AimsAndScope>&lt;AimAndScope&gt;&lt;para&gt;The purpose of this study was  to evaluate the overall safety and tolerability of &lt;ulink linkType="Drug" linkID="54136"&gt;ARC-1779&lt;/ulink&gt;, a therapeutic oligonucleotide
       in patients with three types of von Willebrand Factor (vWD-2b) related platelet
      disorders.&lt;/para&gt;&lt;/AimAndScope&gt;</AimsAndScope><Outcomes>&lt;Outcomes&gt;&lt;para&gt;In December 2008, results were presented for two of the cohorts. In cohort 3, median plasma concentrations of the drug of approximately 10 microg/ml were reached under steady state. More than 95% of inhibition of collagen binding site of vWF A1 domain was reported, while plasma exchange (PEX) removed 50% of drug from blood. Platelet counts in all patients normalized with concurrent treatment with &lt;ulink linkType="Drug" linkID="54136"&gt;ARC-1779&lt;/ulink&gt; and PEX which was 2 and 6 days after initiation of &lt;ulink linkType="Drug" linkID="54136"&gt;ARC-1779&lt;/ulink&gt; in two patients, and the third patient. In the third patient, &lt;ulink linkType="Drug" linkID="54136"&gt;ARC-1779&lt;/ulink&gt; was reported to restore platelet counts, and thus interfered with the disease process. When PEX was stopped the platelet counts reached 125/nl, with 4 more days of therapy the platelet counts increased to 260/nl. Discontinuation of  &lt;ulink linkType="Drug" linkID="54136"&gt;ARC-1779&lt;/ulink&gt; infusion was reported to be associated with an immediate drop in platelet counts, so that PEX had to be restarted after 2 days. &lt;ulink linkType="Drug" linkID="54136"&gt;ARC-1779&lt;/ulink&gt; was well tolerated without any evidence of bleeding in the patients [&lt;ulink linkType="Reference" linkID="967648"&gt;967648&lt;/ulink&gt;]. &lt;/para&gt;&lt;para&gt;In vWD-type2b cohort, the plasma concentration of &lt;ulink linkType="Drug" linkID="54136"&gt;ARC-1779&lt;/ulink&gt; was increased  4 to 5 microg/ml after infusion of &lt;ulink linkType="Drug" linkID="54136"&gt;ARC-1779&lt;/ulink&gt;, also there was a decrease in vWF activity to &amp;lt; 3%. There was an increase in vWF : Ag and vWF : RiCo (within 30 min) in the desmopressin alone treated group with also a decrease in the platelet counts by 87%. The &lt;ulink linkType="Drug" linkID="54136"&gt;ARC-1779&lt;/ulink&gt; treated group showed a substantial increase in vWF : Ag, vWF : RiCO and FVIII which lasted longer, there was an increase in all parameters slowly over time observed in the &lt;ulink linkType="Drug" linkID="54136"&gt;ARC-1779&lt;/ulink&gt; alone treated population [&lt;ulink linkType="Reference" linkID="967956"&gt;967956&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;Results were published in September 2010. &lt;ulink linkType="Drug" linkID="54136"&gt;ARC-1779&lt;/ulink&gt; concentrations in the range of 1 to 3 microg/ml blocked free A1 domain binding sites by 90% in vitro. In vivo, desmopressin alone induced a profound (-90%) drop in platelet counts in one of the patients. Treatment with &lt;ulink linkType="Drug" linkID="54136"&gt;ARC-1779&lt;/ulink&gt; (4 to 5 microg/ml) completely inhibited VWF A1 domains and prevented this desmopressin-induced platelet drop. Treatment with desmopressin alone increased VWF antigen two- to three-fold, accompanied by concordant changes in VWF Ristocetin cofactor activity (RCo) and coagulation factor VIII activity. &lt;ulink linkType="Drug" linkID="54136"&gt;ARC-1779&lt;/ulink&gt; substantially enhanced the desmopressin-induced maximal increase in these parameters, and improved multimer patterns [&lt;ulink linkType="Reference" linkID="1135522"&gt;1135522&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In March 2011, results were published. VWF activity was reduced to 5% with mean steady state &lt;ulink linkType="Drug" linkID="54136"&gt;ARC-1779&lt;/ulink&gt; plasma concentrations of 9.9 microg/ml (mean baseline activity was 125% in TTP patients compared to reference plasma). PEX reduced &lt;ulink linkType="Drug" linkID="54136"&gt;ARC-1779&lt;/ulink&gt; levels by 50%, but steady state concentrations were restored rapidly with a mini-bolus. In one patient, after discontinuation of PEX, &lt;ulink linkType="Drug" linkID="54136"&gt;ARC-1779&lt;/ulink&gt; alone further increased platelet counts. Stopping &lt;ulink linkType="Drug" linkID="54136"&gt;ARC-1779&lt;/ulink&gt; was associated with an immediate drop of platelet counts in this patient  [&lt;ulink linkType="Reference" linkID="1526964"&gt;1526964&lt;/ulink&gt;].&lt;/para&gt;&lt;/Outcomes&gt;</Outcomes><ProtocolDescription>&lt;ProtocolDescription&gt;&lt;para&gt;&lt;ulink linkType="Drug" linkID="54136"&gt;ARC-1779&lt;/ulink&gt; injection would be investigated in four cohorts of  thrombotic thrombocytopenic purpura  (TTP) patients as an uncontrolled,
      open-label study.  Patients with vWD-2b would be enrolled in an additional cohort in a
      randomized, blinded, double-dummy, and placebo-controlled study.
Collectively, patients representing three different vWF-related platelet function disorders: TTP
      in remission, acute TTP, and vWD-2b would be treated in a total of five cohorts.  Three cohorts
      would consist of patients who are status post an episode of TTP and
      would be treated with &lt;ulink linkType="Drug" linkID="54136"&gt;ARC-1779&lt;/ulink&gt; injection in a dose- and duration-escalation design.  Up to four patients would be included in each of the TTP
      cohorts.  The vWD-2b cohort would be  expected to consist of up to 12 vWD-2b patients. The five cohorts would be  divided as follows:&lt;/para&gt;&lt;para&gt;TTP remission cohort 1: Patients would receive a total dose of 0.47 mg/kg of &lt;ulink linkType="Drug" linkID="54136"&gt;ARC-1779&lt;/ulink&gt; over 4 h to achieve a target plasma concentration of 6 microg/ml. Initial stepwise infusion of 0.23 mg/kg given over 30 min and subsequent continuous infusion of an additional 0.24 mg/kg given over 4 h at a rate of 0.001 mg/kg/min.&lt;/para&gt;&lt;para&gt;TTP remission cohort 2: Patients would receive a total dose of 1.67 mg/kg of &lt;ulink linkType="Drug" linkID="54136"&gt;ARC-1779&lt;/ulink&gt; over 24 h to achieve a target plasma concentration of 6 microg/ml. Initial stepwise infusion of 0.23 mg/kg given over 30 min and subsequent continuous infusion of an additional 1.44 mg/kg given over 24 h at a rate of 0.001 mg/kg/min.&lt;/para&gt;&lt;para&gt;TTP remission cohort 3: Patients would receive a total dose of 3.34 mg/kg of &lt;ulink linkType="Drug" linkID="54136"&gt;ARC-1779&lt;/ulink&gt; over 24 h to achieve a target plasma concentration of 12 microg/ml. Initial stepwise infusion of 0.46 mg/kg over 30 min and subsequent continuous infusion of an additional 2.88 mg/kg given over 24 h at a rate of 0.002 mg/kg/min.&lt;/para&gt;&lt;para&gt;Acute TTP cohort 4: Patients would receive up to a total dose of 40.78 mg/kg of &lt;ulink linkType="Drug" linkID="54136"&gt;ARC-1779&lt;/ulink&gt; for &amp;lt;/= 14 days to achieve a target plasma concentration of 12 microg/ml. Initial stepwise infusion of 0.23 mg/kg given over 30 min and subsequent continuous infusion of an additional 1.44 mg/kg given over 24 h at a rate of 0.001 mg/kg/min to produce a target plasma concentration of 6 microg/ml.&lt;/para&gt;&lt;para&gt;vWD-Type2b Cohort 5: Subjects would receive either &lt;ulink linkType="Drug" linkID="54136"&gt;ARC-1779&lt;/ulink&gt;, desmopressin or a combination of &lt;ulink linkType="Drug" linkID="54136"&gt;ARC-1779&lt;/ulink&gt; and desmopressin in a 3-period crossover design. The maximum dose of &lt;ulink linkType="Drug" linkID="54136"&gt;ARC-1779&lt;/ulink&gt; would be 0.47 mg/kg to achieve a target plasma concentration of 6 microg/ml. In one period of the sequence, &lt;ulink linkType="Drug" linkID="54136"&gt;ARC-1779&lt;/ulink&gt; would be administered to all subjects as a stepwise infusion of 0.23 mg/kg over 30 min and subsequent continuous infusion of an additional 0.24 mg/kg given over 4 h at a rate of 0.001 mg/kg/min in combination with a dummy 30-min infusion of placebo. &lt;/para&gt;&lt;para&gt;In another period, subjects would receive a single infusion of desmopressin at a dose of 0.4 microg/kg given over 30 min in combination with a dummy 30-min stepwise infusion followed by 4 h continuous infusion of placebo. In a further  period, subjects would receive the combination of desmopressin at a dose of 0.4 microg/kg given over 30 min and &lt;ulink linkType="Drug" linkID="54136"&gt;ARC-1779&lt;/ulink&gt; given as a stepwise infusion of 0.23 mg/kg over 30 min and subsequent continuous infusion of an additional 0.24 mg/kg given over 4 h at a rate of 0.001 mg/kg/min.&lt;/para&gt;&lt;/ProtocolDescription&gt;</ProtocolDescription><Regimens>&lt;Regimens&gt;&lt;para&gt;Patients (n = 7) received bolus primed continuous iv infusions of &lt;ulink linkType="Drug" linkID="54136"&gt;ARC-1779&lt;/ulink&gt; (1 to 2 microg/kg/min) in addition to PEX until remission of TTP was induced or for 14 days [&lt;ulink linkType="Reference" linkID="1526964"&gt;1526964&lt;/ulink&gt;].&lt;/para&gt;&lt;/Regimens&gt;</Regimens></ProtocolAndOutcomes><AdverseEventsByInterventions></AdverseEventsByInterventions><DoseRouteByInterventions><DoseRouteByIntervention><Intervention id="31578">desmopressin</Intervention><Treatments><Treatment><Dose>0.4 microgram/kg</Dose><Route></Route></Treatment></Treatments></DoseRouteByIntervention><DoseRouteByIntervention><Intervention id="31523">egaptivon pegol</Intervention><Treatments><Treatment><Dose>40.78 milligram/kg</Dose><Route></Route></Treatment></Treatments></DoseRouteByIntervention><DoseRouteByIntervention><Intervention id="31577">egaptivon pegol</Intervention><Treatments><Treatment><Dose>0.47 milligram/kg</Dose><Route></Route></Treatment><Treatment><Dose>1.67 milligram/kg</Dose><Route></Route></Treatment><Treatment><Dose>3.34 milligram/kg</Dose><Route></Route></Treatment></Treatments></DoseRouteByIntervention></DoseRouteByInterventions><SitesByCountries><SitesByCountry country="Austria"><Sites><Site><Name>Archemix Investigational Site</Name><Address1>Vienna</Address1><Address3>A-1090</Address3><RecruitmentStatus id="2">Recruiting</RecruitmentStatus><Contacts></Contacts></Site></Sites></SitesByCountry><SitesByCountry country="US"><Sites><Site><Name>Archemix Corp.</Name><Contacts></Contacts></Site></Sites></SitesByCountry></SitesByCountries><PatientSegmentTerms><PatientSegmentByDisease><Disease>Systemic lupus erythematosus</Disease><PatientSegments><PatientSegment><PatientSegment id="7570">Subjects with comorbid conditions</PatientSegment></PatientSegment></PatientSegments></PatientSegmentByDisease><PatientSegmentByDisease><Disease>Thrombosis</Disease><PatientSegments><PatientSegment><PatientSegment id="7310">Subjects at risk of developing disease</PatientSegment><SubSegments><SubSegment id="7313">Subjects with inherited or acquired coagulation disorders</SubSegment></SubSegments></PatientSegment><PatientSegment><PatientSegment id="7350">Subjects with History of/Undergoing Procedures/Surgery</PatientSegment><SubSegments><SubSegment id="7357">Subjects with history of/undergoing other major surgeries</SubSegment></SubSegments></PatientSegment><PatientSegment><PatientSegment id="7358">Subjects Scheduled for Specific Procedures/Surgery</PatientSegment></PatientSegment></PatientSegments></PatientSegmentByDisease><PatientSegmentByDisease><Disease>Von Willebrands disease</Disease><PatientSegments><PatientSegment><PatientSegment id="10488">Subjects with Type 2B Von Willebrand Disease</PatientSegment></PatientSegment></PatientSegments></PatientSegmentByDisease><PatientSegmentByDisease><Disease>Thrombocytopenia</Disease><PatientSegments><PatientSegment><PatientSegment id="9510">Subjects with Thrombotic Thrombocytopenic Purpura</PatientSegment></PatientSegment><PatientSegment><PatientSegment id="11415">Subjects with Other Forms of Thrombocytopenia</PatientSegment></PatientSegment></PatientSegments></PatientSegmentByDisease><PatientSegmentByDisease><Disease>Thrombotic thrombocytopenic purpura</Disease><PatientSegments><PatientSegment><PatientSegment id="9957">Subjects with Idiopathic Thrombotic Thrombocytopenic Purpura</PatientSegment></PatientSegment><PatientSegment><PatientSegment id="9958">Subjects with Hereditary Thrombotic Thrombocytopenic Purpura</PatientSegment></PatientSegment><PatientSegment><PatientSegment id="9959">Subjects with Acquired Thrombotic Thrombocytopenic Purpura</PatientSegment><SubSegments><SubSegment id="9961">Subjects with acute thrombotic thrombocytopenic purpura</SubSegment></SubSegments></PatientSegment><PatientSegment><PatientSegment id="10803">Subjects with comorbid conditions</PatientSegment></PatientSegment></PatientSegments></PatientSegmentByDisease></PatientSegmentTerms><TrialRegistries><Registry><Name id="1000">NLM ClinicalTrials.gov</Name><Identifiers><Identifier type="NCT">NCT00632242</Identifier></Identifiers></Registry><Registry><Name id="1001">European Clinical Trials Database (EudraCT)</Name><Identifiers><Identifier>2007-004371-19</Identifier></Identifiers></Registry><Registry><Name id="1002">International Standard Randomised Controlled Trial Number Register (ISRCTN)</Name><Identifiers><Identifier>ISRCTN28462186</Identifier></Identifiers></Registry></TrialRegistries><OutcomeMeasureTerms><PrimaryEndpoints><PrimaryEndpoint disease="Thrombosis" id="10344"><Endpoint>Assessment of Safety and Tolerability</Endpoint></PrimaryEndpoint><PrimaryEndpoint disease="Systemic lupus erythematosus" id="14608"><Endpoint>Assessment of Safety and Tolerability</Endpoint></PrimaryEndpoint><PrimaryEndpoint disease="Thrombocytopenia" id="16401"><Endpoint>Assessment of Safety and Tolerability</Endpoint></PrimaryEndpoint><PrimaryEndpoint disease="Thrombotic thrombocytopenic purpura" id="19232"><Endpoint>Assessment of Safety and Tolerability</Endpoint></PrimaryEndpoint><PrimaryEndpoint disease="Von Willebrands disease" id="20368"><Endpoint>Assessment of Safety and Tolerability</Endpoint></PrimaryEndpoint></PrimaryEndpoints><SecondaryEndpoints><SecondaryEndpoint disease="Thrombosis" id="10281"><Endpoint>Assessment of Blood Coagulation</Endpoint><SubEndpoints><SubEndpoint disease="Thrombosis" id="10285">Assessment of coagulation factors</SubEndpoint><SubEndpoint disease="Thrombosis" id="10289">Assessment of platelet function/aggregation</SubEndpoint></SubEndpoints></SecondaryEndpoint><SecondaryEndpoint disease="Thrombosis" id="10339"><Endpoint>Assessment of Pharmacokinetic/Pharmacodynamic Parameters</Endpoint></SecondaryEndpoint><SecondaryEndpoint disease="Systemic lupus erythematosus" id="14589"><Endpoint>Assessment of Laboratory/Diagnostic Measures</Endpoint><SubEndpoints><SubEndpoint disease="Systemic lupus erythematosus" id="14590">Hematological/bone marrow assessment</SubEndpoint></SubEndpoints></SecondaryEndpoint><SecondaryEndpoint disease="Systemic lupus erythematosus" id="14607"><Endpoint>Assessment of Pharmacokinetic/Pharmacodynamic Parameters</Endpoint></SecondaryEndpoint><SecondaryEndpoint disease="Thrombocytopenia" id="16381"><Endpoint>Assessment of Pharmacokinetic/Pharmacodynamic Parameters</Endpoint></SecondaryEndpoint><SecondaryEndpoint disease="Thrombotic thrombocytopenic purpura" id="19165"><Endpoint>Assessment of Therapy Related Outcomes</Endpoint><SubEndpoints><SubEndpoint disease="Thrombotic thrombocytopenic purpura" id="19168">Assessment of efficacy</SubEndpoint></SubEndpoints></SecondaryEndpoint><SecondaryEndpoint disease="Thrombotic thrombocytopenic purpura" id="19211"><Endpoint>Assessment of Pharmacokinetic/Pharmacodynamic Parameters</Endpoint></SecondaryEndpoint><SecondaryEndpoint disease="Von Willebrands disease" id="20361"><Endpoint>Assessment of Pharmacokinetic/Pharmacodynamic Parameters</Endpoint></SecondaryEndpoint><SecondaryEndpoint disease="Thrombotic thrombocytopenic purpura" id="45076"><Endpoint>Hematological Assessments</Endpoint><SubEndpoints><SubEndpoint disease="Thrombotic thrombocytopenic purpura" id="19153">Assessment of platelet response</SubEndpoint></SubEndpoints></SecondaryEndpoint></SecondaryEndpoints></OutcomeMeasureTerms><EligibilityCriteriaTerms><InclusionCriteria><Inclusion disease="Thrombosis" id="5930"><Criterion>Subjects at Risk of Developing Disease</Criterion><SubCriteria><SubCriterion disease="Thrombosis" id="5933">Subjects with inherited or acquired coagulation disorders</SubCriterion></SubCriteria></Inclusion><Inclusion disease="Thrombosis" id="6000"><Criterion>Subjects with History/Scheduled for Surgery/Intervention</Criterion></Inclusion><Inclusion disease="Thrombocytopenia" id="15135"><Criterion>Subjects with Other Forms of Thrombocytopenia</Criterion></Inclusion><Inclusion disease="Thrombocytopenia" id="15147"><Criterion>Subjects co-morbid with hematological diseases/disorders</Criterion></Inclusion><Inclusion disease="Thrombocytopenia" id="15155"><Criterion>Subjects with Normal/Acceptable Clinical Assessments</Criterion></Inclusion><Inclusion disease="Thrombocytopenia" id="15162"><Criterion>Subjects with Normal/Acceptable Laboratory Criteria</Criterion></Inclusion><Inclusion disease="Systemic lupus erythematosus" id="15385"><Criterion>SLE Subjects on Remission</Criterion></Inclusion><Inclusion disease="Thrombotic thrombocytopenic purpura" id="17201"><Criterion>Subjects with Idiopathic Thrombotic Thrombocytopenic Purpura (TTP)</Criterion></Inclusion><Inclusion disease="Thrombotic thrombocytopenic purpura" id="17202"><Criterion>Subjects with Hereditary TTP</Criterion></Inclusion><Inclusion disease="Thrombotic thrombocytopenic purpura" id="17203"><Criterion>Subjects with Acquired TTP</Criterion><SubCriteria><SubCriterion disease="Thrombotic thrombocytopenic purpura" id="17205">Subjects with acute TTP</SubCriterion></SubCriteria></Inclusion><Inclusion disease="Thrombotic thrombocytopenic purpura" id="17207"><Criterion>Subjects with Symptomatic Disease</Criterion><SubCriteria><SubCriterion disease="Thrombotic thrombocytopenic purpura" id="17210">Subjects with thrombocytopenia as a symptom</SubCriterion><SubCriterion disease="Thrombotic thrombocytopenic purpura" id="17212">Subjects with hemolytic anemia as disease symptom</SubCriterion></SubCriteria></Inclusion><Inclusion disease="Thrombotic thrombocytopenic purpura" id="17215"><Criterion>Subjects with Other Forms of TTP</Criterion><SubCriteria><SubCriterion disease="Thrombotic thrombocytopenic purpura" id="17217">Subjects with TTP secondary to transplant</SubCriterion></SubCriteria></Inclusion><Inclusion disease="Thrombotic thrombocytopenic purpura" id="17221"><Criterion>Subjects with Co-morbid Conditions</Criterion><SubCriteria><SubCriterion disease="Thrombotic thrombocytopenic purpura" id="18046">Subjects co-morbid with Haemolytic Uraemic Syndrome (HUS)</SubCriterion></SubCriteria></Inclusion><Inclusion disease="Thrombotic thrombocytopenic purpura" id="17231"><Criterion>Subjects co-morbid with hematological diseases/disorders</Criterion></Inclusion><Inclusion disease="Thrombotic thrombocytopenic purpura" id="17242"><Criterion>Subjects with Normal/Acceptable Laboratory Criteria</Criterion></Inclusion><Inclusion disease="Thrombotic thrombocytopenic purpura" id="17286"><Criterion>TTP Subjects in Remission</Criterion></Inclusion><Inclusion disease="Thrombotic thrombocytopenic purpura" id="18045"><Criterion>Subjects with Drug-Induced TTP</Criterion></Inclusion><Inclusion disease="Von Willebrands disease" id="18626"><Criterion>Subjects with Type 2B Von Willebrand Disease</Criterion></Inclusion><Inclusion disease="Von Willebrands disease" id="18638"><Criterion>Subjects co-morbid with hematological diseases/disorders</Criterion><SubCriteria><SubCriterion disease="Von Willebrands disease" id="18639">Subjects with other coagulation disorders</SubCriterion></SubCriteria></Inclusion><Inclusion disease="Von Willebrands disease" id="18659"><Criterion>Subjects with Normal/Acceptable Laboratory Criteria</Criterion></Inclusion><Inclusion disease="Systemic lupus erythematosus" id="33309"><Criterion>Subjects with Normal/Acceptable Organ Function</Criterion><SubCriteria><SubCriterion disease="Systemic lupus erythematosus" id="15389">Subjects with normal/acceptable hematological functions</SubCriterion></SubCriteria></Inclusion><Inclusion disease="Thrombocytopenia" id="35091"><Criterion>Subjects with specific disease</Criterion><SubCriteria><SubCriterion disease="Thrombocytopenia" id="15127">Subjects with Thrombotic Thrombocytopenic Purpura</SubCriterion></SubCriteria></Inclusion></InclusionCriteria><ExclusionCriteria><Exclusion disease="Thrombosis" id="7578"><Criterion>Subjects with Co-morbid Conditions</Criterion><SubCriteria><SubCriterion disease="Thrombosis" id="7581">Subjects with malignancy/tumors</SubCriterion></SubCriteria></Exclusion><Exclusion disease="Thrombosis" id="7584"><Criterion>Subjects co-morbid with cardiovascular diseases/disorders</Criterion></Exclusion><Exclusion disease="Thrombosis" id="7637"><Criterion>Subjects with History of/Scheduled for Intervention/Surgery</Criterion></Exclusion><Exclusion disease="Thrombocytopenia" id="12517"><Criterion>Subjects with Co-morbid Conditions</Criterion><SubCriteria><SubCriterion disease="Thrombocytopenia" id="12525">Subjects with premalignant/malignant condition</SubCriterion></SubCriteria></Exclusion><Exclusion disease="Thrombocytopenia" id="12519"><Criterion>Subjects co-morbid with cardiovascular diseases/disorders</Criterion></Exclusion><Exclusion disease="Thrombocytopenia" id="12569"><Criterion>Subjects with history of/scheduled to receive therapy for other indication</Criterion></Exclusion><Exclusion disease="Systemic lupus erythematosus" id="12634"><Criterion>Subjects co-morbid with cardiovascular diseases/disorders</Criterion></Exclusion><Exclusion disease="Systemic lupus erythematosus" id="12666"><Criterion>Subjects with History of/Scheduled for Intervention/Surgery</Criterion></Exclusion><Exclusion disease="Thrombotic thrombocytopenic purpura" id="14840"><Criterion>Subjects with Co-morbid Conditions</Criterion><SubCriteria><SubCriterion disease="Thrombotic thrombocytopenic purpura" id="14849">Subjects with premalignant/malignant condition</SubCriterion></SubCriteria></Exclusion><Exclusion disease="Thrombotic thrombocytopenic purpura" id="14843"><Criterion>Subjects co-morbid with cardiovascular diseases/disorders</Criterion></Exclusion><Exclusion disease="Thrombotic thrombocytopenic purpura" id="14902"><Criterion>Subjects with history of/scheduled to receive therapy for other indication</Criterion></Exclusion><Exclusion disease="Von Willebrands disease" id="16640"><Criterion>Subjects with Co-morbid Conditions</Criterion><SubCriteria><SubCriterion disease="Von Willebrands disease" id="16648">Subjects with premalignant/malignant condition</SubCriterion></SubCriteria></Exclusion><Exclusion disease="Von Willebrands disease" id="16642"><Criterion>Subjects co-morbid with cardiovascular diseases/disorders</Criterion></Exclusion><Exclusion disease="Von Willebrands disease" id="16698"><Criterion>Subjects with history of/scheduled to receive therapy for other indication</Criterion></Exclusion><Exclusion disease="Systemic lupus erythematosus" id="25900"><Criterion>Immunocompromised Subjects</Criterion><SubCriteria><SubCriterion disease="Systemic lupus erythematosus" id="12641">Subjects immunocompromised with cancer/malignancy</SubCriterion></SubCriteria></Exclusion></ExclusionCriteria></EligibilityCriteriaTerms><PrimaryCompletionDate>2008-12-31T00:00:00Z</PrimaryCompletionDate><DateEnrollmentEnd type="actual">2008-08-31T00:00:00Z</DateEnrollmentEnd><EnrollmentPeriod>7.03 Months</EnrollmentPeriod><EnrollmentRate>3.98 Patients/Month</EnrollmentRate><DateFirstReceived>2008-03-03T00:00:00Z</DateFirstReceived><FundersType><Type>Company</Type></FundersType><ChangeHistory><Change type="added"><Date>2008-07-21T14:18:49Z</Date><Reason id="301">Clinical trial added</Reason></Change><Change type="updated"><Date>2013-08-04T13:54:02Z</Date><Reason id="305">Change history start date</Reason></Change></ChangeHistory></Trial><Trial id="214505"><TitleDisplay>Auricular Acupuncture in the Treatment of Obesity</TitleDisplay><TitleOfficial>Auricular Acupuncture in the Treatment of Obesity: a Randomized, Placebo-controlled, Trial</TitleOfficial><OutcomesAvailable>No</OutcomesAvailable><EndpointsAchieved>Unknown</EndpointsAchieved><Identifiers><Identifier type="NCT">NCT02269371</Identifier><Identifier type="Organisational Study">FWH20140089H</Identifier><Identifier type="Trial Acronym">AcupObesity</Identifier></Identifiers><Indications><Indication id="238">Obesity</Indication></Indications><BiomarkerNames><BiomarkerName id="113" role="Therapeutic effect marker" type="Anthropomorphic">Body Mass Index</BiomarkerName><BiomarkerName id="418" role="Therapeutic effect marker" type="Anthropomorphic">Waist circumference</BiomarkerName><BiomarkerName id="12058" role="Therapeutic effect marker" type="Anthropomorphic">Total body mass</BiomarkerName><BiomarkerName id="17697" role="Therapeutic effect marker" type="Anthropomorphic">Body height</BiomarkerName></BiomarkerNames><InterventionsPrimaryByRegimen regimenType="single"><Interventions><Intervention type="InterventionPrimary"><Name>auricular acupuncture</Name></Intervention></Interventions></InterventionsPrimaryByRegimen><InterventionsPrimaryByRegimen regimenType="single"><Interventions><Intervention type="InterventionPrimary"><Name>standard of care weight loss intervention</Name></Intervention></Interventions></InterventionsPrimaryByRegimen><InterventionsControlByRegimens></InterventionsControlByRegimens><DrugsAsInterventionPrimary></DrugsAsInterventionPrimary><CrossReferences><SourceEntity id="1122210" type="Company"><TargetEntity id="5050720215" type="organizationId">Mike O'Callaghan Federal Hospital</TargetEntity></SourceEntity><SourceEntity id="238" type="ciIndication"><TargetEntity id="E66" type="ICD10"></TargetEntity><TargetEntity id="10029883" type="MEDDRA"></TargetEntity><TargetEntity id="D009765" type="MeSH"></TargetEntity><TargetEntity id="-1640888899" type="omicsDisease"></TargetEntity><TargetEntity id="985" type="siCondition"></TargetEntity></SourceEntity></CrossReferences><Phase>Phase 4 Clinical</Phase><RecruitmentStatus id="4">Completed</RecruitmentStatus><NumberOfSites>1</NumberOfSites><CompaniesSponsor><Company id="1122210">Mike O'Callaghan Federal Hospital</Company></CompaniesSponsor><CompaniesCollaborator></CompaniesCollaborator><IsCommerciallySignificant>No</IsCommerciallySignificant><Technologies></Technologies><TermsPatientSelection><Term>Aged Adults (65-79 yrs)</Term><Term>Elderly Adults (80 and over)</Term><Term>Middle-aged Adults (45-64 yrs)</Term><Term>Young Adults (18-44 yrs)</Term></TermsPatientSelection><TrialCategories><Category>Medical procedure</Category><Category>Behavioral intervention</Category></TrialCategories><TermsDesign><Term>Randomized</Term><Term>Placebo Control</Term><Term>Single Blind</Term><Term>Treatment</Term><Term>Parallel Assignment</Term><Term>Interventional</Term></TermsDesign><TermsEndpoint><Term>Efficacy</Term></TermsEndpoint><PatientCountEnrollment>82</PatientCountEnrollment><DateStart>2015-02-28T00:00:00Z</DateStart><DateEnd type="actual">2016-12-31T00:00:00Z</DateEnd><DateChangeLast>2017-12-18T22:00:09Z</DateChangeLast><DateAdded>2014-10-30T00:00:00Z</DateAdded><Contacts><Contact type="Scientific contact"><Affiliation>Mike O'Callaghan Federal Medical Center</Affiliation><Name>Clinton Borchardt, MD</Name></Contact></Contacts><CriteriaInclusion>&lt;Inclusion&gt;&lt;ul&gt;&lt;li&gt;Male and female DoD beneficiaries&lt;/li&gt;&lt;li&gt;Age &gt;/=  18 years, with a body mass index of &gt;/= 30&lt;/li&gt;&lt;li&gt;Referred to a standard of care weight loss intervention&lt;/li&gt;&lt;li&gt;Must have military insurance in order to participate in this study&lt;/li&gt;&lt;/ul&gt;&lt;/Inclusion&gt;</CriteriaInclusion><CriteriaExclusion>&lt;Exclusion&gt;&lt;ul&gt;&lt;li&gt;Pregnant women&lt;/li&gt;&lt;li&gt;Patients who are taking weight loss medication&lt;/li&gt;&lt;li&gt;Uncontrolled hypothyroidism&lt;/li&gt;&lt;li&gt;Absence of ear&lt;/li&gt;&lt;li&gt;Active cellulitis of ear&lt;/li&gt;&lt;li&gt;Ear anatomy precluding identification of acupuncture landmarks&lt;/li&gt;&lt;li&gt;Use of hearing aids that preclude the insertion of needles&lt;/li&gt;&lt;/ul&gt;&lt;/Exclusion&gt;</CriteriaExclusion><MeasuresOutcome><MeasuresPrimary><Measure><Description>Greater weight loss: as assessed by weight, waist circumference, and body mass index calculations</Description><Timeframe>22 weeks</Timeframe></Measure></MeasuresPrimary><MeasureSecondary></MeasureSecondary></MeasuresOutcome><ProtocolAndOutcomes><AimsAndScope>&lt;AimAndScope&gt;&lt;para&gt;The investigators proposed to complete a randomized, placebo-controlled trial to compare      auricular (ear) acupuncture at shen men, point zero, and appetite control point plus a      standard of care weight loss intervention (eg, better body, better life), versus      sham acupuncture plus a standard of care weight loss intervention, for treatment of obesity.&lt;/para&gt;&lt;/AimAndScope&gt;</AimsAndScope><ProtocolDescription>&lt;ProtocolDescription&gt;&lt;para&gt;Subjects would receive treatment in accordance with their randomization group for 12 weeks      then have one additional follow-up visit at week 24. The following measures would be      obtained: height, weight, waist circumference, and body mass index would be calculated.	&lt;/para&gt;&lt;para&gt;Screening visit:&lt;br/&gt;Obtain signed informed consent document and HIPAA Authorization.&lt;br/&gt;Review past medical history in Armed Forces Health Longitudinal Technology Application           (AHLTA) to verify the inclusion/exclusion criteria and to verify the           inclusion/exclusion criteria including previous encounter, vital signs review,           medication list, co-morbidities, demographics, problems list, and note any prior           acupuncture received.&lt;br/&gt;Record: date of birth, age, gender, race, ethnicity, last four of social security number,           name of standard of care weight loss intervention, current email address, height (in           inches), weight (in pounds), waist circumference (in inches) measurement, previous           bariatric surgery, and body mass index calculated.&lt;/para&gt;&lt;para&gt;Visit 1-week 1: (first week of standard of care weight intervention) &lt;br/&gt;Subjects would be      randomized into one of two groups and treated: &lt;br/&gt;Group 1: standard of care weight loss      intervention plus auricular acupuncture at Shen Men, Point Zero, and appetite control      point/hunger point in each ear. The three needles would remain in each ear for 15 min.&lt;br/&gt;Group 2: standard of care weight loss intervention  plus sham acupuncture at three      non-acupoints in each ear.  The 3 needles would remain in each ear for 15 min.&lt;br/&gt;All subjects, regardless of randomization group, would be instructed to have no heavy meals,      no excessive hot or cold foods, no heavy exercise or intercourse, and no alcohol for 24      h after this visit.&lt;/para&gt;&lt;para&gt;Visit 2 to 12 (week 2 to 12 of standard of care weight intervention):&lt;br/&gt;Subjects would be given treatment according to their randomization group. The           acupuncture needles would be applied and remain in each ear for 15 min.&lt;br/&gt;Record: weight, waist circumference measurement, and document compliance for standard           of care weight loss intervention (ie, attendance and measurements form class).&lt;br/&gt;All subjects, regardless of randomization group, would be instructed to have no heavy           meals, no excessive hot or cold foods, no heavy exercise or intercourse, and no alcohol           for 24 h after this visit.&lt;/para&gt;&lt;para&gt;Visit 13 (week 24/12 weeks post visit 12):&lt;br/&gt;Record: weight, and waist circumference measurement.&lt;br/&gt;Subjects would  be asked the following questions: &lt;br/&gt;Do they follow a regular routine of physical exercise? Yes/No. If yes, what type of exercise (mark all that apply): aerobic (cardiovascular endurance, eg, cycling, swimming, walking, hiking); anaerobic (strength or resistance, eg, weight lifting, sprinting, interval training)&lt;br/&gt;Flexibility (stretching, eg, yoga, pilates, gymnastics)&lt;br/&gt;On average, how many times per week do they exercise? 0 to 1, 2 to 4, 5+ how many min on average is each exercise session? 10 to 20, 20 to 30, 30 to 60, 60 at what level of intensity? Light, moderate, heavy how would you rate the health of your eating habits?  poor, fair, average, good, and excellent.&lt;/para&gt;&lt;/ProtocolDescription&gt;</ProtocolDescription></ProtocolAndOutcomes><AdverseEventsByInterventions></AdverseEventsByInterventions><DoseRouteByInterventions></DoseRouteByInterventions><SitesByCountries><SitesByCountry country="US"><Sites><Site><Name>Mike O'Callaghan Federal Hospital/Nellis Air Force Base</Name><Address1>Las Vegas</Address1><Address2>Nevada</Address2><Address3>89191</Address3><CountrySubDivision code="NV">Nevada</CountrySubDivision><Contacts></Contacts></Site></Sites></SitesByCountry></SitesByCountries><PatientSegmentTerms></PatientSegmentTerms><TrialRegistries><Registry><Name id="1000">NLM ClinicalTrials.gov</Name><Identifiers><Identifier type="NCT">NCT02269371</Identifier></Identifiers></Registry></TrialRegistries><OutcomeMeasureTerms><PrimaryEndpoints><PrimaryEndpoint disease="Obesity" id="20791"><Endpoint>Anthropometric Assessments</Endpoint><SubEndpoints><SubEndpoint disease="Obesity" id="20402">Assessment of waist circumference</SubEndpoint><SubEndpoint disease="Obesity" id="20405">Assessment of BMI</SubEndpoint></SubEndpoints></PrimaryEndpoint></PrimaryEndpoints><OtherEndpoints><OtherEndpoint disease="Obesity" id="20585"><Endpoint>Assessment of Vital Signs</Endpoint></OtherEndpoint><OtherEndpoint disease="Obesity" id="20791"><Endpoint>Anthropometric Assessments</Endpoint><SubEndpoints><SubEndpoint disease="Obesity" id="20726">Assessment of height</SubEndpoint></SubEndpoints></OtherEndpoint></OtherEndpoints></OutcomeMeasureTerms><EligibilityCriteriaTerms><InclusionCriteria><Inclusion disease="Obesity" id="19678"><Criterion>Subjects with Protocol Specified BMI</Criterion><SubCriteria><SubCriterion disease="Obesity" id="19682">Subjects with BMI&gt;30</SubCriterion></SubCriteria></Inclusion><Inclusion disease="Obesity" id="34455"><Criterion>Subjects with Protocol Specified Participation Status</Criterion><SubCriteria><SubCriterion disease="Obesity" id="19791">Subjects with compliance to informed consent process</SubCriterion></SubCriteria></Inclusion></InclusionCriteria><ExclusionCriteria><Exclusion disease="Obesity" id="15311"><Criterion>Subjects co-morbid with Endocrine/Metabolic Disorders</Criterion><SubCriteria><SubCriterion disease="Obesity" id="15313">Subjects with thyroid disorders</SubCriterion></SubCriteria></Exclusion><Exclusion disease="Obesity" id="15342"><Criterion>Subjects with History of/Scheduled to Receive Therapy</Criterion><SubCriteria><SubCriterion disease="Obesity" id="15411">Subjects on/treated with weight loss medications</SubCriterion></SubCriteria></Exclusion><Exclusion disease="Obesity" id="15364"><Criterion>Protocol Specified Other Exclusion Criteria</Criterion><SubCriteria><SubCriterion disease="Obesity" id="15382">Any medical/surgical condition interfering with participation in the study</SubCriterion></SubCriteria></Exclusion><Exclusion disease="Obesity" id="24974"><Criterion>Subjects with Protocol Specified Reproductive Status</Criterion><SubCriteria><SubCriterion disease="Obesity" id="15397">Pregnancy/Lactation/Women of childbearing potential/Intend to become pregnant/Without adequate contraception</SubCriterion></SubCriteria></Exclusion></ExclusionCriteria></EligibilityCriteriaTerms><PrimaryCompletionDate type="Actual">2016-12-31T00:00:00Z</PrimaryCompletionDate><DateEnrollmentEnd type="actual">2016-05-31T00:00:00Z</DateEnrollmentEnd><EnrollmentPeriod>15.13 Months</EnrollmentPeriod><EnrollmentRate>5.42 Patients/Month</EnrollmentRate><DateFirstReceived>2014-10-14T00:00:00Z</DateFirstReceived><FundersType><Type>Government</Type></FundersType><ChangeHistory><Change type="added"><Date>2014-10-30T00:00:00Z</Date><Reason id="301">Clinical trial added</Reason></Change><Change type="updated"><Date>2015-04-29T00:00:00Z</Date><Reason id="302">Recruitment Status Changed</Reason></Change><Change type="updated"><Date>2016-05-10T00:00:00Z</Date><Reason id="302">Recruitment Status Changed</Reason></Change><Change type="updated"><Date>2016-12-20T00:00:00Z</Date><Reason id="302">Recruitment Status Changed</Reason></Change></ChangeHistory></Trial><Trial id="259314"><TitleDisplay>A Phase IIa Study of TAS-205 for Duchenne Muscular Dystrophy</TitleDisplay><TitleOfficial>A Randomized, Phase IIa Study of TAS-205 in Patients With Duchenne Muscular Dystrophy</TitleOfficial><OutcomesAvailable>No</OutcomesAvailable><EndpointsAchieved>Unknown</EndpointsAchieved><Identifiers><Identifier type="NCT">NCT02752048</Identifier><Identifier type="Organisational Study">TAIHO10053040</Identifier></Identifiers><Indications><Indication id="2020">Duchenne dystrophy</Indication></Indications><BiomarkerNames><BiomarkerName id="147" role="Therapeutic effect marker" type="Physiological">Six-minute walk distance</BiomarkerName><BiomarkerName id="8024" role="Therapeutic effect marker" type="Genomic;Proteomic">Creatine kinase</BiomarkerName><BiomarkerName id="11397" role="Therapeutic effect marker" type="Biochemical">Prostaglandin D2</BiomarkerName><BiomarkerName id="12059" role="Therapeutic effect marker" type="Anthropomorphic">Lean body mass</BiomarkerName><BiomarkerName id="19714" role="Therapeutic effect marker" type="Physiological">Muscle strength</BiomarkerName><BiomarkerName id="30904" role="Therapeutic effect marker" type="Anthropomorphic">Skeletal muscle mass</BiomarkerName></BiomarkerNames><InterventionsPrimaryByRegimen regimenType="single"><Interventions><Intervention type="InterventionPrimary"><Name>TAS-205</Name><Drug id="92975">TAS-205</Drug></Intervention></Interventions></InterventionsPrimaryByRegimen><InterventionsControlByRegimens></InterventionsControlByRegimens><DrugsAsInterventionPrimary><DrugAsInterventionPrimary><Drug id="92975">TAS-205</Drug><IndicationsPioneer></IndicationsPioneer><Companies><Company><Company id="18720">Taiho Pharmaceutical Co Ltd</Company><RelationshipDirect>CURRENT</RelationshipDirect><RelationshipInDirect>NONE</RelationshipInDirect></Company></Companies></DrugAsInterventionPrimary></DrugsAsInterventionPrimary><CrossReferences><SourceEntity id="18720" type="Company"><TargetEntity id="5000071049" type="organizationId">Taiho Pharmaceutical Co Ltd</TargetEntity></SourceEntity><SourceEntity id="2020" type="ciIndication"><TargetEntity id="10013801" type="MEDDRA"></TargetEntity><TargetEntity id="D020388" type="MeSH"></TargetEntity><TargetEntity id="98896" type="ORPHANET"></TargetEntity><TargetEntity id="-2123687174" type="omicsDisease"></TargetEntity><TargetEntity id="143" type="siCondition"></TargetEntity></SourceEntity></CrossReferences><Phase>Phase 2a Clinical</Phase><RecruitmentStatus id="4">Completed</RecruitmentStatus><NumberOfSites>11</NumberOfSites><CompaniesSponsor><Company id="18720">Taiho Pharmaceutical Co Ltd</Company></CompaniesSponsor><CompaniesCollaborator></CompaniesCollaborator><IsCommerciallySignificant>Yes</IsCommerciallySignificant><ActionsPrimaryInterventionsPrimary><Action id="24171">Prostaglandin D synthase inhibitor</Action></ActionsPrimaryInterventionsPrimary><Technologies><Technology id="585">Oral formulation</Technology><Technology id="762">Small molecule therapeutic</Technology></Technologies><TermsPatientSelection><Term>Aged Adults (65-79 yrs)</Term><Term>Adolescents (13-17 yrs)</Term><Term>Children (6-12 yrs)</Term><Term>Elderly Adults (80 and over)</Term><Term>Middle-aged Adults (45-64 yrs)</Term><Term>Preschool Children (2-5 yrs)</Term><Term>Young Adults (18-44 yrs)</Term><Term>Male</Term></TermsPatientSelection><TrialCategories><Category>Small molecule</Category></TrialCategories><TermsDesign><Term>Randomized</Term><Term>Placebo Control</Term><Term>Multiple Blind</Term><Term>Treatment</Term><Term>Parallel Assignment</Term><Term>Interventional</Term></TermsDesign><TermsEndpoint><Term>Efficacy</Term><Term>Pharmacodynamics</Term><Term>Safety</Term></TermsEndpoint><PatientCountEnrollment>36</PatientCountEnrollment><DateStart>2016-05-31T00:00:00Z</DateStart><DateEnd type="actual">2017-10-17T00:00:00Z</DateEnd><DateChangeLast>2019-02-02T00:23:21Z</DateChangeLast><DateAdded>2016-04-29T00:00:00Z</DateAdded><Contacts><Contact type="Scientific contact"><Affiliation>Taiho Pharmaceutical Co., Ltd.</Affiliation><Name>Taiho Pharmaceutical Co., Ltd.</Name></Contact></Contacts><CriteriaInclusion>&lt;Inclusion&gt;&lt;ul&gt;&lt;li&gt;Able to give an informed consent. If applicable, able to give an informed assent&lt;/li&gt;&lt;li&gt;Phenotypic evidence of DMD&lt;/li&gt;&lt;li&gt;Male and &gt;/= 5 years of age&lt;/li&gt;&lt;li&gt;Bodyweight &gt;/= 7.5 kg and ＜60 kg&lt;/li&gt;&lt;li&gt;Able to complete the 6MWD test with a distance of &gt;/= 75 m&lt;/li&gt;&lt;li&gt;Able to take tablets&lt;/li&gt;&lt;li&gt;If taking oral glucocorticoids no significant change in the total daily or dosing 6 months before enrollment&lt;/li&gt;&lt;/ul&gt;&lt;/Inclusion&gt;</CriteriaInclusion><CriteriaExclusion>&lt;Exclusion&gt;&lt;ul&gt;&lt;li&gt;Any serious drug allergy&lt;/li&gt;&lt;li&gt;A forced vital capacity (FVC) of&amp;lt;50% of predicted value&lt;/li&gt;&lt;li&gt;Wearing a respirator continuously (except for the use during sleep)&lt;/li&gt;&lt;li&gt;A left ventricular ejection fraction (EF) of&amp;lt; 40% or fractional shortening (FS) of &amp;lt; 25% on echocardiogram&lt;/li&gt;&lt;li&gt;Clinically significant cardiac failure and respiratory failure&lt;/li&gt;&lt;li&gt;Ongoing immunosuppressive therapy (other than corticosteroids)&lt;/li&gt;&lt;li&gt;Surgical history or plan for surgery that may affect muscular strength or motor function&lt;/li&gt;&lt;li&gt;Any injury that may affect muscular strength or motor function&lt;/li&gt;&lt;li&gt;With any systemic allergic disease or any chronic inflammatory disease&lt;/li&gt;&lt;li&gt;Previous gene therapy (exon skipping, or stop codon read through therapy), cell-based therapy, or any other investigational agents&lt;/li&gt;&lt;/ul&gt;&lt;/Exclusion&gt;</CriteriaExclusion><MeasuresOutcome><MeasuresPrimary><Measure><Description>Mean change from baseline to 24 weeks in the 6-min walk distance (6MWD)</Description><Timeframe>Baseline, 24 weeks</Timeframe></Measure></MeasuresPrimary><MeasureSecondary><Measure><Description>Incidence of adverse events and side effects</Description><Timeframe>Up to 27 weeks</Timeframe></Measure><Measure><Description>Mean change from baseline in lean body mass on bioelectrical impedance analysis (BIA)</Description><Timeframe>Baseline, 24 weeks</Timeframe></Measure><Measure><Description>Mean change from baseline in pulmonary function as measured by spirometry</Description><Timeframe>Baseline, 1, 4, 12, 24 weeks</Timeframe></Measure><Measure><Description>Mean change from baseline in quantitative muscle strength using hand-held dynamometer (ex microFET2)</Description><Timeframe>Baseline, 12, 24 weeks</Timeframe></Measure><Measure><Description>Mean change from baseline in serum creatine kinase concentration</Description><Timeframe>Baseline, 1, 12, 24 weeks</Timeframe></Measure><Measure><Description>Mean change from baseline in time to rise from the floor</Description><Timeframe>Baseline, 12 and 24 weeks</Timeframe></Measure><Measure><Description>Mean change from baseline in time to up and go (TUG)</Description><Timeframe>Baseline, 12 and 24 weeks</Timeframe></Measure><Measure><Description>Mean change from baseline in time to walk/run for 10 m</Description><Timeframe>Baseline, 12 and 24 weeks</Timeframe></Measure><Measure><Description>Mean change from baseline to 12 weeks in the 6MWD</Description><Timeframe>Baseline, 12 weeks</Timeframe></Measure><Measure><Description>Mean change from baseline to 24 weeks in skeletal muscle mass using muscle CT</Description><Timeframe>Baseline, 24 weeks</Timeframe></Measure><Measure><Description>The urinary excretion amount of PD marker (PGD2 metabolite) in 24 h-pooled urine</Description><Timeframe>Baseline, 0.5, 12, 24 weeks</Timeframe></Measure></MeasureSecondary></MeasuresOutcome><ProtocolAndOutcomes><AimsAndScope>&lt;AimAndScope&gt;&lt;para&gt;The objective of this study was to evaluate the efficacy after 24-week repeated oral doses of      &lt;ulink linkType="Drug" linkID="92975"&gt;TAS-205&lt;/ulink&gt; in patients with Duchenne muscular dystrophy (DMD) in an exploratory manner and also      to evaluate the safety, the dose-response and the urinary excretion of pharmacodynamic (PD)      marker after 24-week repeated oral doses of TAS-205 in DMD patients.&lt;/para&gt;&lt;/AimAndScope&gt;</AimsAndScope><ProtocolDescription>&lt;ProtocolDescription&gt;&lt;para&gt;Patients would  receive low or high dose of oral TAS-205 or placebo for 24 weeks, bis in die (BID) after meal.&lt;/para&gt;&lt;/ProtocolDescription&gt;</ProtocolDescription></ProtocolAndOutcomes><AdverseEventsByInterventions></AdverseEventsByInterventions><DoseRouteByInterventions></DoseRouteByInterventions><SitesByCountries><SitesByCountry country="Japan"><Sites><Site><Name>Kobe University Hospital</Name><Address1>Hyogo</Address1><Address3>650-0017</Address3><Contacts></Contacts></Site><Site><Name>Nagoya City University Hospital</Name><Address1>Aichi</Address1><Address3>467-8601</Address3><Contacts></Contacts></Site><Site><Name>National Center of Neurology and Psychiatry</Name><Address1>Tokyo</Address1><Address3>187-8551</Address3><Contacts></Contacts></Site><Site><Name>National Hospital Organization Higashisaitama Hospital</Name><Address1>Saitama</Address1><Address3>349-0196</Address3><Contacts></Contacts></Site><Site><Name>National Hospital Organization Nagara Medical Center</Name><Address1>Gifu</Address1><Address3>502-8558</Address3><Contacts></Contacts></Site><Site><Name>National Hospital Organization Niigata National Hospital</Name><Address1>Niigata</Address1><Address3>945-8585</Address3><Contacts></Contacts></Site><Site><Name>National Hospital Organization Toneyama National Hospital</Name><Address1>Osaka</Address1><Address3>560-8552</Address3><Contacts></Contacts></Site><Site><Name>National Hospital Organization Utano Hospital</Name><Address1>Kyoto</Address1><Address3>616-8255</Address3><Contacts></Contacts></Site><Site><Name>Shinshu University Hospital</Name><Address1>Nagano</Address1><Address3>390-8621</Address3><Contacts></Contacts></Site><Site><Name>Tokyo Women's Medical University Hospital</Name><Address1>Tokyo</Address1><Address3>162-8666</Address3><Contacts></Contacts></Site><Site><Name>Tottori University Hospital</Name><Address1>Tottori</Address1><Address3>683-8504</Address3><Contacts></Contacts></Site></Sites></SitesByCountry></SitesByCountries><PatientSegmentTerms><PatientSegmentByDisease><Disease>Duchenne dystrophy</Disease><PatientSegments><PatientSegment><PatientSegment id="10629">Ambulant Subjects with Duchenne Muscular Dystrophy</PatientSegment></PatientSegment><PatientSegment><PatientSegment id="11946">Subjects with Genetically Confirmed DMD</PatientSegment></PatientSegment></PatientSegments></PatientSegmentByDisease></PatientSegmentTerms><TrialRegistries><Registry><Name id="1000">NLM ClinicalTrials.gov</Name><Identifiers><Identifier type="NCT">NCT02752048</Identifier></Identifiers></Registry></TrialRegistries><OutcomeMeasureTerms><PrimaryEndpoints><PrimaryEndpoint disease="Duchenne dystrophy" id="21582"><Endpoint>Assessment of Laboratory/Diagnostic Measures</Endpoint></PrimaryEndpoint><PrimaryEndpoint disease="Duchenne dystrophy" id="45059"><Endpoint>Assessment of Functional Disability/Physical Function</Endpoint></PrimaryEndpoint></PrimaryEndpoints><SecondaryEndpoints><SecondaryEndpoint disease="Duchenne dystrophy" id="21577"><Endpoint>Assessment of Pulmonary Function</Endpoint></SecondaryEndpoint><SecondaryEndpoint disease="Duchenne dystrophy" id="21602"><Endpoint>Assessment of Pharmacokinetic/Pharmacodynamic Parameters</Endpoint></SecondaryEndpoint><SecondaryEndpoint disease="Duchenne dystrophy" id="21622"><Endpoint>Assessment of adverse events</Endpoint></SecondaryEndpoint><SecondaryEndpoint disease="Duchenne dystrophy" id="44071"><Endpoint>Assessment of Exercise Capacity/Tolerance</Endpoint><SubEndpoints><SubEndpoint disease="Duchenne dystrophy" id="21536">Assessment of muscle strength</SubEndpoint></SubEndpoints></SecondaryEndpoint><SecondaryEndpoint disease="Duchenne dystrophy" id="45059"><Endpoint>Assessment of Functional Disability/Physical Function</Endpoint></SecondaryEndpoint><SecondaryEndpoint disease="Duchenne dystrophy" id="45889"><Endpoint>Assessment of Biomarkers</Endpoint><SubEndpoints><SubEndpoint disease="Duchenne dystrophy" id="21595">Assessment of other biomarkers</SubEndpoint></SubEndpoints></SecondaryEndpoint></SecondaryEndpoints></OutcomeMeasureTerms><EligibilityCriteriaTerms><InclusionCriteria><Inclusion disease="Duchenne dystrophy" id="19116"><Criterion>Ambulant Subjects with DMD</Criterion></Inclusion><Inclusion disease="Duchenne dystrophy" id="19119"><Criterion>Subjects with Genetically Confirmed DMD</Criterion></Inclusion><Inclusion disease="Duchenne dystrophy" id="19145"><Criterion>Subjects with Protocol Specified Anthropometric Measurements</Criterion></Inclusion><Inclusion disease="Duchenne dystrophy" id="19165"><Criterion>Subjects with History of/Scheduled to Receive Therapy</Criterion><SubCriteria><SubCriterion disease="Duchenne dystrophy" id="19166">Subjects with history of steroid therapy</SubCriterion></SubCriteria></Inclusion><Inclusion disease="Duchenne dystrophy" id="34365"><Criterion>Subjects with Protocol Specified Participation Status</Criterion><SubCriteria><SubCriterion disease="Duchenne dystrophy" id="19182">Subjects willing/able to provide informed consent/assent</SubCriterion></SubCriteria></Inclusion><Inclusion disease="Duchenne dystrophy" id="34820"><Criterion>Subjects with Protocol Specified Compliance Status</Criterion><SubCriteria><SubCriterion disease="Duchenne dystrophy" id="19183">Subjects able to comply with the study protocol procedures/ requirements</SubCriterion></SubCriteria></Inclusion></InclusionCriteria><ExclusionCriteria><Exclusion disease="Duchenne dystrophy" id="17119"><Criterion>Subjects with Co-morbid Conditions</Criterion></Exclusion><Exclusion disease="Duchenne dystrophy" id="17152"><Criterion>Subjects with Hypersensitivity/Contraindications to Drugs/Excipients</Criterion><SubCriteria><SubCriterion disease="Duchenne dystrophy" id="17153">Hypersensitivity/Contraindications to study medications or its excipients</SubCriterion></SubCriteria></Exclusion><Exclusion disease="Duchenne dystrophy" id="17159"><Criterion>Subjects with History of/Scheduled to Receive Therapy</Criterion><SubCriteria><SubCriterion disease="Duchenne dystrophy" id="17162">Subjects with history of gene therapy</SubCriterion></SubCriteria></Exclusion><Exclusion disease="Duchenne dystrophy" id="17166"><Criterion>Subjects with history of/scheduled to receive therapy for other indication</Criterion></Exclusion><Exclusion disease="Duchenne dystrophy" id="17170"><Criterion>Protocol Specified Other Exclusion Criteria</Criterion><SubCriteria><SubCriterion disease="Duchenne dystrophy" id="17178">Subjects with medical condition interfering with the study protocol</SubCriterion></SubCriteria></Exclusion><Exclusion disease="Duchenne dystrophy" id="26335"><Criterion>Subjects with Abnormal Organ Function</Criterion><SubCriteria><SubCriterion disease="Duchenne dystrophy" id="17135">Subjects with abnormal/unacceptable cardiac function</SubCriterion><SubCriterion disease="Duchenne dystrophy" id="17136">Subjects with abnormal/unacceptable lung function</SubCriterion></SubCriteria></Exclusion></ExclusionCriteria></EligibilityCriteriaTerms><PrimaryCompletionDate type="Actual">2017-05-15T00:00:00Z</PrimaryCompletionDate><DateEnrollmentEnd type="actual">2016-12-31T00:00:00Z</DateEnrollmentEnd><EnrollmentPeriod>7.03 Months</EnrollmentPeriod><EnrollmentRate>5.12 Patients/Month</EnrollmentRate><DateFirstReceived>2016-04-06T00:00:00Z</DateFirstReceived><FundersType><Type>Company</Type></FundersType><ChangeHistory><Change type="added"><Date>2016-04-29T00:00:00Z</Date><Reason id="301">Clinical trial added</Reason></Change><Change type="updated"><Date>2016-06-08T00:00:00Z</Date><Reason id="302">Recruitment Status Changed</Reason></Change><Change type="updated"><Date>2017-01-02T00:00:00Z</Date><Reason id="302">Recruitment Status Changed</Reason></Change><Change type="updated"><Date>2018-02-14T00:00:00Z</Date><Reason id="302">Recruitment Status Changed</Reason></Change></ChangeHistory></Trial><Trial id="28347"><TitleDisplay>Chemotherapy and Avastin Followed by Maintenance Treatment With Avastin +/- Tarceva</TitleDisplay><TitleOfficial>Avasatin and Chemotherapy Followed by Avastin Alone or in Combination With Tarceva for the Treatment of Metastatic Colorectal Cancer</TitleOfficial><OutcomesAvailable>Yes</OutcomesAvailable><EndpointsAchieved>No</EndpointsAchieved><Identifiers><Identifier type="Organisational Study">ML19033</Identifier><Identifier type="NCT">NCT00598156</Identifier><Identifier type="Secondary Organisational">EUDRACT 2006-002295-18</Identifier><Identifier type="Trial Acronym">Nordic ACT</Identifier></Identifiers><Indications><Indication id="3658">Metastatic colorectal cancer</Indication></Indications><BiomarkerNames><BiomarkerName id="52" role="Therapeutic effect marker" type="Genomic;Proteomic">GTPase KRas</BiomarkerName><BiomarkerName id="82" role="Therapeutic effect marker" type="Genomic;Proteomic">B-Raf proto-oncogene serine/threonine-protein kinase</BiomarkerName><BiomarkerName id="92" role="Therapeutic effect marker" type="Genomic;Proteomic">Phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha isoform</BiomarkerName></BiomarkerNames><InterventionsPrimaryByRegimen regimenType="single"><Interventions><Intervention type="InterventionPrimary"><Name>bevacizumab</Name><Drug id="8047">bevacizumab</Drug></Intervention></Interventions></InterventionsPrimaryByRegimen><InterventionsPrimaryByRegimen regimenType="combo"><Interventions><Intervention type="InterventionPrimary"><Name>bevacizumab</Name><Drug id="8047">bevacizumab</Drug></Intervention><Intervention type="InterventionPrimary"><Name>bevacizumab + erlotinib</Name></Intervention><Intervention type="InterventionPrimary"><Name>erlotinib</Name><Drug id="11961">erlotinib</Drug></Intervention></Interventions></InterventionsPrimaryByRegimen><InterventionsControlByRegimens></InterventionsControlByRegimens><DrugsAsInterventionPrimary><DrugAsInterventionPrimary><Drug id="11961">erlotinib</Drug><IndicationsPioneer></IndicationsPioneer><Companies><Company><Company id="19446">Roche Holding AG</Company><RelationshipDirect>CURRENT</RelationshipDirect><RelationshipInDirect>CURRENT</RelationshipInDirect></Company><Company><Company id="25208">University of Lund</Company><RelationshipDirect>NONE</RelationshipDirect><RelationshipInDirect>NONE</RelationshipInDirect></Company></Companies></DrugAsInterventionPrimary><DrugAsInterventionPrimary><Drug id="8047">bevacizumab</Drug><IndicationsPioneer></IndicationsPioneer><Companies><Company><Company id="19446">Roche Holding AG</Company><RelationshipDirect>CURRENT</RelationshipDirect><RelationshipInDirect>CURRENT</RelationshipInDirect></Company><Company><Company id="25208">University of Lund</Company><RelationshipDirect>NONE</RelationshipDirect><RelationshipInDirect>NONE</RelationshipInDirect></Company></Companies></DrugAsInterventionPrimary><DrugAsInterventionPrimary><Drug id="8047">bevacizumab</Drug><IndicationsPioneer></IndicationsPioneer><Companies><Company><Company id="19446">Roche Holding AG</Company><RelationshipDirect>CURRENT</RelationshipDirect><RelationshipInDirect>CURRENT</RelationshipInDirect></Company><Company><Company id="25208">University of Lund</Company><RelationshipDirect>NONE</RelationshipDirect><RelationshipInDirect>NONE</RelationshipInDirect></Company></Companies></DrugAsInterventionPrimary></DrugsAsInterventionPrimary><CrossReferences><SourceEntity id="8047" type="Drug"><TargetEntity id="223839" type="siDrug">Bevacizumab</TargetEntity><TargetEntity id="223839" type="siDrug">Bevacizumab</TargetEntity></SourceEntity><SourceEntity id="11961" type="Drug"><TargetEntity id="250837" type="siDrug">Erlotinib hydrochloride</TargetEntity></SourceEntity><SourceEntity id="19446" type="Company"><TargetEntity id="4295890594" type="organizationId">Roche Holding AG</TargetEntity></SourceEntity><SourceEntity id="25208" type="Company"><TargetEntity id="5001165074" type="organizationId">Lund University</TargetEntity></SourceEntity><SourceEntity id="3658" type="ciIndication"><TargetEntity id="10052358" type="MEDDRA"></TargetEntity><TargetEntity id="595" type="siCondition"></TargetEntity></SourceEntity><SourceEntity id="3754" type="Action"><TargetEntity id="1222" type="Mechanism">HER (erbB) Inhibitors</TargetEntity></SourceEntity><SourceEntity id="740" type="Action"><TargetEntity id="1071" type="Mechanism">EGFR (HER1; erbB1) Inhibitors</TargetEntity><TargetEntity id="1613" type="Mechanism">Anti-EGFR</TargetEntity><TargetEntity id="4344" type="Mechanism">EGFR (HER1; erbB1) (Mutant) Inhibitors</TargetEntity><TargetEntity id="4345" type="Mechanism">EGFR (Thr790Met Mutant) Inhibitors</TargetEntity></SourceEntity></CrossReferences><Phase>Phase 3 Clinical</Phase><RecruitmentStatus id="4">Completed</RecruitmentStatus><NumberOfSites>15</NumberOfSites><CompaniesSponsor><Company id="25208">University of Lund</Company></CompaniesSponsor><CompaniesCollaborator><Company id="19446">Roche Holding AG</Company></CompaniesCollaborator><IsCommerciallySignificant>Yes</IsCommerciallySignificant><ActionsPrimaryInterventionsPrimary><Action id="12521">VEGF ligand inhibitor</Action><Action id="3754">EGFR family tyrosine kinase receptor inhibitor</Action><Action id="740">Epidermal growth factor receptor antagonist</Action></ActionsPrimaryInterventionsPrimary><Class><Class id="1545">Anticancer</Class><Class id="2953">Anti-inflammatory</Class><Class id="55685">Anticancer monoclonal antibody</Class><Class id="61">Angiogenesis inhibitor</Class><Class id="62255">Anticancer protein kinase inhibitor</Class></Class><Technologies><Technology id="761">Biological therapeutic</Technology><Technology id="751">Film coating</Technology><Technology id="573">Immunoglobulin-G</Technology><Technology id="740">Infusion</Technology><Technology id="648">Intravenous formulation</Technology><Technology id="169">Monoclonal antibody humanized</Technology><Technology id="585">Oral formulation</Technology><Technology id="85">Protein recombinant</Technology><Technology id="762">Small molecule therapeutic</Technology><Technology id="746">Solution</Technology><Technology id="595">Tablet formulation</Technology></Technologies><TermsPatientSelection><Term>Aged Adults (65-79 yrs)</Term><Term>Elderly Adults (80 and over)</Term><Term>Middle-aged Adults (45-64 yrs)</Term><Term>Young Adults (18-44 yrs)</Term></TermsPatientSelection><TrialCategories><Category>Biological</Category><Category>Small molecule</Category></TrialCategories><TermsDesign><Term>Randomized</Term><Term>Active Control</Term><Term>Open Label</Term><Term>Treatment</Term><Term>Parallel Assignment</Term><Term>Interventional</Term></TermsDesign><TermsEndpoint><Term>Efficacy</Term><Term>Safety</Term></TermsEndpoint><PatientCountEnrollment>249</PatientCountEnrollment><PatientCountEvaluable>249</PatientCountEvaluable><DateStart>2007-06-30T00:00:00Z</DateStart><DateEnd type="actual">2012-08-31T00:00:00Z</DateEnd><DateChangeLast>2018-12-17T12:37:16Z</DateChangeLast><DateAdded>2008-09-23T11:38:55Z</DateAdded><Contacts><Contact type="Scientific contact"><Affiliation>Lund University Hospital Sweden</Affiliation><Name>Anders Johnsson, MD PhD</Name></Contact><Contact type="Scientific contact"><Affiliation>Lund University Hospital Sweden</Affiliation><Name>Anders Johnsson, MD PhD</Name></Contact></Contacts><CriteriaInclusion>&lt;Inclusion&gt;&lt;ul&gt;&lt;li&gt;Adenocarcinoma of the colon or rectum&lt;/li&gt;&lt;li&gt;Age&amp;gt; 18 years&lt;/li&gt;&lt;li&gt;Measurable disease according to RECIST (Response Evaluation Criteria In Solid Tumors) criteria&lt;/li&gt;&lt;li&gt;Expected survival more than 3 months&lt;/li&gt;&lt;li&gt;Adequate bone marrow, liver and kidney function&lt;/li&gt;&lt;li&gt;INR&amp;lt; 1.5 x upper limit&lt;/li&gt;&lt;li&gt;ECOG performance status (PS) 0 to 1&lt;/li&gt;&lt;li&gt;Adequate contraception for fertile patients&lt;/li&gt;&lt;li&gt;Signed written informed consent&lt;/li&gt;&lt;/ul&gt;&lt;/Inclusion&gt;</CriteriaInclusion><CriteriaExclusion>&lt;Exclusion&gt;&lt;ul&gt;&lt;li&gt;Earlier chemotherapy for metastatic colorectal cancer&lt;/li&gt;&lt;li&gt;Adjuvant treatment within 6 months&lt;/li&gt;&lt;li&gt;Surgery or significant trauma within 28 days prior to study entry&lt;/li&gt;&lt;li&gt;Planned radiotherapy against target lesions&lt;/li&gt;&lt;li&gt;CNS metastases&lt;/li&gt;&lt;li&gt;Prior malignancy within five years except cancer in situ of cervix and basal cell carcinoma&lt;/li&gt;&lt;li&gt;Bleeding diasthesis&lt;/li&gt;&lt;li&gt;Uncontrolled hypertension&lt;/li&gt;&lt;li&gt;Significant cardiovascular disease&lt;/li&gt;&lt;li&gt;Treatment with anticoagulant drugs&lt;/li&gt;&lt;li&gt;Participation in other clinical trial&lt;/li&gt;&lt;li&gt;Pregnant or lactating&lt;/li&gt;&lt;/ul&gt;&lt;/Exclusion&gt;</CriteriaExclusion><MeasuresOutcome><MeasuresPrimary><Measure><Description>Progression-free survival</Description><Timeframe>Three years</Timeframe></Measure></MeasuresPrimary><MeasureSecondary><Measure><Description>Overall response</Description></Measure><Measure><Description>Safety</Description></Measure><Measure><Description>Overall survival</Description><Timeframe>Three years</Timeframe></Measure></MeasureSecondary></MeasuresOutcome><ProtocolAndOutcomes><AdverseEvents>&lt;AdverseEvents&gt;&lt;para&gt;In June 2011, results were presented. Adverse events grade 3/4 occurred in 44% of patiens during induction phase. Diarrhea and nausea/vomiting were the most commonly reported grade 3/4 toxicities. In the maintenance phase 31% experienced grade 3/4 toxicity, with rash in 8%, hypertension in 4% and bleeding in 2% of patients. There were three toxic deaths; intestinal perforation (n = 2) and abdominal bleeding (n = 1).&lt;b&gt; &lt;/b&gt;During maintenance therapy, grade 3/4 toxicities were reported in 51 and 14% patients in the combination and &lt;ulink linkType="Drug" linkID="8047"&gt;bevacizumab&lt;/ulink&gt; alone arms, respectively. In both arms, 1% patients each experienced grade 4 cardiac toxicity, and in the combination arm, 1 and 3% patients experienced grade 4 fatigue and pain, respectively. Due to toxicities, 15% patient in the combination arm and 4% patients in the &lt;ulink linkType="Drug" linkID="8047"&gt;bevacizumab&lt;/ulink&gt; monotherapy arm discontinued the maintenance treatment. Grade 3 adverse events observed were pain (9 and 4%  in the combination and &lt;ulink linkType="Drug" linkID="8047"&gt;bevacizumab&lt;/ulink&gt; monotherapy arms, respectively), fatigue (8% in the combination arm), diarrhea (5% in the combination arm), infection/fever (5 and 3% in the combination and &lt;ulink linkType="Drug" linkID="8047"&gt;bevacizumab&lt;/ulink&gt; monotherapy arms, respectively), hypertension (3% in each arm) and nausea (1%  in the combination arm)  [&lt;ulink linkType="Reference" linkID="1196428"&gt;1196428&lt;/ulink&gt;]. &lt;/para&gt;&lt;para&gt;Results were published in September 2013. The rate of any grade 3/4 toxic effect was 53 and 13% in arms A  and B, respectively [&lt;ulink linkType="Reference" linkID="1498974"&gt;1498974&lt;/ulink&gt;].&lt;/para&gt;&lt;/AdverseEvents&gt;</AdverseEvents><AimsAndScope>&lt;AimAndScope&gt;&lt;para&gt;This phase III study was to evaluate the efficacy of &lt;ulink linkType="Drug" linkID="8047"&gt;Avastin&lt;/ulink&gt; and chemotherapy followed by &lt;ulink linkType="Drug" linkID="8047"&gt;Avastin&lt;/ulink&gt; alone or in combination with &lt;ulink linkType="Drug" linkID="11961"&gt;Tarceva&lt;/ulink&gt; for the treatment of metastatic colorectal cancer. Chemotherapy and &lt;ulink linkType="Drug" linkID="8047"&gt;bevacizumab&lt;/ulink&gt; would  be given for 4 months. Patients who  have not progressed would  continue with maintenance treatment with either &lt;ulink linkType="Drug" linkID="8047"&gt;bevacizumab&lt;/ulink&gt; alone, or &lt;ulink linkType="Drug" linkID="8047"&gt;bevacizumab&lt;/ulink&gt; and &lt;ulink linkType="Drug" linkID="11961"&gt;erlotinib&lt;/ulink&gt;.&lt;/para&gt;&lt;/AimAndScope&gt;</AimsAndScope><Outcomes>&lt;Outcomes&gt;&lt;para&gt;In June 2011, results were presented.  After 18 weeks on induction chemotherapy plus &lt;ulink linkType="Drug" linkID="8047"&gt;bevacizumab&lt;/ulink&gt;, 48% patients showed partial response, and 43 and 9% patients had stable and progressive diseases, respectively.    The median progression-free survival duration was 5.93 and 4.23 months in the combination and monotherapy arms, respectively (p = 0.24)   [&lt;ulink linkType="Reference" linkID="1196428"&gt;1196428&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In June 2012, results were published. It was observed that A24G single nucleotide polymorphism (SNP) was not related to PFS, but a significant association was observed between genotypes and miRNA-126 expression levels. Patients with high tumor miRNA-126 expression showed more PFS when compared to patients with low expression (p = 0.015). The median PFS was 6.2 and 4.0 months in the respectively groups. Results were comparable between treatment arms, but the Cox regression analysis revealed an independent prognostic value of the tumor miRNA-126 expression (p = 0.030) [&lt;ulink linkType="Reference" linkID="1299206"&gt;1299206&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In November 2012, results from an analysis (n = 110) of KRAS, BRAF and PIK3Ca mutations as predictors of outcome from maintenance therapy with &lt;ulink linkType="Drug" linkID="8047"&gt;bevacizumab&lt;/ulink&gt; with or without &lt;ulink linkType="Drug" linkID="11961"&gt;erlotinib&lt;/ulink&gt; after first-line combination therapy were presented. A significantly longer PFS was seen in patients with wt tumors compared to patients with one or more mutations (4.7 versus 4.2 months; p = 0.027) [&lt;ulink linkType="Reference" linkID="1336655"&gt;1336655&lt;/ulink&gt;].  &lt;/para&gt;&lt;para&gt;Results were published in September 2013. Median PFS was 5.7 and 4.2 months in arms A and  B, respectively (p = 0.19). From start of induction chemotherapy, overall survival (OS) was 26.7 months in the randomized population, with no difference between the two arms [&lt;ulink linkType="Reference" linkID="1498974"&gt;1498974&lt;/ulink&gt;].&lt;br/&gt;&lt;br/&gt;&lt;br/&gt;&lt;/para&gt;&lt;/Outcomes&gt;</Outcomes><ProtocolDescription>&lt;ProtocolDescription&gt;&lt;para&gt;Patients with metastatic colorectal cancer would  be treated with standard chemotherapy according to the investigators choice. In addition to chemotherapy,   &lt;ulink linkType="Drug" linkID="8047"&gt;bevacizumab&lt;/ulink&gt; (Avastin) would be given during the treatment period. After the chemotherapy was finished (after 18 weeks) maintenance therapy would  be given and the patients would  be randomized to treatment with either with &lt;ulink linkType="Drug" linkID="8047"&gt;bevacizumab&lt;/ulink&gt; alone or &lt;ulink linkType="Drug" linkID="8047"&gt;bevacizumab&lt;/ulink&gt; in combination with  &lt;ulink linkType="Drug" linkID="11961"&gt;erlotinib&lt;/ulink&gt; (Tarceva). Patients with progressive disease, or patients suitable to curative resection of metastases would  be taken out of study.&lt;/para&gt;&lt;/ProtocolDescription&gt;</ProtocolDescription><Regimens>&lt;Regimens&gt;&lt;para&gt;Patients received   chemotherapy and 2.5 mg/kg &lt;ulink linkType="Drug" linkID="8047"&gt;bevacizumab&lt;/ulink&gt;, for 18 weeks during the induction therapy. Following induction therapy, patients were randomized   to maintenance therapy with 7.5 mg/kg &lt;ulink linkType="Drug" linkID="8047"&gt;bevacizumab&lt;/ulink&gt;  q3w  alone (n = 80) (arm B) or in combination (n = 79) with 150 mg &lt;ulink linkType="Drug" linkID="11961"&gt;erlotinib&lt;/ulink&gt;     po qd (arm A), until progression or unacceptable toxic effect [&lt;ulink linkType="Reference" linkID="1196428"&gt;1196428&lt;/ulink&gt;], [&lt;ulink linkType="Reference" linkID="1299206"&gt;1299206&lt;/ulink&gt;], [&lt;ulink linkType="Reference" linkID="1498974"&gt;1498974&lt;/ulink&gt;].&lt;/para&gt;&lt;/Regimens&gt;</Regimens></ProtocolAndOutcomes><AdverseEventsByInterventions><AdverseEventsByIntervention><Intervention type="InterventionPrimary"><Name>bevacizumab + erlotinib</Name></Intervention><AdverseEvents><AdverseEvent><Indication id="102">Diarrhea</Indication><CountPatientsAffectedPercentage>5.0</CountPatientsAffectedPercentage></AdverseEvent><AdverseEvent><Indication id="178">Hypertension</Indication><CountPatientsAffectedPercentage>3.0</CountPatientsAffectedPercentage></AdverseEvent><AdverseEvent><Indication id="20">Pain</Indication><CountPatientsAffectedPercentage>9.0</CountPatientsAffectedPercentage></AdverseEvent><AdverseEvent><Indication id="226">Nausea</Indication><CountPatientsAffectedPercentage>1.0</CountPatientsAffectedPercentage></AdverseEvent><AdverseEvent><Indication id="829">Fatigue</Indication><CountPatientsAffectedPercentage>8.0</CountPatientsAffectedPercentage></AdverseEvent></AdverseEvents></AdverseEventsByIntervention><AdverseEventsByIntervention><Intervention type="InterventionPrimary"><Name>bevacizumab</Name><Drug id="8047">bevacizumab</Drug><Dose unit="milligram/kg dose">7.5</Dose></Intervention><AdverseEvents><AdverseEvent><Indication id="20">Pain</Indication><CountPatientsAffectedPercentage>4.0</CountPatientsAffectedPercentage></AdverseEvent></AdverseEvents></AdverseEventsByIntervention><AdverseEventsByIntervention><Intervention type="InterventionPrimary"><Name>bevacizumab</Name><Drug id="8047">bevacizumab</Drug><Dose unit="milligram/kg dose">7.5</Dose></Intervention><AdverseEvents><AdverseEvent><Indication id="178">Hypertension</Indication><CountPatientsAffectedPercentage>3.0</CountPatientsAffectedPercentage></AdverseEvent></AdverseEvents></AdverseEventsByIntervention></AdverseEventsByInterventions><DoseRouteByInterventions><DoseRouteByIntervention><Intervention id="53868">bevacizumab</Intervention><Treatments><Treatment><Dose>2.5 milligram/kg</Dose><Route></Route></Treatment><Treatment><Dose>7.5 milligram/kg</Dose><Route></Route></Treatment></Treatments></DoseRouteByIntervention><DoseRouteByIntervention><Intervention id="54141">erlotinib</Intervention><Treatments><Treatment><Dose>150 milligram</Dose><Route>Oral</Route></Treatment></Treatments></DoseRouteByIntervention></DoseRouteByInterventions><SitesByCountries><SitesByCountry country="Denmark"><Sites><Site><Name>Vejle Hospital, Department of Oncology</Name><Address1>Copenhagen</Address1><Contacts></Contacts></Site><Site><Name>Roskilde Hospital, Department of Oncology</Name><Address1>Roskilde</Address1><Contacts></Contacts></Site><Site><Name>Hillerod Hospital, Department of Oncology</Name><Address1>Hillerod</Address1><Contacts></Contacts></Site><Site><Name>Herning Hospital</Name><Address1>Herning</Address1><Contacts></Contacts></Site><Site><Name>Esbjerg Hospital</Name><Address1>Esbjerg</Address1><Contacts></Contacts></Site><Site><Name>Odense Hospital, Department of Oncology</Name><Address1>Odense</Address1><Contacts></Contacts></Site></Sites></SitesByCountry><SitesByCountry country="Sweden"><Sites><Site><Name>Lund University Hospital, Department of Oncology</Name><Address1>Lund</Address1><Address3>22185</Address3><Contacts></Contacts></Site><Site><Name>University Hospital MAS</Name><Address1>Malmo</Address1><Contacts></Contacts></Site><Site><Name>Ryhov Hospital, Department of Oncology</Name><Address1>Jonkoping</Address1><Contacts></Contacts></Site><Site><Name>Akademiska Hospital, Department of Oncology</Name><Address1>Uppsala</Address1><Contacts></Contacts></Site><Site><Name>Karolinska University Hospital, Department of Oncology</Name><Address1>Stockholm</Address1><Contacts></Contacts></Site><Site><Name>Sundsvall Hospital, Department of Oncology</Name><Address1>Sundsvall</Address1><Contacts></Contacts></Site><Site><Name>University Hospital of Norrland, Department of Oncology</Name><Address1>Umeå</Address1><Contacts></Contacts></Site><Site><Name>Vaxjo Hospital, Department of Oncology</Name><Address1>Vaxjo</Address1><Contacts></Contacts></Site><Site><Name>Kalmar Hospital, Department of Oncology</Name><Address1>Kalmar</Address1><Contacts></Contacts></Site></Sites></SitesByCountry></SitesByCountries><PatientSegmentTerms><PatientSegmentByDisease><Disease>Colorectal tumor</Disease><PatientSegments><PatientSegment><PatientSegment id="3813">Subjects with Rectal Cancer</PatientSegment></PatientSegment><PatientSegment><PatientSegment id="3814">Subjects with Colon Cancer</PatientSegment></PatientSegment><PatientSegment><PatientSegment id="3824">Subjects with TNM  stage IV/Metastatic/Advanced Colorectal Cancer</PatientSegment></PatientSegment></PatientSegments></PatientSegmentByDisease></PatientSegmentTerms><TrialRegistries><Registry><Name id="1000">NLM ClinicalTrials.gov</Name><Identifiers><Identifier type="NCT">NCT00598156</Identifier></Identifiers></Registry><Registry><Name id="1001">European Clinical Trials Database (EudraCT)</Name><Identifiers><Identifier type="Secondary Organisational">EUDRACT 2006-002295-18</Identifier></Identifiers></Registry></TrialRegistries><OutcomeMeasureTerms><PrimaryEndpoints><PrimaryEndpoint disease="Colorectal tumor" id="8163"><Endpoint>Assessment of Progression Free Survival (PFS)</Endpoint></PrimaryEndpoint><PrimaryEndpoint disease="Colorectal tumor" id="8383"><Endpoint>Patient Reported Outcomes/Quality of Life Assessments</Endpoint></PrimaryEndpoint></PrimaryEndpoints><SecondaryEndpoints><SecondaryEndpoint disease="Colorectal tumor" id="8151"><Endpoint>Assessment of Overall Survival (OS)</Endpoint></SecondaryEndpoint></SecondaryEndpoints><OtherEndpoints><OtherEndpoint disease="Colorectal tumor" id="8182"><Endpoint>Assessment of Disease Progression</Endpoint></OtherEndpoint><OtherEndpoint disease="Colorectal tumor" id="8235"><Endpoint>Assessment of Oncogenes/Oncoproteins</Endpoint></OtherEndpoint><OtherEndpoint disease="Colorectal tumor" id="8409"><Endpoint>Assessment of Mortality/Morbidity</Endpoint></OtherEndpoint><OtherEndpoint disease="Colorectal tumor" id="8429"><Endpoint>Assessment of Safety and Tolerability</Endpoint><SubEndpoints><SubEndpoint disease="Colorectal tumor" id="8430">Assessment of adverse events/serious adverse events</SubEndpoint></SubEndpoints></OtherEndpoint><OtherEndpoint disease="Colorectal tumor" id="9370"><Endpoint>Assessment of Response Rates (RR)</Endpoint><SubEndpoints><SubEndpoint disease="Colorectal tumor" id="8187">Assessment of Objective/Overall Response Rate (ORR)</SubEndpoint><SubEndpoint disease="Colorectal tumor" id="9368">Assessment of Partial Response (PR)</SubEndpoint><SubEndpoint disease="Colorectal tumor" id="9376">Assessment of Stable Disease</SubEndpoint></SubEndpoints></OtherEndpoint></OtherEndpoints></OutcomeMeasureTerms><EligibilityCriteriaTerms><InclusionCriteria><Inclusion disease="Colorectal tumor" id="4467"><Criterion>Subjects with Rectal Cancer</Criterion></Inclusion><Inclusion disease="Colorectal tumor" id="4468"><Criterion>Subjects with Colon Cancer</Criterion></Inclusion><Inclusion disease="Colorectal tumor" id="4470"><Criterion>Subjects with Measurable Disease</Criterion><SubCriteria><SubCriterion disease="Colorectal tumor" id="4471">Subjects with measurable disease as per modified RECIST Criteria</SubCriterion></SubCriteria></Inclusion><Inclusion disease="Colorectal tumor" id="4483"><Criterion>Subjects with Advanced/Metastatic Cancer</Criterion></Inclusion><Inclusion disease="Colorectal tumor" id="4519"><Criterion>Subjects with Protocol Specified Life Expectancy</Criterion><SubCriteria><SubCriterion disease="Colorectal tumor" id="4522">Subjects with life expectancy of three months or more</SubCriterion></SubCriteria></Inclusion><Inclusion disease="Colorectal tumor" id="32554"><Criterion>Subjects with Normal/Acceptable Organ Function</Criterion><SubCriteria><SubCriterion disease="Colorectal tumor" id="4564">Subjects with normal/acceptable liver function</SubCriterion><SubCriterion disease="Colorectal tumor" id="4569">Subjects with normal/acceptable hematopoetic/marrow function</SubCriterion></SubCriteria></Inclusion><Inclusion disease="Colorectal tumor" id="33970"><Criterion>Subjects with Protocol Specified Renal Function</Criterion><SubCriteria><SubCriterion disease="Colorectal tumor" id="4565">Subjects with normal/acceptable renal function</SubCriterion></SubCriteria></Inclusion></InclusionCriteria><ExclusionCriteria><Exclusion disease="Colorectal tumor" id="5825"><Criterion>Subjects with Metastatic Colorectal Cancer</Criterion><SubCriteria><SubCriterion disease="Colorectal tumor" id="5826">Subjects with brain metastases or leptomeningeal carcinomatosis</SubCriterion></SubCriteria></Exclusion><Exclusion disease="Colorectal tumor" id="5841"><Criterion>Subjects with History of/Active Malignancy/Cancer</Criterion></Exclusion><Exclusion disease="Colorectal tumor" id="5864"><Criterion>Subjects co-morbid with cardiovascular diseases/disorders</Criterion></Exclusion><Exclusion disease="Colorectal tumor" id="5879"><Criterion>Subjects with Co-morbid Conditions</Criterion><SubCriteria><SubCriterion disease="Colorectal tumor" id="5885">Subjects co-morbid with hematological disease/disorders</SubCriterion></SubCriteria></Exclusion><Exclusion disease="Colorectal tumor" id="5928"><Criterion>Subjects with History of/Scheduled to Receive Colorectal Cancer Therapy</Criterion><SubCriteria><SubCriterion disease="Colorectal tumor" id="20284">Subjects with history of/scheduled to receive intervention/surgery</SubCriterion></SubCriteria></Exclusion><Exclusion disease="Colorectal tumor" id="5949"><Criterion>Subjects with history of/scheduled to receive radiation therapy</Criterion></Exclusion><Exclusion disease="Colorectal tumor" id="5954"><Criterion>Subjects with History of/Scheduled for Intervention/Surgery</Criterion></Exclusion><Exclusion disease="Colorectal tumor" id="5962"><Criterion>Subjects with history of/scheduled to receive therapy for other indication</Criterion></Exclusion><Exclusion disease="Colorectal tumor" id="26894"><Criterion>Subjects with History of/Scheduled to Receive Therapy</Criterion><SubCriteria><SubCriterion disease="Colorectal tumor" id="5934">Subjects with history of/scheduled for chemotherapy</SubCriterion></SubCriteria></Exclusion></ExclusionCriteria></EligibilityCriteriaTerms><PrimaryCompletionDate type="Actual">2009-10-31T00:00:00Z</PrimaryCompletionDate><DateEnrollmentEnd type="actual">2009-12-31T00:00:00Z</DateEnrollmentEnd><EnrollmentPeriod>30.06 Months</EnrollmentPeriod><EnrollmentRate>8.28 Patients/Month</EnrollmentRate><DateFirstReceived>2008-01-09T00:00:00Z</DateFirstReceived><FundersType><Type>Academic</Type><Type>Company</Type></FundersType><ChangeHistory><Change type="added"><Date>2008-09-23T11:38:55Z</Date><Reason id="301">Clinical trial added</Reason></Change><Change type="updated"><Date>2013-08-04T13:54:02Z</Date><Reason id="305">Change history start date</Reason></Change></ChangeHistory></Trial><Trial id="61777"><TitleDisplay>Genetic Mechanisms in Human Hypertension Renin-angiotensin-aldosterone System (RAAS) Inhibition Study</TitleDisplay><TitleOfficial>Genetic Mechanisms in Human Hypertension RAAS Inhibition Study</TitleOfficial><OutcomesAvailable>No</OutcomesAvailable><EndpointsAchieved>Unknown</EndpointsAchieved><Identifiers><Identifier type="Organisational Study">2007p002290</Identifier><Identifier type="NCT">NCT01009944</Identifier></Identifiers><Indications><Indication id="178">Hypertension</Indication></Indications><BiomarkerNames></BiomarkerNames><InterventionsPrimaryByRegimen regimenType="single"><Interventions><Intervention type="InterventionPrimary"><Name>atenolol</Name><Drug id="44280">atenolol</Drug></Intervention></Interventions></InterventionsPrimaryByRegimen><InterventionsPrimaryByRegimen regimenType="single"><Interventions><Intervention type="InterventionPrimary"><Name>lisinopril</Name><Drug id="44601">lisinopril</Drug></Intervention></Interventions></InterventionsPrimaryByRegimen><InterventionsControlByRegimens></InterventionsControlByRegimens><DrugsAsInterventionPrimary><DrugAsInterventionPrimary><Drug id="44280">atenolol</Drug><IndicationsPioneer></IndicationsPioneer><Companies><Company><Company id="20690">University of Utah</Company><RelationshipDirect>NONE</RelationshipDirect><RelationshipInDirect>NONE</RelationshipInDirect></Company><Company><Company id="21048">Brigham &amp; Women's Hospital</Company><RelationshipDirect>NONE</RelationshipDirect><RelationshipInDirect>NONE</RelationshipInDirect></Company></Companies></DrugAsInterventionPrimary><DrugAsInterventionPrimary><Drug id="44601">lisinopril</Drug><IndicationsPioneer></IndicationsPioneer><Companies><Company><Company id="20690">University of Utah</Company><RelationshipDirect>NONE</RelationshipDirect><RelationshipInDirect>NONE</RelationshipInDirect></Company><Company><Company id="21048">Brigham &amp; Women's Hospital</Company><RelationshipDirect>NONE</RelationshipDirect><RelationshipInDirect>NONE</RelationshipInDirect></Company></Companies></DrugAsInterventionPrimary></DrugsAsInterventionPrimary><CrossReferences><SourceEntity id="44280" type="Drug"><TargetEntity id="137514" type="siDrug">Atenolol</TargetEntity></SourceEntity><SourceEntity id="44601" type="Drug"><TargetEntity id="90853" type="siDrug">Lisinopril</TargetEntity></SourceEntity><SourceEntity id="20690" type="Company"><TargetEntity id="4296025726" type="organizationId">University of Utah</TargetEntity></SourceEntity><SourceEntity id="21048" type="Company"><TargetEntity id="4296476182" type="organizationId">Brigham and Women's Hospital Inc</TargetEntity></SourceEntity><SourceEntity id="178" type="ciIndication"><TargetEntity id="10020772" type="MEDDRA"></TargetEntity><TargetEntity id="D006973" type="MeSH"></TargetEntity><TargetEntity id="-369992864" type="omicsDisease"></TargetEntity><TargetEntity id="240" type="siCondition"></TargetEntity></SourceEntity><SourceEntity id="18" type="Action"><TargetEntity id="381" type="Mechanism">Angiotensin-I Converting Enzyme (ACE) Inhibitors</TargetEntity></SourceEntity><SourceEntity id="39" type="Action"><TargetEntity id="45" type="Mechanism">beta1-Adrenoceptor Antagonists</TargetEntity></SourceEntity></CrossReferences><Phase>Phase 2 Clinical</Phase><RecruitmentStatus id="6">Terminated</RecruitmentStatus><NumberOfSites>1</NumberOfSites><CompaniesSponsor><Company id="21048">Brigham &amp; Women's Hospital</Company></CompaniesSponsor><CompaniesCollaborator><Company id="20690">University of Utah</Company></CompaniesCollaborator><IsCommerciallySignificant>No</IsCommerciallySignificant><ActionsPrimaryInterventionsPrimary><Action id="18">ACE inhibitor</Action><Action id="39">Beta 1 adrenoceptor antagonist</Action></ActionsPrimaryInterventionsPrimary><Class><Class id="1545">Anticancer</Class><Class id="2657">Antihypertensive</Class><Class id="66">Class II antiarrhythmic agent</Class><Class id="966">Cardiac agent</Class></Class><Technologies><Technology id="585">Oral formulation</Technology><Technology id="80">Peptide</Technology><Technology id="762">Small molecule therapeutic</Technology><Technology id="595">Tablet formulation</Technology></Technologies><TermsPatientSelection><Term>Aged Adults (65-79 yrs)</Term><Term>Middle-aged Adults (45-64 yrs)</Term><Term>Young Adults (18-44 yrs)</Term></TermsPatientSelection><TrialCategories><Category>Small molecule</Category></TrialCategories><TermsDesign><Term>Open Label</Term><Term>Treatment</Term><Term>Single Group Assignment</Term><Term>Interventional</Term></TermsDesign><TermsEndpoint><Term>Efficacy</Term></TermsEndpoint><PatientCountEnrollment>100</PatientCountEnrollment><DateStart>2007-01-31T00:00:00Z</DateStart><DateEnd type="actual">2019-03-19T00:00:00Z</DateEnd><DateChangeLast>2019-03-22T08:44:24Z</DateChangeLast><DateAdded>2009-11-10T09:09:25Z</DateAdded><Contacts><Contact type="Scientific contact"><Affiliation>Brigham and Women's Hospital</Affiliation><Name>Gordon H. Williams, MD</Name></Contact></Contacts><CriteriaInclusion>&lt;Inclusion&gt;&lt;ul&gt;&lt;li&gt;Male and female hypertensive participants who were previously studied in SCOR
             program&lt;/li&gt;&lt;/ul&gt;&lt;/Inclusion&gt;</CriteriaInclusion><CriteriaExclusion>&lt;Exclusion&gt;&lt;ul&gt;&lt;li&gt;Diabetes&lt;/li&gt;&lt;li&gt;Taking other medications beside thyroid or estrogen supplements&lt;/li&gt;&lt;/ul&gt;&lt;/Exclusion&gt;</CriteriaExclusion><MeasuresOutcome><MeasuresPrimary><Measure><Description>One type of blood pressure medication will better treat individuals with certain genetic backgrounds</Description><Timeframe>16 weeks</Timeframe></Measure></MeasuresPrimary><MeasureSecondary></MeasureSecondary></MeasuresOutcome><ProtocolAndOutcomes><AimsAndScope>&lt;AimAndScope&gt;&lt;para&gt;The purpose of this study was to develop an approach to provide personalized medicine to
      patients who have hypertension (high blood pressure).  The investigators plan to use
      people's genetic characteristics (traits) to determine what medication they should use to
      lower their blood pressure most effectively.  The investigators would give patients one of
      two medications to treat hypertension (&lt;ulink linkType="Drug" linkID="44601"&gt;lisinopril&lt;/ulink&gt; or &lt;ulink linkType="Drug" linkID="44280"&gt;atenolol&lt;/ulink&gt;).  The investigators believe
      that depending on the patients genetic background one medication will work better in
      lowering their blood pressure.&lt;/para&gt;&lt;/AimAndScope&gt;</AimsAndScope><ProtocolDescription>&lt;ProtocolDescription&gt;&lt;para&gt;Patients would receive &lt;ulink linkType="Drug" linkID="44601"&gt;lisinopril&lt;/ulink&gt; or &lt;ulink linkType="Drug" linkID="44280"&gt;atenolol&lt;/ulink&gt; once a day for 14 weeks.&lt;/para&gt;&lt;/ProtocolDescription&gt;</ProtocolDescription><SuspensionReason>&lt;SuspensionReason&gt;&lt;para&gt;This trial had been terminated because it was not funded.&lt;/para&gt;&lt;/SuspensionReason&gt;</SuspensionReason></ProtocolAndOutcomes><AdverseEventsByInterventions></AdverseEventsByInterventions><DoseRouteByInterventions></DoseRouteByInterventions><SitesByCountries><SitesByCountry country="US"><Sites><Site><Name>Brigham and Women's Hospital</Name><Address1>Boston</Address1><Address2>Massachusetts</Address2><Address3>02115</Address3><CountrySubDivision code="MA">Massachusetts</CountrySubDivision><Contacts></Contacts></Site></Sites></SitesByCountry></SitesByCountries><PatientSegmentTerms><PatientSegmentByDisease><Disease>Hypertension</Disease><PatientSegments><PatientSegment><PatientSegment id="1">Subjects with Primary/Essential Hypertension</PatientSegment></PatientSegment></PatientSegments></PatientSegmentByDisease></PatientSegmentTerms><TrialRegistries><Registry><Name id="1000">NLM ClinicalTrials.gov</Name><Identifiers><Identifier type="NCT">NCT01009944</Identifier></Identifiers></Registry></TrialRegistries><OutcomeMeasureTerms></OutcomeMeasureTerms><EligibilityCriteriaTerms><InclusionCriteria><Inclusion disease="Hypertension" id="1"><Criterion>Subjects with Primary/Essential Hypertension</Criterion></Inclusion></InclusionCriteria><ExclusionCriteria><Exclusion disease="Hypertension" id="56"><Criterion>Subjects with Diabetic Complications</Criterion></Exclusion><Exclusion disease="Hypertension" id="101"><Criterion>Subjects with history of/scheduled to receive therapy for other indication</Criterion><SubCriteria><SubCriterion disease="Hypertension" id="123">Subjects with history/scheduled to receive hormonal therapy for other indication</SubCriterion></SubCriteria></Exclusion></ExclusionCriteria></EligibilityCriteriaTerms><PrimaryCompletionDate type="Actual">2019-03-19T00:00:00Z</PrimaryCompletionDate><DateEnrollmentEnd type="actual">2016-02-29T00:00:00Z</DateEnrollmentEnd><EnrollmentPeriod>109.03 Months</EnrollmentPeriod><EnrollmentRate>0.92 Patients/Month</EnrollmentRate><DateFirstReceived>2009-11-06T00:00:00Z</DateFirstReceived><FundersType><Type>Academic</Type></FundersType><ChangeHistory><Change type="added"><Date>2009-11-10T09:09:25Z</Date><Reason id="301">Clinical trial added</Reason></Change><Change type="updated"><Date>2013-08-04T13:54:02Z</Date><Reason id="305">Change history start date</Reason></Change><Change type="updated"><Date>2016-02-17T00:00:00Z</Date><Reason id="302">Recruitment Status Changed</Reason></Change><Change type="updated"><Date>2019-03-25T00:00:00Z</Date><Reason id="302">Recruitment Status Changed</Reason></Change><Change type="updated"><Date>2019-03-25T00:00:00Z</Date><Reason id="310">Protocol &amp; Results section updates</Reason></Change><Change type="updated"><Date>2019-03-25T00:00:00Z</Date><Reason id="310">Protocol &amp; Results section updates</Reason></Change></ChangeHistory></Trial><Trial id="94584"><TitleDisplay>Women's Isoflavone Soy Health (WISH) Trial</TitleDisplay><TitleOfficial>Phytoestrogens and Progression of Atherosclerosis</TitleOfficial><OutcomesAvailable>Yes</OutcomesAvailable><EndpointsAchieved>No</EndpointsAchieved><Identifiers><Identifier type="Organisational Study">U01 AT001653</Identifier><Identifier type="NCT">NCT00118846</Identifier><Identifier type="Secondary Organisational">U01 AT001653-02S2</Identifier><Identifier type="Secondary Organisational">U01 AT001653-02S4</Identifier><Identifier type="Secondary Organisational">U01 AT001653-02S5</Identifier><Identifier type="Trial Acronym">WISH</Identifier></Identifiers><Indications></Indications><BiomarkerNames><BiomarkerName id="3374" role="Therapeutic effect marker" type="Physiological">Bone mineral density</BiomarkerName></BiomarkerNames><InterventionsPrimaryByRegimen regimenType="single"><Interventions><Intervention type="InterventionPrimary"><Name>soy protein</Name></Intervention></Interventions></InterventionsPrimaryByRegimen><InterventionsControlByRegimens></InterventionsControlByRegimens><DrugsAsInterventionPrimary></DrugsAsInterventionPrimary><CrossReferences><SourceEntity id="1006987" type="Company"><TargetEntity id="4297176861" type="organizationId">Solae LLC</TargetEntity></SourceEntity><SourceEntity id="1036410" type="Company"><TargetEntity id="5035525593" type="organizationId">National Center for Complementary and Integrative Health</TargetEntity></SourceEntity><SourceEntity id="1055617" type="Company"><TargetEntity id="5035550493" type="organizationId">Office Of Research On Womens Health</TargetEntity></SourceEntity><SourceEntity id="1074503" type="Company"><TargetEntity id="5046722886" type="organizationId">Office of Dietary Supplements</TargetEntity></SourceEntity><SourceEntity id="20673" type="Company"><TargetEntity id="4297574348" type="organizationId">University of Southern California</TargetEntity></SourceEntity></CrossReferences><Phase>Phase 2/Phase 3 Clinical</Phase><RecruitmentStatus id="4">Completed</RecruitmentStatus><NumberOfSites>1</NumberOfSites><CompaniesSponsor><Company id="20673">University of Southern California</Company></CompaniesSponsor><CompaniesCollaborator><Company id="1006987">Solae LLC</Company><Company id="1036410">National Center for Complementary and Alternative Medicine</Company><Company id="1055617">Office of Research on Women's Health</Company><Company id="1074503">Office of Dietary Supplements</Company></CompaniesCollaborator><IsCommerciallySignificant>No</IsCommerciallySignificant><Technologies></Technologies><TermsPatientSelection><Term>Aged Adults (65-79 yrs)</Term><Term>Elderly Adults (80 and over)</Term><Term>Middle-aged Adults (45-64 yrs)</Term><Term>Young Adults (18-44 yrs)</Term><Term>Female</Term><Term>Healthy volunteers only</Term></TermsPatientSelection><TrialCategories><Category>Dietary supplement</Category></TrialCategories><TermsDesign><Term>Randomized</Term><Term>Placebo Control</Term><Term>Multiple Blind</Term><Term>Prevention</Term><Term>Parallel Assignment</Term><Term>Interventional</Term></TermsDesign><TermsEndpoint><Term>Efficacy</Term><Term>Safety</Term></TermsEndpoint><PatientCountEnrollment>350</PatientCountEnrollment><PatientCountEvaluable>350</PatientCountEvaluable><DateStart>2004-03-31T00:00:00Z</DateStart><DateEnd type="actual">2009-03-31T00:00:00Z</DateEnd><DateChangeLast>2018-08-02T10:16:22Z</DateChangeLast><DateAdded>2012-10-16T12:54:35Z</DateAdded><Contacts><Contact type="Scientific contact"><Affiliation>University of Southern California Keck School of Medicine</Affiliation><Name>Howard N. Hodis, MD</Name></Contact></Contacts><CriteriaInclusion>&lt;Inclusion&gt;&lt;ul&gt;&lt;li&gt;Postmenopausal, defined as having no vaginal bleeding for at least one year and having a
             serum estradiol level higher than 20 pg/ml&lt;/li&gt;&lt;/ul&gt;&lt;/Inclusion&gt;</CriteriaInclusion><CriteriaExclusion>&lt;Exclusion&gt;&lt;ul&gt;&lt;li&gt;Signs or history of cardiovascular disease&lt;/li&gt;&lt;li&gt;Diabetes mellitus or fasting serum glucose of 140 mg/dl or greater&lt;/li&gt;&lt;li&gt;Plasma triglyceride levels of 500 mg/dl or greater&lt;/li&gt;&lt;li&gt;Serum creatinine &gt; 2.0 mg/dl&lt;/li&gt;&lt;li&gt;Uncontrolled hypertension&lt;/li&gt;&lt;li&gt;Untreated thyroid disease&lt;/li&gt;&lt;li&gt;Life expectancy less than five years&lt;/li&gt;&lt;li&gt;Current use of hormone replacement therapy (HRT)&lt;/li&gt;&lt;li&gt;Soy- or nut-related food allergies&lt;/li&gt;&lt;li&gt;Follow a vegan diet&lt;/li&gt;&lt;/ul&gt;&lt;/Exclusion&gt;</CriteriaExclusion><MeasuresOutcome><MeasuresPrimary><Measure><Description>Progression of subclinical atherosclerosis measured by the rate of change in distal common carotid artery far wall intima-media thickness in computer image processed B-mode ultrasonograms</Description><Timeframe>Baseline and every 6 months</Timeframe></Measure></MeasuresPrimary><MeasureSecondary><Measure><Description>Longitudinal change in cognitive function</Description><Timeframe>Baseline and end-of-study</Timeframe></Measure><Measure><Description>Longitudinal change in bone mineral density</Description><Timeframe>Baseline, 12 and 30 months</Timeframe></Measure><Measure><Description>Longitudinal change in mammographic percent density</Description><Timeframe>Baseline, 12 and 24 months</Timeframe></Measure></MeasureSecondary></MeasuresOutcome><ProtocolAndOutcomes><AdverseEvents>&lt;AdverseEvents&gt;&lt;para&gt;Results were published in November 2011. No major adverse events were reported due to soy protein supplementation [&lt;ulink linkType="Reference" linkID="1496092"&gt;1496092&lt;/ulink&gt;].&lt;/para&gt;&lt;/AdverseEvents&gt;</AdverseEvents><AimsAndScope>&lt;AimAndScope&gt;&lt;para&gt;The purpose of this study was to determine whether soy supplements can reduce hardening of the
      arteries in postmenopausal  subjects. This study was to determine the effects of soy supplements on atherosclerosis progression, cognition, bone mineral density, and breast tissue density changes in postmenopausal  subjects. &lt;/para&gt;&lt;/AimAndScope&gt;</AimsAndScope><Outcomes>&lt;Outcomes&gt;&lt;para&gt;Results were published in November 2011. The study reported a mean carotid artery intima-media thickness progression rate of 4.77 and 5.68 microm/year in the soy protein and placebo groups, respectively. Although there was a decrease in carotid artery intima-media thickness progression by 16% in the soy protein group compared to the placebo group, the treatment effect was not statistically significant (p = 0.36). Compared to the  placebo group, the soy protein group reported on average a 68%  lower carotid artery intima-media thickness progression rate, among the subgroup of subjets who were randomized within five years of menopause (6.79 versus 2.16  microm/year; p = 0.05). In subjects who were more than five years beyond menopause when randomized, soy protein supplementation had no effect.&lt;/para&gt;&lt;/Outcomes&gt;</Outcomes><ProtocolDescription>&lt;ProtocolDescription&gt;&lt;para&gt;Subjects would be randomly assigned to receive either soy
      supplements or placebo daily for the duration of the study.
The active product, which would be given as two divided doses, is 25 g bid soy protein containing
      85 mg aglycone weight naturally-occurring isoflavones (150 mg total isoflavone), genistein 45
      mg aglycone weight (80 mg total weight), daidzein 35 mg aglycone weight (60 mg total weight)
      and glycitein 5 mg aglycone weight (10 mg total weight). Blood collection, cognitive tests,
      and mammograms would be used to assess subjects at study entry, at each monthly visit, and
      at study completion. A matching placebo, milk protein  would be administered twice-daily. This study would last 2.5 years. &lt;/para&gt;&lt;/ProtocolDescription&gt;</ProtocolDescription><Regimens>&lt;Regimens&gt;&lt;para&gt;Subjects (n = 350) were randomized to two evenly divided daily doses of 25 g soy protein (isoflavone soy supplement [ISP]) supplement containing 91 mg aglycon isoflavone equivalents or placebo for 2.7 years [&lt;ulink linkType="Reference" linkID="1496092"&gt;1496092&lt;/ulink&gt;].&lt;/para&gt;&lt;/Regimens&gt;</Regimens></ProtocolAndOutcomes><AdverseEventsByInterventions></AdverseEventsByInterventions><DoseRouteByInterventions><DoseRouteByIntervention><Intervention id="234442">soy protein</Intervention><Treatments><Treatment><Dose>25 gram</Dose><Route></Route></Treatment></Treatments></DoseRouteByIntervention></DoseRouteByInterventions><SitesByCountries><SitesByCountry country="US"><Sites><Site><Name>University of Southern California Keck School of Medicine</Name><Address1>Los Angeles</Address1><Address2>California</Address2><Address3>90033</Address3><CountrySubDivision code="CA">California</CountrySubDivision><Contacts></Contacts></Site></Sites></SitesByCountry></SitesByCountries><PatientSegmentTerms><PatientSegmentByDisease><Disease>Atherosclerosis</Disease><PatientSegments><PatientSegment><PatientSegment id="7236">Subjects at risk of developing disease</PatientSegment></PatientSegment></PatientSegments></PatientSegmentByDisease><PatientSegmentByDisease><Disease>Osteoporosis</Disease><PatientSegments><PatientSegment><PatientSegment id="7653">Subjects at risk of developing disease</PatientSegment><SubSegments><SubSegment id="7665">Women at risk of developing osteoporosis</SubSegment></SubSegments></PatientSegment></PatientSegments></PatientSegmentByDisease><PatientSegmentByDisease><Disease>Menopause</Disease><PatientSegments><PatientSegment><PatientSegment id="19017">Subjects with Protocol Specified Menstrual Status</PatientSegment><SubSegments><SubSegment id="11612">Postmenopausal Subjects</SubSegment></SubSegments></PatientSegment></PatientSegments></PatientSegmentByDisease></PatientSegmentTerms><TrialRegistries><Registry><Name id="1000">NLM ClinicalTrials.gov</Name><Identifiers><Identifier type="NCT">NCT00118846</Identifier></Identifiers></Registry></TrialRegistries><OutcomeMeasureTerms><PrimaryEndpoints><PrimaryEndpoint disease="Breast tumor" id="8744"><Endpoint>Assessment of Disease Progression</Endpoint></PrimaryEndpoint><PrimaryEndpoint disease="Breast tumor" id="9310"><Endpoint>Imaging/Radiological Assessments</Endpoint><SubEndpoints><SubEndpoint disease="Breast tumor" id="9315">Assessment by ultrasonography</SubEndpoint></SubEndpoints></PrimaryEndpoint><PrimaryEndpoint disease="Atherosclerosis" id="9739"><Endpoint>Assessment of Vascular Indices or Parameters</Endpoint><SubEndpoints><SubEndpoint disease="Atherosclerosis" id="9746">Assessment of intima media thickness (IMT)</SubEndpoint></SubEndpoints></PrimaryEndpoint><PrimaryEndpoint disease="Atherosclerosis" id="9893"><Endpoint>Protocol Specified Other Endpoints</Endpoint><SubEndpoints><SubEndpoint disease="Atherosclerosis" id="9903">Assessment of atherosclerotic disease progression</SubEndpoint></SubEndpoints></PrimaryEndpoint><PrimaryEndpoint disease="Osteoporosis" id="13817"><Endpoint>Assessment of Co-morbidity</Endpoint></PrimaryEndpoint><PrimaryEndpoint disease="Menopause" id="23561"><Endpoint>Assessment of Therapy Related Outcomes</Endpoint><SubEndpoints><SubEndpoint disease="Menopause" id="23562">Assessment of response to cancer therapy</SubEndpoint></SubEndpoints></PrimaryEndpoint></PrimaryEndpoints><SecondaryEndpoints><SecondaryEndpoint disease="Breast tumor" id="9310"><Endpoint>Imaging/Radiological Assessments</Endpoint><SubEndpoints><SubEndpoint disease="Breast tumor" id="9311">Mammography</SubEndpoint></SubEndpoints></SecondaryEndpoint><SecondaryEndpoint disease="Osteoporosis" id="13772"><Endpoint>Assessment of Bone</Endpoint><SubEndpoints><SubEndpoint disease="Osteoporosis" id="13771">Assessment by Bone mineral density (BMD)</SubEndpoint></SubEndpoints></SecondaryEndpoint><SecondaryEndpoint disease="Menopause" id="23552"><Endpoint>Assessment of Bone</Endpoint><SubEndpoints><SubEndpoint disease="Menopause" id="23553">Assessment by Bone mineral density (BMD)</SubEndpoint></SubEndpoints></SecondaryEndpoint><SecondaryEndpoint disease="Breast tumor" id="46045"><Endpoint>Assessment of Bone</Endpoint><SubEndpoints><SubEndpoint disease="Breast tumor" id="8970">Assessment by Bone mineral density (BMD)</SubEndpoint></SubEndpoints></SecondaryEndpoint></SecondaryEndpoints></OutcomeMeasureTerms><EligibilityCriteriaTerms><InclusionCriteria><Inclusion disease="Breast tumor" id="4817"><Criterion>Postmenopausal Breast Cancer Women</Criterion></Inclusion><Inclusion disease="Breast tumor" id="4877"><Criterion>Subjects with Protocol Specified Life Expectancy</Criterion></Inclusion><Inclusion disease="Osteoporosis" id="8680"><Criterion>Subjects at Risk of Developing Disease</Criterion><SubCriteria><SubCriterion disease="Osteoporosis" id="8681">Women at risk of developing osteoporosis</SubCriterion></SubCriteria></Inclusion><Inclusion disease="Osteoporosis" id="8709"><Criterion>Subjects with Normal/Acceptable Laboratory Criteria</Criterion></Inclusion><Inclusion disease="Menopause" id="20769"><Criterion>Subjects with protocol Specified Hormonal Levels</Criterion><SubCriteria><SubCriterion disease="Menopause" id="20771">Subjects with protocol specified estradiol levels</SubCriterion></SubCriteria></Inclusion><Inclusion disease="Menopause" id="33715"><Criterion>Subjects with Protocol Specified Menstrual Status</Criterion><SubCriteria><SubCriterion disease="Menopause" id="20758">Postmenopausal subjects</SubCriterion></SubCriteria></Inclusion><Inclusion disease="Atherosclerosis" id="33736"><Criterion>Subjects with Protocol Specified Menstrual Status</Criterion><SubCriteria><SubCriterion disease="Atherosclerosis" id="5696">Postmenopausal women</SubCriterion></SubCriteria></Inclusion></InclusionCriteria><ExclusionCriteria><Exclusion disease="Breast tumor" id="6257"><Criterion>Subjects co-morbid with endocrine/metabolic diseases/disorders</Criterion></Exclusion><Exclusion disease="Breast tumor" id="6258"><Criterion>Subjects co-morbid with cardiovascular diseases/disorders</Criterion></Exclusion><Exclusion disease="Breast tumor" id="6267"><Criterion>Subjects co-morbid with renal disease/disorder</Criterion></Exclusion><Exclusion disease="Breast tumor" id="6301"><Criterion>Subjects with Hypersensitivity/Contraindications to Drugs/Excipients</Criterion><SubCriteria><SubCriterion disease="Breast tumor" id="6302">Subjects with hypersensitivity/contraindication to any investigational agents</SubCriterion></SubCriteria></Exclusion><Exclusion disease="Breast tumor" id="6393"><Criterion>Subjects with History of/Scheduled to Receive Therapy</Criterion></Exclusion><Exclusion disease="Atherosclerosis" id="7313"><Criterion>Subjects co-morbid with endocrine/metabolic diseases/disorders</Criterion></Exclusion><Exclusion disease="Atherosclerosis" id="7314"><Criterion>Subjects co-morbid with cardiovascular diseases/disorders</Criterion></Exclusion><Exclusion disease="Atherosclerosis" id="7319"><Criterion>Subjects co-morbid with renal disease/disorder</Criterion></Exclusion><Exclusion disease="Atherosclerosis" id="7334"><Criterion>Subjects with Protocol Specified Life Expectancy</Criterion><SubCriteria><SubCriterion disease="Atherosclerosis" id="7341">Subjects with life expectancy of five years or less</SubCriterion></SubCriteria></Exclusion><Exclusion disease="Atherosclerosis" id="7342"><Criterion>Subjects with Hypersensitivity/Contraindications to Drugs/Excipients</Criterion><SubCriteria><SubCriterion disease="Atherosclerosis" id="7354">Hypersensitivity/Contraindications to study medications or its excipients</SubCriterion></SubCriteria></Exclusion><Exclusion disease="Atherosclerosis" id="7363"><Criterion>Subjects with History of/Scheduled to Receive Therapy</Criterion><SubCriteria><SubCriterion disease="Atherosclerosis" id="7372">Subjects with history of/scheduled for immunomodulators /immunosuppressants</SubCriterion></SubCriteria></Exclusion><Exclusion disease="Osteoporosis" id="10243"><Criterion>Subjects co-morbid with cardiovascular diseases/disorders</Criterion></Exclusion><Exclusion disease="Osteoporosis" id="10248"><Criterion>Subjects co-morbid with endocrine/metabolic diseases/disorders</Criterion></Exclusion><Exclusion disease="Osteoporosis" id="10262"><Criterion>Subjects with Abnormal Laboratory Findings</Criterion></Exclusion><Exclusion disease="Osteoporosis" id="10266"><Criterion>Subjects with History of/Scheduled to Receive Therapy</Criterion><SubCriteria><SubCriterion disease="Osteoporosis" id="10819">Subjects with history of/scheduled to receive hormone replacement therapy</SubCriterion></SubCriteria></Exclusion><Exclusion disease="Menopause" id="18302"><Criterion>Subjects co-morbid with cardiovascular diseases/disorders</Criterion></Exclusion><Exclusion disease="Menopause" id="18305"><Criterion>Subjects co-morbid with renal disease/disorder</Criterion></Exclusion><Exclusion disease="Menopause" id="18306"><Criterion>Subjects co-morbid with Endocrine/Metabolic Disorders</Criterion></Exclusion><Exclusion disease="Menopause" id="18308"><Criterion>Subjects co-morbid with infections</Criterion></Exclusion><Exclusion disease="Menopause" id="18309"><Criterion>Subjects with Co-morbid Conditions</Criterion></Exclusion><Exclusion disease="Menopause" id="18310"><Criterion>Subjects with History of/Scheduled to Receive Therapy</Criterion><SubCriteria><SubCriterion disease="Menopause" id="18311">Subjects with history of/scheduled to receive hormone therapy</SubCriterion></SubCriteria></Exclusion><Exclusion disease="Atherosclerosis" id="25707"><Criterion>Subjects co-morbid with Endocrine/Metabolic Disorders</Criterion><SubCriteria><SubCriterion disease="Atherosclerosis" id="7558">Subjects co-morbid with dyslipidemia</SubCriterion></SubCriteria></Exclusion><Exclusion disease="Osteoporosis" id="26328"><Criterion>Subjects with Abnormal Organ Function</Criterion><SubCriteria><SubCriterion disease="Osteoporosis" id="10260">Subjects with abnormal/unacceptable renal function</SubCriterion></SubCriteria></Exclusion></ExclusionCriteria></EligibilityCriteriaTerms><PrimaryCompletionDate type="Actual">2005-09-30T00:00:00Z</PrimaryCompletionDate><DateEnrollmentEnd type="actual">2006-02-28T00:00:00Z</DateEnrollmentEnd><EnrollmentPeriod>23.03 Months</EnrollmentPeriod><EnrollmentRate>15.20 Patients/Month</EnrollmentRate><DateFirstReceived>2005-07-07T00:00:00Z</DateFirstReceived><FundersType><Type>Academic</Type><Type>Company</Type><Type>Government</Type></FundersType><ChangeHistory><Change type="added"><Date>2012-10-16T12:54:35Z</Date><Reason id="301">Clinical trial added</Reason></Change><Change type="updated"><Date>2013-08-04T13:54:02Z</Date><Reason id="305">Change history start date</Reason></Change><Change type="updated"><Date>2013-11-07T00:00:00Z</Date><Reason id="303">Results Available</Reason></Change><Change type="updated"><Date>2013-12-27T00:00:00Z</Date><Reason id="302">Recruitment Status Changed</Reason></Change><Change type="updated"><Date>2016-03-04T00:00:00Z</Date><Reason id="302">Recruitment Status Changed</Reason></Change><Change type="updated"><Date>2017-05-29T00:00:00Z</Date><Reason id="302">Recruitment Status Changed</Reason></Change></ChangeHistory></Trial></ns2:com.thomsonreuters.ls.service.contract.soap.trials.v2.TrialRecordsOutput>